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1 INTRODUCTION 
 
Patients with abnormalities in uric acid metabolism form a significant portion of cases 
evaluated in metabolic centres such as the Institute of Metabolic Disorders in Prague [1]. 
Mechanisms of uric acid handling in the kidneys are mostly unknown. They include glomerular 
filtration, reabsorption, secretion and postsecretory reabsorption.  
Involved uric acid metabolism contributes to complex traits such as the metabolic 
syndrome X. The possible way to understand those complex traits is to examine molecular basis 
of extreme hereditary forms of hyperuricaemia. They include particularly disorders leading to 
hyperuricaemia due to urate overproduction (phosphoribosylpyrophosphate synthetase 
superactivity, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome) and due to urate 
underexcretion in the kidneys. 
This work was focused on the latter disorders represented by familial juvenile 
hyperuricaemic nephropathy and nephronophthisis-medullary cystic kidney disease complex.  
The introduction describes the history of identification of those disorders and presents in 
chronological order knowledge gathered on clinical presentation and genetic dissection of 
hereditary nephropathies associated with hyperuricaemia and gout up to 2001 when I started to 
work on this subject. 
 
1.1 Familial juvenile hyperuricaemic nephropathy (FJHN, OMIM 162000) 
 
In 1960, Duncan and Dixon described a family with hyperuricaemia, gout and renal 
insufficiency [2]. The patient was 19 years old man suffering from acute gouty arthritis, 
hyperuricaemia, hypertension and severe renal failure. Both his kidneys were abnormally small. 
All his seven first-degree relatives had hyperuricaemia and five of them had renal failure. Since 
then, more than 50 kindreds of various ethnic origin - Whites [3-14], Japanese [15-17], Chinese 
[18], Polynesian [19], Chilean [20] - had been described in the literature by 2001.  
 The disorder is inherited in consecutive generations. Both males and females are equally 
affected. The condition is transmitted from father to son and about half of the offspring is 
affected. This suggested autosomal dominant (AD) inheritance with high penetrance.  
 
Clinical presentation  
Hyperuricaemia, resulting from reduced urate excretion, is usually diagnosed in 
childhood, adolescence or early adult life but cases presenting later have also been observed. 
Disease progresses to gouty arthritis and renal insufficiency in second decade of life. The renal 
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insufficiency progresses further to renal failure between 20th and 40th year of life and affected 
individuals end up on dialysis and require renal transplantation in third to fourth decade of life. 
Isolated attack of gout in one or more family members is an important factor drawing 
attention to kindreds being until then diagnosed as familial nephritis or familial renal disease [7, 
21]. However, gout is not constant feature of the condition [7, 21], which is therefore meant to 
have been missed and underdiagnosed in the past. For the same reason, gout in clinical 
description of “familial nephropathy with gout” or “familial juvenile gouty nephropathy”, 
having been used in the past, is preferentially replaced by “hyperuricaemia” or “hyperuricaemic 
nephropathy” as more appropriate terms. The majority of patients are normotensive, although 
hypertension may be found in later stages of renal disease and conversely accelerates the 
progression of chronic renal failure. 
 
Biochemistry 
There are two biochemical hallmarks of FJHN: i) hyperuricaemia disproportionate to 
age, sex or degree of renal involvement, ii) markedly decreased fractional excretion of urate 
(FEur = (urate clearance/creatinine clearance)*100). The mean FEur in FJHN 5.1% is equally low 
in young men, women and children [22]. However, as low as 1% FEur were reported, whereas 
normal values range from 7% to 12%. Even more obvious discrepancy can be seen in children, 
in which normal values ranges from 12% to 30% [23].  Important thing with respect to the 
pathogenesis of the disease is that the low FEur precedes all other symptoms in apparently 
normal, though affected individuals [22, 24]. Proteinuria is minimal or absent in FJHN patients 
as are abnormalities of urinary sediment. Microscopic haematuria may be present. In differential 
diagnosis, there are taken into account mainly hypoxanthine-guanine phosphoribosyl transferase 
(HGPRT) deficiency and phosphoribosyl pyrophosphate synthetase (PRPS) superactivity in 
erythrocytes. 
 
Pathology 
Renal manifestation of FJHN has features of non-specific interstitial nephropathy. The 
kidneys show interstitial fibrosis associated with infiltration of lymphocytes and histiocytes, 
focal atrophy of distal tubules, thickening and sometimes reduplication of basal membranes in 
distal tubules and collecting ducts and partial glomerular sclerosis [22, 25-27]. Crystals of urate 
were detected only in fraction of examined biopsies, which however could be caused by 
unsuitable sample fixation [27] or by their reabsorption [26].  
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Management and treatment of clinical and biochemical symptoms 
Approaches to management of FJHN were and still remain a subject of heated 
discussions. Using of xanthine oxidase inhibitor allopurinol to reduce hyperuricaemia and to 
slow down the progression of renal disease remains controversial. Its beneficial effect was 
emphasised in several studies [22, 24, 27] but disputed in other [7, 28, 29]. 
The control of high blood pressure, if present, is generally meant to be a prerequisite for 
successful treatment.  
More efficient approach to treatment may be the combination of allopurinol to reduce 
renal urate load and benzbromarone or probenecid to block tubular anion exchanger and thus 
restoring FEur towards normal, provided that the decreased uric acid excretion is caused by gain-
of-function mutation in proximal tubule (PT) anion exchanger [11, 30]. Others suggested that 
blockade of renin-angiotensin system in patients with early stage nephropathy may delay the 
progression of renal insufficiency [31, 32].  
 
Pathogenesis 
The pathogenesis of FJHN was not clear. Decreased FEur can be proven in FJHN patients 
before any renal malfunctions occur, suggesting a primary defect in urate handling [22, 24]. A 
gain-of-function mutation of the luminal urate/anion exchanger would be consistent with 
decreased FEur, dominant inheritance and PT epithelial cells apoptosis, hypothetically caused by 
increased transcellular flux of urate [11]. Possible candidate could have been human urate 
transporter hUAT, localised to chromosome 17p [33], or another not fully characterised anion 
exchanger [34]. Alternatively, hyperuricaemia induced in rat model by uricase inhibition was 
shown to cause hypertension and renal fibrosis by a crystal-independent mechanism [35], 
further suggesting primary role of urate in the renal damage. On the contrary, others suggested 
uric acid underexcretion and hyperuricaemia to be a consequence of primary impairment of 
renal hemodynamics [7, 36]. This was observed not only in patients from five kindreds, but also 
in obligate carriers in preclinical status [37]. This hypothesis was further supported by 
ultrasound imaging and colour Doppler studies in FJHN patients showing renal vasoconstriction 
[38]. Another proposal was that the abnormal urate handling in this condition is a result of 
primary renal disease consisting in abnormal nephronogenesis due to a defect in G protein-
coupled receptor [12].  
 
1.2 Complex Nephronophthisis-Medullary Cystic Kidney Disease (NPH-MCKD, OMIM 
174000, 603860, 256100, 602088, 604387) 
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MCKD 
 Medullary cystic kidney disease was first described by Thorn et al. in 1944 as “salt-
loosing nephritis“ [39], although some authors state that it were Smith and Graham in 1945 who 
reported first case [40]. They used the term “congenital medullary cystic disease of the kidney” 
in relation to 8-years-old girl suffering from severe anaemia, hyposthenuria and uraemia. Since 
then, there had been reported further cases and families presenting with renal failure, medullary 
cysts, anaemia and salt loss [41-46]. It is a rare disorder. By 2001, MCKD had been described in 
more than 50 families mainly from Europe and North America [47].  
NPH 
In 1951, Fanconi et al. recognised very similar familial renal disease affecting children 
4-14 years old characterised by renal insufficiency, anaemia, polyuria, hyposthenuria and 
tubulointerstitial involvement [48]. Medullary cysts were also present, although not mentioned 
in the article [47]. The condition was designated nephronophthisis (NPH) by the authors. It was 
recognised early that NPH and MCKD share several clinical (polyuria, polydipsia, anaemia), 
pathological (cysts primarily located at the cortico-medullary border) and histological (tubular 
atrophy, interstitial fibrosis, cell infiltration) features.  
 
NPH-MCKD 
In the 1960s, inability to clearly distinguish both entities and confused diagnoses lead to 
proposal of the term NPH-MCKD complex and several studies tried to prove the identity of the 
two disorders [44, 49-51]. Further decades, however, have also shown differences, namely mode 
of inheritance (autosomal recessive in NPH versus autosomal dominant in MCKD), age of onset 
of clinical symptoms and progression to end-stage renal disease (ESRD; usually childhood or 
adolescence in NPH and adulthood in MCKD) and extrarenal organ involvement (tapeto-retinal 
degeneration in NPH and hyperuricaemia with or without gout in MCKD).  
Distinction of these two entities had become more obvious through the identification of 
underlying genetic loci by linkage analyses. NPH, at present referred to as NPHP, had been 
linked to three loci by 2001, namely 2q13 (NPHP1) [52, 53], 9q22 (NPHP2) [54] and 3q21 
(NPHP3) [55], while MCKD had been mapped to different loci (see later). Mutations in NPHP1 
gene encoding for nephrocystin were found causative in case of NPHP1 [56, 57]. Additional loci 
and underlying genes in NPHP were identified later (see Results and Discussion).  
 
Clinical presentation and biochemistry of MCKD 
 Reduced urine concentrating ability with salt wasting, preceding decreased glomerular 
filtration rate (GFR), can be the only finding early in the course. Proteinuria is absent or 
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minimal, urinary sediment is non-specific. When urine-concentrating ability decreases 
substantially, polyuria usually accompanied by polydipsia appears in early or later adulthood 
(average 28 years). It is usually in this stage the affected individuals are diagnosed. Following 
anaemia, metabolic acidosis and uraemia are related to progressive renal insufficiency. 
Hypertension is usual and often precocious, despite the presence of polyuria. The renal 
insufficiency usually slowly progresses to ESRD in the third to fifth decade of life and affected 
individuals end up on dialysis and require renal transplantation [58]. 
It is of note that there were described families, in which onset of clinical symptoms was 
in childhood or adolescence [43, 59] as well as occurrence of juvenile and adult form within one 
family [50]. These findings decrease the value of age of onset for differential diagnosis in the 
eyes of some authors [47].  
 
Pathology of MCKD 
Histological findings such as diffuse tubulointerstitial nephritis, thickened tubular 
basement membranes, focal tubular atrophy, interstitial fibrosis and inflammatory cells 
infiltration are typical. Tubular dilation is present and formation of cysts at the cortico-
medullary border and/or in the medulla may be seen (in contrast to FJHN). The kidneys, overall, 
are small and echogenic.  
 
Management and treatment of clinical and biochemical symptoms in MCKD 
There were no specific therapeutic approaches to MCKD. Before the development of 
ESRD, the control of water and electrolyte imbalance and later, when ESRD breaks out, dialysis 
followed by kidney transplantation are applied. 
Pathogenesis of MCKD 
The pathogenesis of MCKD had been unclear. Without the knowledge of causative genes, it had 
been impossible to speculate about observed clinical and pathological features. It was observed 
that the condition never occurred again after kidneys transplantation. This suggested kidney 
restricted involvement.  
 
MCKD and FJHN 
Besides renal involvement, hyperuricaemia with or without gout had been observed in 
portion of MCKD families. In 1978 for example, Thomson et al. described a family clinically 
resembling FJHN but medullary cysts were also present [60]. Hyperuricaemia and gouty 
arthritis occurred at late adolescence and preceded renal failure. Similar condition, complicated 
by epilepsy, was reported by Burke et al. in 1982 [61]. Since then, more MCKD families with 
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hyperuricaemia and/without gout had been reported [12, 59, 62] but also MCKD families in 
which portion of affected members showed hyperuricaemia but did not have cysts, resembling 
thus FJHN phenotype [62, 63]. Unfortunately, only little data were available on FEur in MCKD 
patients [64] and none from affected patients in pre-symptomatic period.  
As can be seen, there were recognised remarkable similarities in phenotype between 
FJHN and MCKD associated with hyperuricaemia with or without gout. Together with advances 
in molecular genetics of the two disorders, their relationship and molecular bases had become 
clearer.  
 
1.3 Molecular genetics of MCKD/FJHN 
 
MCKD  
The first genetic linkage to chromosome 1q21 found Christodoulou et al. in two large 
Cypriot MCKD families in 1998 [62]. MCKD in those families was associated with 
hyperuricaemia, gout and late onset of ESRD (means 62.2 and 51.5 years).  
One year later, Scolari et al. found linkage to another locus on chromosome 16p12 in 
large Italian family with MCKD associated with hyperuricaemia and gouty arthritis [63]. In all 
families was previously excluded linkage to NPHP1 locus on chromosome 2q13. These 
observations lead to differentiation of MCKD to two variants: (AD)MCKD1 with the linkage to 
chromosome 1q21 and (AD)MCKD2 with the linkage to chromosome 16q12.  
Further linkage studies in MCKD families revealed two important points: i) further 
genetic heterogeneity of the disease and ii) no concordance of phenotype with identified locus. 
Kroiss et al. excluded genetic linkage to both MCKD1 and MCKD2 loci in five MCKD families 
with the absence of hyperuricaemia and gout [65]. Both loci were excluded from linkage also in 
one of six Finnish families reported by Auranen et al. [17]. This single family presented 
hyperuricaemia, while remaining five families, mapped to chromosome 1q21, did not. 
Interestingly, Parvari et al. proved linkage to MCKD1 locus in large family of Jewish origin, 
clinically characterised by hypertension and progressive renal insufficiency. No polyuria, 
anaemia, gout, haematuria or proteinuria was observed. Renal histology showed extensive 
tubulointerstitial fibrosis and global glomerulosclerosis [66]. This study further broadened the 
spectrum of clinical presentations linked to 1q21 locus. Finally, Hateboer et al. reported linkage 
to MCKD2 locus in large Welsh MCKD family, which however did not present hyperuricaemia 
or gout [67]. This indicated that these clinical features are not invariably related to MCKD2 
mutations.  
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FJHN 
In 2000, Kamatani et al. performed genome-wide linkage analysis in a large Japanese 
family with FJHN to find locus segregating with the disease [68]. The family transmitting gouty 
arthritis, renal failure and hypertension in autosomal dominant mode was originally described 
by Yokota et al. in 1991 [28]. Kamatani et al. at first found linkage to chromosome 16p and 
using additional 12 polymorphic markers they delimited candidate interval of 9 cM in the 16p12 
region. In the same year, Stibůrková et al. reported linkage to 16p11.2 in two of three Czech 
FJHN families presenting with hyperuricaemia, decreased FEur, gouty arthritis and renal 
insufficiency [10]. This study also provided other important results: i) genetic heterogeneity of 
FJHN and ii) variable penetrance of the disease. In further study, Dahan et al. confirmed linkage 
to 16p12 locus in large Belgian family [12] and among others promoted hypothesis that FJHN 
and MCKD2 are in fact allelic disorders. However, alternate hypothesis of two disease genes in 
close proximity could not be excluded as well. Solution of this situation was possible only 
through the identification of responsible gene(s) in 16p12 locus. 
 
2 AIMS OF THE STUDY 
 
The main goal of this thesis has been to contribute to understanding of FJHN and other 
inherited diseases presenting with familial occurrence of hyperuricaemia, gouty arthritis and 
progressive kidney failure at an early age. We have been especially interested in molecular bases 
and mechanisms underlying these disorders. The project was based on the following strategy:  
1. Continuous collection and characterization of FJHN/MCKD patients and families. 
2. Identification of disease causing genes in affected families by positional cloning approaches. 
3. Characterisation of the identified proteins and their mutated forms by standard molecular 
biology methods and evaluation of mechanisms involved in the disease pathogenesis. 
4. Isolation and characterisation of interacting partners of newly identified proteins as a parallel 
approach to the positional cloning in definition of potential candidate disease causing genes 
and disease related pathways. 
 
3 RESULTS AND DISCUSSION 
 
During last years, considerable achievements have been reached in molecular 
characterisation of inherited kidney diseases. Characterisation of nephronophthisis and its 
distinction from MCKD has been evidenced by identification of further NPHP loci and 
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underlying genes. So far, six NPHP genes have been identified [56, 69-74] and there is evidence 
of further genetic heterogeneity [75]. At the same time, common pathogenesis of NPHP and 
polycystic kidney disease (PKD) involving cilium/centrosome pathology has been revealed [70, 
76, 77].  
A couple of years ago, MCKD and FJHN were partially genetically characterised and 
their close relationship came out [10, 12, 63]. The following section describes and discusses 
results obtained in our four partially overlapping projects addressing strategic concepts outlined 
in previous chapter. Results are presented with respect to four published manuscripts, one 
manuscript prepared for the publication and one unpublished work. Each part is structured in 
introduction, specific methods, results and their discussion. Unless otherwise stated, water 
mentioned in specific methods sections was ultrapure water prepared from common distilled 
water in Milli-Q® RG Ultrapure Water Purification System (Millipore). 
 
3.1 Collection and characterisation of additional FJHN/MCKD patients and families 
(2001-2003) - European Journal of Human Genetics 11(2): p. 145-154, 2003  
 
3.1.1 Introduction 
  
 In the situation described in chapter 1.3, we had the opportunity to obtain biological 
samples from additional FJHN/MCKD families from abroad to perform further molecular 
genetic analyses. We collected samples from members of 15 families coming mainly from the 
United Kingdom and also from Spain and Belgium. Thus we were driven into the international 
race of finding the first gene responsible for FJHN/MCKD, in which participated in addition to 
countries mentioned also the USA, Japan, Germany and Italy. In question, there was mainly the 
ability of presymptomatic detection of the disease, related helpfulness of allopurinol for the 
therapy in increasing number of families and allelism of FJHN and MCKD2. 
 
3.1.2 Specific methods 
 
Bioinformatics 
 Information on gene organisation and DNA sequences of exons, introns and gene 
promotors were obtained from The Entrez Nucleotide database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore) and The UCSC Genome Browser 
database using BLASTN tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) for pairwise alignment of 
nucleotide sequences. Results of sequencing were confronted with the UniGene database 
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(http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene) and the Entrez SNP database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp). 
 
Primer design 
 Polymerase chain reaction (PCR) and sequencing primers were designed on retrieved 
sequences by Oligo 6.44 software (Molecular Biology Insights) in automatic mode with high 
stringency and filtration of frequent 6-mers of human and primate origin. Where automatic 
approach failed, primers were designed by hand following the recommendation of higher 
internal stability (∆G) at the 5´ end or in the middle of the primer and relatively lower internal 
stability at the 3´ end of the primer.  
 
Other used methods are described in General methods section, chapters 5.4 - 5.7.  
 
3.1.3 Results and discussion 
 
Following the work of Stibůrková et al. [10], we performed linkage analysis to 
previously identified locus on chromosome 16p12 in 15 families consistent with FJHN 
diagnosis [78]. We were able to prove linkage in six families. In two families, linkage was 
excluded based on logarithm of odds (LOD) score ≤ -2 criterion. In the rest of families, negative 
LOD scores but not reaching the -2 threshold or inconsistency of segregating haplotypes with 
linkage was detected. Haplotype analysis was used in this work as an alternative approach for 
determination of linkage rate in the group of studied families. This was shown to be 0.4 (6/15) 
compared to value of parameter α = 0.374 maximizing the LOD score in linkage analysis. We 
were therefore able to estimate that between 37% and 40% of FJHN cases from our cohort could 
be explained by linkage to 16p11.2. Haplotype analysis also showed that there was no common 
haplotype or allele segregating with the disease that would be shared across families. This 
suggested either independent mutational events or one ancestral but ancient mutation.  
Compilation of our haplotyping data with similar data from other studies in both FJHN 
and MCKD2 kindreds [10, 12, 63, 67, 68] suggested possible existence of two non-overlapping 
candidate regions in close proximity on chromosome 16p. Similar conclusion (without our data) 
was at the same time presented by Scolari et al [47]. It brought further confusion to 
understanding the genetic bases of FJHN and its relationship to MCKD2. Providing genetic 
distinctness of FJHN and MCKD2, there were possible up to three disease genes. Providing 
FJHN and MCKD2 allelism, two loci still came into consideration. 
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 To evaluate genetic content and make possible the assessment of candidate genes, we 
constructed integrated genetic, physical and transcript map of 16p chromosome region 
comprising both critical intervals. Compilation of four genomic contigs and three gap-closing 
bacterial artificial chromosome (BAC) clones provided contiguous sequence of 7.5 mega-base 
pairs (Mbp) harbouring, according to NCBI annotation that time, 45 genes and 129 gene-like 
sequences. Taking the multilocus hypothesis into account, we selected seven candidate genes 
involved in G-protein signalling, regulated protein degradation, thyroid hormone homeostasis 
and hypertension for sequence analysis. Kidney specific UMOD (encoding Tamm-Horsfall 
protein, or uromodulin) and ACSM3 (encoding acyl-CoA synthetase medium-chain family 
member 3) genes, proposed as promising candidates by Scolari et al. in 1999 [63] were not 
analysed by us as the sequence analysis performed by Pirulli et al. in 2001 in single MCKD2 
family showed no mutations [79]. In all of the seven candidate genes analysed by us, no classic 
deleterious mutations were found within promoter region, exon/intron junctions and coding 
sequences. 
 
Identification and characterisation of UMOD as a disease-causing gene 
At the time of acceptance of our manuscript (end of the year 2002), Hart et al. came out 
with work in which they clearly described mutations in the UMOD gene (OMIM 191845), 
encoding for uromodulin, in two FJHN families as well as in one MCKD2 family, proving thus 
allelism of both disorders [80]. Thus the USA actually won the international race mentioned in 
chapter 3.1.1.  
Based on their findings, authors suggested using the term “uromodulin-associated kidney 
disease” (UAKD) for both FJHN and MCKD2 for the sake of clarity. Some researchers, 
including us, currently prefer this term [80-82], while others prefer the term “uromodulin 
storage diseases” [83, 84] (see later). 
It is of note, that the obvious contradiction with data of Pirulli et al. [79] (see above) was 
resolved after they revised their data and identified the UMOD mutation as well [85]. 
 
Another gene in single FJHN family with atypical clinical presentation  
Interestingly, another research group studied one of our families in parallel. Onset of the 
diabetes type 2 in this family, originally described by Calabrese et al. in 1990 [86], led the group 
to the identification of the mutation in HNF-1β gene located on chromosome 17q21.3. This 
finding was also published at the time our publication was coming out [87]. Clinical features in 
affected members included renal cysts, renal development abnormalities and diabetes. HNF-1β 
gene has been previously associated with “renal cysts and diabetes syndrome” (OMIM 137920), 
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the disorder comprising i) nondiabetic renal disease resulting from abnormal renal development 
and ii) disorder consistent with a diagnosis of maturity-onset diabetes of the young (MODY) 
[88, 89]. 
 
Uromodulin 
A mucoprotein was isolated by salt precipitation from human urine in 1950 by Tamm 
and Horsfall as a potent inhibitor of virus-mediated haemagglutination [90]. Same authors 
characterised the protein chemically two years later [91]. Gottschalk and Odin showed that 
about 30% of molecular weight (MW) of the protein, called from now on Tamm-Horsfall 
protein (THP), is formed by glycans with a high sialic acid content [92, 93]. A study of THP 
complexes with influenza virions by electron microscopy (EM) showed that the protein 
aggregates to fibrils with a diameter of 4-24 nm, further creating filamentous network [94]. 
Similar observations were made much later, in 1987 by Wiggins who studied THP aggregation 
under various conditions [95], and by Jovine et al. in 2002 [96]. The protein was further 
characterised by series of studies in 1970s [97-101]. They showed that uromodulin runs in SDS-
PAGE as a single band with MW of 80-90 kDa, is the most abundant protein in normal urine 
being excreted at the rate of about 50 mg/day and is present in urine of other mammals.  
 Interestingly, Muchmore and Decker reported in 1985 isolation of uromodulin, a 
glycoprotein with immunosuppressive properties in vitro, from urine of pregnant women. This 
protein has been studied independently [102-106], until Pennica et al. proved the identity of 
uromodulin and THP based on complementary DNA (cDNA) analysis [107]. In the following 
text, the name uromodulin (UMOD) will be used for this protein. 
 Since its discovery in 1950, uromodulin was extensively studied and hundreds of articles 
addressing its biochemistry, physicochemical properties, purification, determination, detection, 
biology, clinical relevance, and genetics have been reported. Its role has been assessed in 
defence against urinary tract infection (UTI) [108-110], cast nephropathy [111-115], urolithiasis 
[116-120], tubulointerstitial nephritis [121-125] and recently also in UAKD (see above). 
Uromodulin urinary excretion in various pathological conditions including nephropathy has also 
been evaluated [126-131]. Despite this extensive research, physiological role of uromodulin 
remains unclear.  Although its various potential roles were studied in vitro, due to its occurrence 
restricted to urinary tract and parts of nephron in vivo (see later), only some of them come to 
question. 
 Uromodulin precursor is composed of 640 amino acids (AA), based on cDNA analysis 
[107]. 48 of them are cysteine residues, all probably involved in disulfide bonds [97, 132]. 
Motifs identified in uromodulin structure include signal peptide (residues 1-24), three calcium-
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binding epidermal growth factor (cbEGF) domains (residues 31-64, 65-107 and 108-149), zona 
pellucida (ZP) domain (residues 334-585), the glycosyl phosphatidylinositol (GPI) attachment 
site (residue 614) and eight potential N-glycosylation sites 
(http://smart.embl.de/smart/show_motifs.pl?ID=P07911). There is a debate about the region 
between third cbEGF domain and ZP domain (residues 150-333). Although similarity searches 
showed no resemblance to any of known protein domains, some researches state that there is 
possibly a fourth EGF domain spanning residues 281-336 [83, 133, 134], or residues 297-335 
[135]. Meanwhile, Yang et al. reported in the debated region a new domain, spanning residues 
199-287, named D8C (Figure 3.1), that is in common to a new family of proteins including 
liver-specific ZP domain-containing protein (LZP), glycoprotein 2 (GP2), UMOD and several 
other uncharacterised proteins [136].  
 
                   
 
Figure 3.1 Domain structure of uromodulin. S - signal peptide, D8C - D8C domain, E - EGF domain, ZP - zona 
pellucida domain. Acquired from [136]. 
 
UMOD gene is located in cytogenetic band p12.3 on chromosome 16 according to 
Ensembl 
(http://www.ensembl.org/Homo_sapiens/geneview?db=core;gene=ENSG00000169344), UCSC 
(http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg18&acembly=full&hgt.out1=1.5x&est=dense&position=chr16:20271538-
20251874) and Entrez gene 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&lis
t_uids=7369) databases while in band 16p13.11 according to HGNC 
(http://www.gene.ucl.ac.uk/nomenclature/data/get_data.php?hgnc_id=12559) and Geneatlas 
(http://www.dsi.univ-paris5.fr/genatlas/fiche.php?n=825) databases. It spans 19.66 kilo-base 
pairs (kbp) of genomic sequence on minus strand 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NC_000016.8&from=20251874&to=202
71538&strand=2&dopt=gb). Two major transcripts encoding the full-length protein were 
observed. They differ in 5’ untranslated region (UTR) (Figure 3.2).  
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Figure 3.2 UMOD gene organisation. Two organisations representing two major transcripts are given. On top, 
there is the accession number of UMOD genomic sequence. Numbered arrows indicate the position of the gene on 
the sequence of chromosome 16 and its orientation. On the left side, GenBank accession numbers of two major 
mRNAs are given. On the right side, accession numbers of corresponding protein sequences and consensus coding 
sequences are given. Acquired from Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=7369).   
 
UMOD is expressed solely in the kidney [107] (http://symatlas.gnf.org/SymAtlas), 
namely in epithelial cells of the thick ascending limb of the loop of Henle (TALH) and early 
distal convoluted tubule (DCT), as showed by immunofluorescence and immunohistochemical 
studies [137-139]. During biosynthesis, uromodulin enters the endoplasmic reticulum (ER) and 
signal peptide is cleaved. In the ER, GPI anchor replacing C-terminal sequence is added 
probably to serine 614, disulfide bridges are formed and glycans are synthesised on seven of 
eight potential N-glycosylation sites [140, 141]. N-glycans are further trimmed in Golgi 
apparatus. Both glycans and GPI anchor act as a sorting signal for transport of the protein to the 
apical membrane of epithelial cells, where anchorage by means of GPI takes place [142, 143]. 
Uromodulin urinary excretion results from proteolytic cleavage at the site 66 residues upstream 
of GPI attachment site [144]. Overall, uromodulin found in urine is by 166 AA shorter than the 
precursor. 
The knowledge of the occurrence of uromodulin in TAL and subsequently in 
downstream parts of nephron and the whole urinary tract together with in vitro experiments 
raised the discussion about its role in vivo. The ability to bind uropathogenic strains of E. coli 
and abundance in urine predetermines uromodulin to be an effective agent in preventing 
adhesion of bacteria to glycoproteins and glycolipids at luminal plasma membrane. Its tendency 
to form large polymers in urine seems to favour this role by forming polyvalent ligand with high 
affinity [110, 145]. Involvement of uromodulin in urinary stone formation has been extensively 
studied and several studies showed its inhibitory effect on both calcium oxalate [146-148] and 
hydroxyapatite [149] crystals aggregation and growth. Among other polyanionic 
macromolecules present in urine, it may potentially act as substantial inhibitor of calcium 
crystallization in tubular fluid. Finally, specific localisation of uromodulin on luminal plasma 
membrane of TAL cells led to suggestion that it could take part in ion transport and maintaining 
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of counter current gradient in interstitium by formation of the water barrier in this segment of 
nephron. 
 
3.2 UMOD mutations in our cohort and their characterisation - Kidney International 70(6): 
p. 1155-1169, 2006 
 
3.2.1 Introduction 
 
 After identification of UMOD as the first gene underlying FJHN and MCKD2, we 
focused on its analysis with respect to our cohort, comprising that time 19 families. They came 
from our previous studies [10, 78] or were obtained from abroad but also several Czech families 
were newly recognised, while we quit working on Spanish families in the meantime [78]. 
 First, we were aimed at identification of UMOD mutations in out cohort and 
determination of true linkage rate and, second, at examination of the impact of these mutations 
on urinary UMOD excretion and on its processing in the kidney. Third, to be able to define and 
evaluate potential mechanisms involved in the disease pathogenesis, we intended to analyse 
affected tissues and to express and characterise identified mutations on cellular level in cell 
culture models.  
 
3.2.2 Specific methods 
 
3.2.2.1 Urine uromodulin and biochemical analyses 
 
Urine biochemical analysis 
 Urine total protein, creatinine, uric acid, magnesium, calcium, and phosphate were 
determined in random spot urine samples stored at -80°C by the Protein (urine) (BioSystems), 
CREA (Roche), UA Plus (Roche), Mg (Roche), Ca (Roche), and PHOS (Roche) kits, 
respectively, on a Hitachi Modular analyser (Roche). Sodium, potassium, and chloride were 
determined by ion-selective electrodes. Osmolality was determined by freezing point method 
using FISKE 2400 osmometer (Advanced Instruments-Fiske Associates).  
All these analyses were performed by Květa Pelinková, M.Sc. at the Institute of Clinical 
Biochemistry and Laboratory Diagnostics of General University Hospital and First Faculty of 
Medicine of Charles University in Prague. 
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Uromodulin enzyme-linked immunosorbent assay (ELISA) 
Buffers and solutions: 
TEA buffer: 0.5% (v/v) Triton X-100, 0.02 M EDTA, pH 7.5 adjusted by 1 M NaOH  (OP-274 
pH/Ion Analyser, Radelkis) [150].  
PBS: see chapter 5.3. 
Blocking buffer (PBS/2%BSA): 2% (w/v) BSA dissolved in PBS.   
Washing buffer (PBS-T): see chapter 5.3. 
Detection solution: 0.09% (w/v) o-phenylenediamine (OPD) and 0.03% (v/v) H2O2 
dissolved/diluted in PBS. 
Stop solution: 2 M H2SO4. 
 
 For quantitative analysis of urinary uromodulin, we established sandwich ELISA with 
mouse monoclonal anti-THP antibody (Cedarlane) as capture antibody, rabbit polyclonal anti-
THP antibody (Biogenesis) as detecting antibody and HRP-linked goat anti-rabbit IgG (Pierce) 
as secondary antibody. 
 Wells of F96 Maxisorp immuno-plate (Nunc) were coated by monoclonal anti-THP 
antibody by incubation with 100 µL of antibody dilution (1:9000 in PBS) overnight at 4°C. 
Following day, wells were washed three times by PBS-T with short horizontal shaking in 
between washes (ELx50™ Microplate Strip Washer, BioTek). Wells were then blocked by 100 
µL of Blocking buffer one hour at room temperature (RT). Following washing three times by 
PBS-T with shaking, urine samples diluted 1:250 in TEA buffer, calibration curve solutions and 
blanks were incubated in wells one hour at RT (100 µL per well). Calibration curve TEA 
solutions were prepared by serial dilution of uromodulin isolated from healthy male urine. 
Concentrations of 0 ng/mL, 1 ng/mL, 10 ng/mL, 50 ng/mL, 100 ng/mL, 140 ng/mL and 
160ng/mL were used. Following washing three times by PBS-T with shaking, polyclonal anti-
THP antibody diluted 1:5000 in PBS was added to wells (100 µL per well) and incubated one 
hour at RT. After washing three times by PBS-T with shaking, secondary HRP-conjugated 
antibody, diluted 1:10000 in PBS was added to wells (100 µL per well) and incubated one hour 
at RT. After final washing three times by PBS-T with shaking, 100 µL of detection solution was 
added to each well and the plate was put in the dark. After colour development, HRP reaction 
was stopped by 50 µL of the Stop solution. Plate was then analysed in automatic Spectra ELISA 
reader (SLT) at 492 nm with 620 nm filter and absorbance data were processed by KimW 
software (Schoeller Pharma). 
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Urinary sediment preparation 
 For qualitative analysis of uromodulin in urinary sediment, 35 µL of total urine was 
centrifuged at 5000g/10 minutes, supernatant was discarded, the pellet was resuspended in 1X 
SDS-PAGE sample buffer and analysed by SDS-PAGE followed by Sypro Ruby (Molecular 
Probes) staining or WB analysis. 
 
Urine concentration 
If concentrated for SDS-PAGE and/or WB analysis, 250 µL of total urine was loaded on 
Microcon YM-30 filter (Millipore) and 1.5 mL tube assembly and centrifuged at 12000g until 
volume on the filter reached less then about 50 µL. Ultrafiltrate was discarded and retentate was 
recovered to a new tube at 10000g. Aliquot equivalent to 10 µg of total protein (based on total 
urinary protein determination) was mixed with SDS-PAGE sample buffer, denatured at 100°C/5 
minutes (Dri-Block DB-3 thermostat, Techne) and analysed by SDS-PAGE followed by Sypro 
Ruby (Molecular Probes) staining or WB analysis. 
 
3.2.2.2 Recombinant uromodulin analysis 
 
Cultured cells lysis 
 Cells were harvested to PBS into 1.5 mL tubes, pelleted by centrifugation at 800g/5 
minutes and washed twice in PBS. The pellet was then resuspended in PBS with 1% (v/v) 
protease inhibitor cocktail (PIC) (Sigma) and sonicated twice for 30 seconds at output of 50% in 
the cuphorn filled with mixture of ice and water and connected to Ultrasonic Homogeniser 
(4710 series, Cole-Parmer Instrument Co). The suspension was then centrifuged at 14000g/5 
minutes at 4°C to remove cell debris. The supernatant was collected to a new tube and analysed, 
or stored at -20°C. 
 
Uromodulin deglycosylation  
 For analysis of glycosylation patterns of wildtype and mutant uromodulins expressed in 
cell cultures, we used GlycoProTM Enzymatic Deglycosylation Kit (ProZyme) according to 
manufacturer’s instructions. Briefly, cell lysate was mixed with 5X Reaction buffer (kit 
component) and Denaturation buffer (kit component) in 0.2 mL tubes (Eppendorf). Reaction 
mix was then denatured at 100°C/5 minutes in the thermal cycler (PTC-225 DNA Engine 
Tetrad, MJ Research), let cool down to RT and Detergent solution (kit component) was added. 
Glycosidases N-glycanase® PNGase F, Sialidase A™ or O-Glycanase® (kit components) or their 
combinations were added to reaction mix and incubated at 37°C/3 hours in biological thermostat 
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(BT 120 M, Ekom). Reactions were then mixed with 6X SDS-PAGE sample buffer, denatured 
at 100°C/5 minutes in the thermal cycler and analysed by SDS-PAGE and WB. 
 
Antibodies fluorescein labelling  
 For fluorescent automated cell sorting (FACS) analysis, we conjugated polyclonal anti-
THP antibody (Biogenesis) with fluorescein by Fluorescein Protein Labelling Kit (Roche) 
according to manufacturer’s instructions. Briefly, 20 mg/mL FLUOS reagent [5(6)-
carboxyfluorescein-N-hydroxysuccinimide ester] solution was prepared by dissolution of 
lyophilised reagent in dimethyl sulfoxide (DMSO). 1 mg of polyclonal antibody was dissolved 
in 1 mL of PBS (kit component) and 7.9 µL of FLUOS solution was added. Reaction mix was 
incubated at RT protected from light during gentle stirring in rotamixer (Multi RS-60, Biosan). 
Meanwhile, Sephadex G-25 column (kit component) was blocked by Blocking reagent (kit 
component) and rinsed by PBS several times. Reaction mix was then applied onto the column to 
remove non-reacted FLUOS. Labelled antibody was eluted from the column by PBS and 
fractions of about 0.5 mL were collected. The amount of antibody in individual fractions and 
labelling yield were calculated based on extinctions at 280 nm (protein) and 495 nm 
(fluorescein) measured by means of photometer (UV/VIS Spectrometer UV4-100, Unicam Ltd.) 
and applying the equation provided by the manufacturer. 
 
Other used methods are described in General methods section, chapters 5.1 - 5.3. 
 
3.2.3 Results and discussion 
 
 In this work, we completed molecular genetic examination of altogether 19 families 
[151]. In summary, we performed linkage analysis in all families to all known FJHN/MCKD 
loci, and analysed the UMOD genomic sequence. We found the genetic linkage to the UMOD 
candidate locus on chromosome 16p12 in nine families and excluded this linkage in three 
families based on LOD ≤ -2 criterion. In the rest of families, no haplotypes consistent with the 
linkage to any of currently known FJHN/MCKD loci were detected.  
 UMOD gene sequence analysis revealed missense mutations in six of nine families 
linked to 16p12 locus. In remaining three families, in addition to coding sequence, 5.7 kbp of 
UMOD promoter region was analysed. Here, several family-specific nucleotide changes were 
identified in two of these families, but their potential pathogenic effect was not further 
investigated.    
 18 
 Of six missense mutations identified, three were reported previously and three were 
novel. To examine their functional consequences, we transiently transfected tissue culture cells 
by wildtype and all six mutant cDNA constructs. By time-course FACS experiments, we 
investigated the dynamics of the amount of uromodulin expressed on plasma membrane. All 
mutant proteins had decreased ability to reach the plasma membrane but to a different extent. 
Accordingly, it was possible to distinguish two separate groups of mutants, one with pattern 
similar to wildtype protein but still lower exposition on plasma membrane (group I) and second 
(group II) with even lower ability to reach the plasma membrane as compared to both wildtype 
and group I proteins. 
 We then performed biochemical characterization of all transiently expressed mutant 
proteins by deglycosylation and WB. Wildtype protein was detected on WBs of cultured cells 
lysates in two separate zones obviously composed of several not properly resolved bands, 
probably representing different degrees of glycans processing. This pattern was observed also in 
other studies [140, 152-154]. It was also shown that lower MW zone represents ER precursor 
lacking branched sialic acid chains added as late as in Golgi apparatus [152, 154], while higher 
MW zone represents properly glycosylated, GPI modified and membrane anchored uromodulin. 
The precursor probably accumulates in transient cultures due to protein overexpression as we 
observed only negligible amounts of it in lysate of wildtype uromodulin stable cell line. All 
group I mutants showed similar level of fully processed protein as the wildtype on WB. On the 
other hand, group II mutants showed low amounts of fully processed protein. Regarding 
precursor form, one group I mutant and all group II mutants manifested zone of somewhat lower 
molecular weight compared to wildtype and other group I mutants.   
Complete deglycosylation of all expressed proteins followed by WB produced double 
band of about 30% lower MW compared to untreated proteins in case of wildtype and group I 
mutants. Observed polypeptides most probably represented uromodulin precursor (higher MW) 
and the precursor after C-terminus cleavage and GPI anchor attachment (lower MW). 
Incomplete processing might be again ascribed to protein overexpression [155, 156]. On the 
contrary, no GPI processing could be observed in group II mutants and it was also less evident 
in one group I mutant. These results were in good agreement with the experiment in which were 
HeLa cells expressing uromodulin treated by the inhibitor of GPI synthesis [153].  
Sialic acid specific deglycosylation of mutant proteins resulted in three different patterns. 
Two group I mutants produced, likewise the wildtype protein, single zone corresponding to the 
ER precursor, while other mutants produced additional zone of two different lower MWs. This 
suggested that polypeptides not properly glycosylated in the ER reached the Golgi apparatus 
where sialic acid modification takes place.  
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Immunofluorescence analysis of all transiently expressed proteins showed plasma 
membrane localisation and almost no detectable intracellular retention of wildtype protein while 
all mutant proteins exhibited granular retention in the ER. It was, however, less apparent in 
group I mutants. Group I mutants also showed considerable plasma membrane display contrary 
to group II mutants that showed almost no localization to plasma membrane.  
To elaborate the idea of altered uromodulin biology to be common to all UAKD cases 
irrespective of underlying genetic defect, we performed in this study extensive qualitative and 
quantitative analysis of urinary uromodulin excretion in 12 and 15 families, respectively. Both 
WB and ELISA revealed significantly decreased urinary uromodulin excretion in all but one 
examined family. In addition, we performed immunohistochemical analysis of uromodulin and 
epithelial membrane antigen mucin (MUC1) in kidney sections representing four different 
genetic defects leading to UAKD. We found abnormal uromodulin staining patterns including 
massive intracellular accumulation in case of UMOD mutation and presence in hyaline casts 
accompanied by low intracellular positivity, irregular staining pattern or strongly reduced 
expression in patients with not yet identified genetic defect. Interestingly, uromodulin staining 
patterns were mostly correlated with those of MUC1. 
Ultrastructural EM examination of kidney specimen from patient with one of group I 
mutant showed, besides numerous morphological abnormalities, large amounts of fibrillar 
material stored in the ER of TALH epithelial cells. By means of immunofluorescence 
colocalisation studies of kidney sections from the same patient, we were able to show that stored 
material was uromodulin. 
 
UMOD mutations analysis and functional studies in other families 
Currently there have been reported about 60 FJHN kindreds of various ethnic origin, but 
it is clear that including unpublished data there are much more kindreds being studied, as for 
example in the United Kingdom alone about 70 investigated kindreds were reported [23] and 
our cohort comprises more than 30 kindreds. 
Following the initial report of Hart et al. [80], a lot of studies identified UMOD 
mutations in formerly as well as newly described FJHN/MCKD families. Interestingly, 
Rampoldi et al. in 2003 [133] included to UMOD mutation analysis in their FJHN and MCKD2 
families also a family, originally reported by Gusmano et al. in 2002, with autosomal dominant 
glomorulocystic kidney disease (ADGCKD) [157]. Re-evaluation of clinical status in this family 
revealed hyperuricaemia and isosthenuria in affected members. GCKD associated with maturity-
onset diabetes was excluded by HNF-1β sequencing and glucose tolerance test. Although 
linkage to 16p12 locus was not significant, causal mutation in UMOD gene was identified in this 
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family and thus a new Mendelian disorder was established (OMIM 609886). Lens et al. reported 
additional GCKD family with UMOD mutation in 2005 [135]. 
 Up to date, 42 different mutations in the UMOD gene were reported in the literature [13, 
80, 82, 133-135, 151, 158-164]. Importantly, the rate of linkage to 16p12 region in those studies 
was found to be 50% at most, reflecting thus underlying genetic heterogeneity. In the rest of 
families, no significant linkage was detected. Moreover, UMOD mutations were not found in all 
16p12 linked families, suggesting either false positivity of linkage analysis, yet unidentified 
mutations or existence of another disease gene in this region. 
Most of UMOD mutations (39) are missense. Remaining three mutations are in-frame 
deletions leading to the loss of 5 to 33 AA. They are summarised in Table 3.1. UMOD 
mutations show clustering in two neighbouring exons  (in the literature referred to as exons 4 
and 5, respectively, based on Hart’s et al. gene organization analysis, which is currently invalid) 
and more than 50% of missense mutations affect one of 48 conserved cysteine residues.  
 
Table 3.1 Summary of reported uromodulin mutations.  
Mutation 
cDNA Protein 
Exon Reference 
c.95G>A p.C32Y 3 [151] 
c.156T>G  p.C52W 3 [161] 
c.176A>C  p.D59A 3 [159] 
c.299T>G p.C77G 3 [164] 
c.230G>A p.C77Y 3 [158] 
c.278_289del/insCCGGCTCCT  p.V93_G97del/insAASC 3 [160] 
c.307G>T p.G103C 3 [80] 
c.334T>C  p.C112R 3 [159] 
c.376T>C  p.C126R 3 [158] 
c.383A>G  p.N128S 3 [158] 
c.403T>A  p.C135S 3 [161] 
c.443G>A  p.C148Y 3 [80] 
c.444T>G  p.C148W 3 [133] 
c.449G>C  p.C150S 3 [133] 
c.509G>A  p.C170Y 3 [159] 
c.529_555del  p.H177_R185del 3 [80] 
c.553C>G  p.R185G 3 [165] 
c.553C>A  p.R185S 3 [159] 
c.563_661del p.E188_L221del 3 [159] 
c.584G>T p.C195F 3 [161] 
c.605G>C p.W202S 3 [161] 
c.610C>G  p.R204G 3 [159] 
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c.649T>C  p.C217R 3 [80] 
c.649T>G  p.C217G 3 [159] 
c.665G>C p.R222P 3 [159] 
c.668G>A p.C223Y 3 [163] 
c.674C>T p.T225M 3 [159] 
c.674C>A p.T225K 3 [160] 
c.686T>C p.M229R 3 [151] 
c.707C>T p.P236L 3 [161] 
c.707C>G p.P236R 3 [162] 
c.744C>G p.C248W 3 [160] 
c.764G>A p.C255Y 3 [158] 
c.817G>T p.V273F 3 [151] 
c.844T>C p.C282R 3 [160] 
c.898T>G p.C300G 4 [158] 
c.899G>A p.C300Y 4 [82] 
c.920A>C p.K307T 4 [13] 
c.943T>C p.C315R 4 [133] 
c.947A>C p.Q316P 4 [135] 
c.950G>A p.C317Y 4 [133] 
c.1039T>G p.C347G 5 [134] 
Positions of mutations in cDNA sequence are indicated “c.” (base counting starts at adenosine in the initiation ATG 
codon). Positions in the protein sequence are indicated “p.”.  Exon counting is based on GeneBank sequence 
NM_003361.2.  
 
First functional studies on UMOD mutations reported Dahan et al. and Rampoldi et al. in 
2003. By means of kidney sections immunohistochemistry and WB of urines, Dahan et al. 
showed that UMOD mutations lead to gross accumulation of uromodulin in TALH epithelial 
cells, together with a drop in the urinary excretion of the protein [159]. Interestingly, 
biochemical analysis including SDS-PAGE of urines under both reducing and non-reducing 
conditions and after deglycosylation together with mass spectrometry analysis of urines showed 
that only the wildtype uromodulin is excreted by patients. These observations suggested that 
UMOD mutations affect the function and expression of uromodulin accompanied by abnormal 
accumulation of the mutated protein in tubular epithelial cells.  
Rampoldi et al., who in a more detail studied effect of cysteine mutations on uromodulin 
trafficking in transiently transfected tissue culture cells [133], supported results of Dahan et al. 
Using time-laps transfection experiments, colocalisation studies and FACS analysis, they 
showed that compared to a wildtype protein, mutant isoforms were delayed in transport to the 
plasma membrane with a prolonged retention time in the ER, probably reflecting an abnormal 
folding of the protein due to the inability to form intrachain disulfide bridges. This behaviour 
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was truly simulated by culturing cells expressing wildtype protein in reducing conditions, 
proving thus the importance of cysteine residues for proper folding and maturation of 
uromodulin. Immunohistochemistry of kidney sections and WB analysis of uromodulin urinary 
excretion provided results consistent with Dahan et al. Heaps of fibrillar material most probably 
coinciding with uromodulin deposits were visualised in the ER of TALH cells by EM.  
Decrease in urinary excretion of uromodulin, which seems to be a consequence of its 
altered processing, was further examined by Bleyer et al. [165]. They tested a set of patients 
from several families harbouring various UMOD mutations, unaffected family members and 
unrelated controls. They found significant decrease of urinary uromodulin excretion independent 
on age, gender or level of renal involvement in the group of individuals with mutation compared 
to groups with no mutation. 
 Data on urinary uromodulin excretion from all three studies revealed that the extent of 
reduction is greater than could be expected for heterozygous mutation status. This finding gave 
support for negative dominant effect of UMOD mutations, in which the mutated protein 
interferes with the wildtype protein and blocks its proper processing. Although simulation of 
heterozygous state by cotransfecting tissue culture cells by both mutant and wildtype constructs 
was not fully consistent with this model, it should not be rejected, as the situation in this kind of 
experiment is obviously very different from the situation in the kidney [133]. 
Group of doctor Rampoldi further reported functional consequences of the only missense 
mutation identified so far to involve ZP domain of uromodulin [134]. They again used FACS 
and immunofluorescence analysis of transfected tissue culture cells to investigate mutant protein 
dynamics. As in their previous study, they found that this cysteine mutation caused a delay in 
transport to plasma membrane due to its retention in the ER. 
Behaviour of uromodulin mutants revealed by tissue culture and immunohistochemistry 
studies suggested consideration of UAKD as the ER storage disease. The hypothesis that 
apoptosis caused by ER storage of mutant uromodulin may be involved in UAKD pathogenesis 
was tested by Choi et al. [152]. Studying two cell lines stably transfected by both wildtype and 
two mutant uromodulin cDNAs, they showed accumulation of mutant proteins in the ER and 
their decreased excretion to culture media by means of immunofluorescence, selective 
deglycosylation, ELISA and WB. Annexin V and propidium iodide assay with FACS analysis 
proved significant increase in early apoptotic signal in both mutant cell lines, indicating a 
possible role of apoptosis in progressive renal damage in UAKD. Evaluating the influence of 
several chemical chaperones, they were able to show that colchicine and sodium 4-
phenylbutyrate significantly improved delivery of mutant proteins from ER to plasma 
membrane as well as cell viability. 
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Right after our study, further reports addressing functional consequences of UMOD 
mutations appeared and their conclusions were generally concordant with our results. Doctor 
Rampoldi’s group provided extensive study of intracellular trafficking and sub cellular 
localization of wildtype and 12 mutant uromodulin proteins [162]. Three of these mutants were 
characterised in a more detail by numerous experimental techniques. Besides methods used in 
other studies, they employed live imaging with fluorescence recovery after photo bleaching 
(FRAP) and immunogold-EM analysis to study real-time dynamics of uromodulin intracellular 
traffic and to quantitatively assess the intracellular distribution of transiently expressed proteins. 
Contrary to our results, they showed that at least in three mutants investigated in a detail, GPI 
modification was not altered as revealed by comprehensive phosphatidylinositol-phospholipase 
C (Pi-PLC) assay.           
Jennings et al. aimed to characterise the effects of UMOD mutations on membrane 
targeting and direction of secretion [166]. They employed stably transfected and polarised renal 
epithelial cell cultures to study two uromodulin mutants in a detail. By means of 
immunohistochemistry and quantitative immunoassay, they showed the two mutants to be 
properly targeted to apical membrane, although their secretion to apical compartment was less 
efficient compared to wildtype protein, most probably due to decreased synthesis rate. By 
caspase 3 and proteasome inhibition studies, they showed that both mutants did not significantly 
activate apoptosis and proteasome-dependent degradation did not contribute significantly to 
their amelioration from the cytoplasm. 
 
UMOD knockout mice models 
 Up to date, two UMOD-/- mice models were generated by independent groups [167, 168]. 
In both of them, targeted disruption of certain parts of the UMOD gene led to a complete shut 
down of its expression. Examination of both models proved that knockout (KO) mice suffered 
significantly more frequently from urinary tract infections. This observation confirmed one of 
the long proposed physiological roles of uromodulin in host defence against type 1-fimbriated E. 
coli [110]. Indeed, it was shown that uromodulin could act as a general host defence factor 
against UTI [169].  
Second extensively discussed topic, the role of uromodulin in calcium oxalate stones 
formation was also evaluated using this model. Mo et al. showed that considerable portion of 
KO mice on special diet spontaneously formed calcium oxalate stones in the collecting duct of 
the medulla, while stone formation has never been observed in wildtype littermates on the same 
diet [170]. This observation supported hypothesis of inhibitory effect of uromodulin on kidney 
stones formation.  
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Several issues related to UAKD pathophysiology were also investigated. Examination of 
renal histological samples derived from these mice showed no developmental or morphological 
changes typically seen in UAKD patients [167, 168], even in several years course [171, 172]. 
This observation is not surprising, as UMOD-/- mice do not represent truly the situation in 
UAKD patients’ kidneys in which intracellular accumulation of mutated protein is meant to be 
the primary cause of morphological changes. The same difference most probably accounts also 
for the absence of kidney stones and increased UTI events in UAKD patients that excrete 
certain, yet sufficient amount of wildtype protein to their urine.  
Examination of steady state electrolyte handling showed no abnormalities in KO mice 
[172]. However, creatinine clearance was significantly reduced. Impaired urine concentration 
ability, a feature found with high prevalence in UAKD patients, was observed under water 
deprivation conditions. Moreover, biochemical and histochemical quantitative approaches used 
to asses changes in the biosynthesis of proteins related to NaCl transport along the nephron 
revealed upregulation of major distal transporters and downregulation of juxtaglomerular 
apparatus (JGA) components, consistently with the adaptation to altered NaCl reabsorption in 
the TALH. The same authors further observed significant difference in ratio of urinary sodium 
concentrations and urinary urate concentrations between KO and wildtype mice [84]. KO mice 
excreted less uric acid for a given amount of sodium, a result consistent with previously 
observed dysregulation of NaCl transport-related proteins. Interestingly, mRNA levels of PT 
urate transporters were found to be normal, suggesting that the upregulation of their expression 
is not responsible for increased urate reabsorption. 
 
UMOD related pathogenesis of UAKD  
 As briefly discussed in chapter 1.1, major biochemical (decreased urine concentration 
ability, hyperuricaemia, decreased FEur) and histological (tubulointerstitial fibrosis, 
cystogenesis) features of UAKD has always been difficult to establish. Opinions on pathogenic 
mechanisms before invention of relationship between FJHN/MCKD/GCKD and uromodulin 
were also summarised.  
Idea of gain-of-function mutation in urate/anion transporter became less promising after 
identification of second urate transporter of PT, URAT1 [173]. URAT1 gene was localised to 
chromosome 11q. However, neither 17p (hUAT locus) nor 11q loci have been associated with 
UAKD so far.  
Hypothesis of impaired renal hemodynamics as primary cause of hyperuricaemia was 
disputed by London group [23, 174] and defended by its authors [175]. However, this argument 
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has faded away after identification of causative UMOD mutations also in kindreds studied by 
authors of this hypothesis [158].  
At the same time, discussion about efficacy of allopurinol treatment and related role of 
hyperuricaemia in the disease progression raised again. Fairbanks et al. reported results of long-
term allopurinol treatment study supporting its beneficial role in ameliorating the progression of 
renal disease [174]. They stressed, however, that efficacy of the treatment decreases with the 
progression of renal impairment and is dependent on patient compliance as well. This 
underscored the importance of pre-symptomatic diagnosis, especially in children, as successful 
management may prevent or delay dialysis and ultimate renal transplantation. On the contrary, 
studies of two other groups could not confirm beneficial role of allopurinol [175-178]. 
Nevertheless, in view of London group, this was due to lack of compliance to the treatment in 
case of Bleyer et al. and late therapy commencement in case of Puig et al. [23, 179].  
Regarding the primacy of hyperuricaemia in pathogenesis of UAKD, in the view of 
Bleyer et al. this discussion also lost significance as hyperuricaemia is secondary to UMOD 
dysfunction, the primary cause of the disease [177].  
Nevertheless, identification of mutations in UMOD gene as a cause of UAKD in 25% to 
50% of patients in different series [23] has not shed much more light on UAKD pathogenesis. 
There cannot be found a direct link between impaired uromodulin biology and decreased FEur 
and other major clinical findings. However, as we propose the impaired uromodulin biology to 
be responsible for most of the cases, it makes sense to discuss indirect mechanisms leading from 
UMOD dysfunction to major symptoms.  
 
Cellular pathology 
Right after invention of causative UMOD mutations in a proportion of 
FJHN/MCKD/GCKD families, experiments addressing cellular effects of these mutations 
started. Immunohistochemical analyses of kidney tissue sections from UAKD patients showed 
large uromodulin deposits in cytoplasm. They were associated with the ER and visualised as 
stacks of fibrillar material by the electron microscopy [133, 151]. Several cell tissue culture 
models of different mutations showed decreased presentation of uromodulin on the plasma 
membrane compared to wildtype due to decreased processing rate and accumulation in the ER. 
This effect was initially observed with mutations affecting conserved cysteine residues [133], 
but later on has been proved in all mutations studied so far. Nevertheless, there is a great 
variability among mutations suggesting different severity of molecular lesion and possibly 
different pathogenic mechanisms [151, 162]. However, genotype-phenotype correlations for 
individual UMOD mutations are lacking at present due to small number of families and 
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inadequate clinical data. Such a correlation could have been made only on cellular level in a 
single case where results from cell culture model corresponded well with immunohistochemical 
and ultrastructural findings in kidney tissue from the patient [151].  
 In our study of six UMOD mutations, based on biochemical and immunofluorescent 
analyses of transient cell cultures, we were able to outline two different pathogenic mechanisms, 
both consistent with negative dominant model [151]. In mutants susceptible to GPI 
modification, which are able to exit the ER, enter the secretory pathway and reach the plasma 
membrane, underlying pathogenic mechanisms might be impaired intracellular trafficking, 
decreased ability to be internalised and exposed on the plasma membrane or inability to form 
protein filaments on the plasma membrane. In vivo, impaired trafficking might be caused by co-
occurrence of mutant and wildtype protein in transport vesicles [180]. The same co-occurrence 
on the plasma membrane may hamper uromodulin polymerisation and filaments formation [96], 
compromising thus the biological function of the protein. In mutants not susceptible to GPI 
modification, proteins with uncleaved GPI signal peptide probably cannot escape and 
accumulate in the ER [156] causing the expansion of the organelle and consequent triggering of 
ER stress signalling pathways [181, 182].  
 Generally, ER stress is a condition resulting from compromised ER functions for any 
reason. The most common cause of ER stress, accumulation of misfolded or malfolded proteins 
in the lumen of the organelle, induces stress response traditionally referred to as unfolded 
protein response (UPR). The ER has resident machinery of chaperones that assist proteins to 
acquire proper conformation. If the protein fails to acquire its natural conformation for any 
reason, it is degraded by the process called ER-associated degradation (ERAD). The process 
involves translocation of the protein through the ER membrane to cytoplasm, polyubiquitination 
and degradation in the proteasome. However, if the capacity of ER chaperones and ERAD is 
exceeded, accumulation of the protein in the ER occurs and UPR is triggered. UPR activation 
leads to downregulation of overall proteosynthesis to decrease the protein load on the ER and 
upregulation of ER chaperones and ERAD components to deal with accumulated protein. If 
these compensatory mechanisms do not solve the situation, apoptotic mechanisms are activated 
as the last line of defence. Currently, there are known three different UPR signalling pathways 
and several UPR-related apoptotic pathways. Their role in UAKD pathogenesis is, however 
poorly understood. Choi et al. showed significant increase in early as well as late apoptotic 
signals in two cell culture models of two UMOD mutations and reported reversibility of 
apoptotic changes by chemical chaperones [152]. On the other hand, Jennings et al. did not 
proved activation of caspase 3-dependent apoptotic pathway in two different cell culture models 
and two different mutations [166]. They also excluded involvement of ERAD in amelioration of 
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mutant uromodulin from the ER by proteasome inhibition studies. More studies in this area are 
therefore needed to evaluate the role of ER stress response and apoptosis in pathogenesis of 
UAKD. 
 A group of diseases in which abnormal ER accumulation of proteins occurs as a 
consequence of any ER related malfunction are called ER storage diseases (ESRD). There are 
known seven groups of those disorders caused by mutated cargo molecules (four subgroups), a 
defect in ER folding or transport machinery, a defect in UPR signalling or by inhibition of UPR-
regulated adaptive responses [183]. According to this division, UAKD might be considered as a 
member of one of the first group’s subgroup characterised by non-functional mutant cargo 
molecule that is not susceptible to ERAD. This proposal, however, needs to be evaluated in 
further studies. 
  
Pathophysiology 
Hyperuricaemia in UAKD is caused by increased tubular reabsorption of urate, as judged 
from normal urinary urate excretion in patients on purine free diet [23]. It is found in 65-75% of 
cases [83]. There was found an inverse correlation between urine osmolarity and uricaemia [83], 
inverse correlation between FEur and creatinine clearance [178] and we found positive 
correlation between urinary urate and uromodulin concentrations in UAKD patients [151]. 
These results suggest implication of blood volume, renal function and uromodulin in abnormal 
urate handling. The influence of uromodulin is considered indirect as urate reabsorption, 
secretion and postsecretory reabsorption are believed to be finished on the level of PT while 
uromodulin expression was repeatedly shown to be confined to TALH and early DCT [145]. 
However, minor UMOD expression was recently found also in PT cells [184] and therefore 
possibility of direct involvement of urate transport by mutant uromodulin should not be 
dismissed entirely. Most discussed hypothesis of hyperuricaemia in UAKD is based on long 
proposed function of uromodulin in salt uptake and formation of water barrier in TALH [185, 
186]. Disruption of this barrier should lead to increased water uptake in this segment, which 
would compromise sodium reabsorption by the Na-K-2Cl cotransporter and maintenance of 
interstitial countercurrent gradient. This would cause not only the compensatory increase in 
sodium reabsorption in PT but also the impaired urine concentration ability and volume 
contraction and consequently the increased reabsorption of urate [83, 133, 187, 188]. This 
hypothesis was supported by results from UMOD KO mice that showed decreased urine 
concentration ability under water deprivation [172] and decreased excretion of urate relatively to 
the excretion of sodium [84]. Although it is currently not known a sodium-linked urate 
transporter in PT, such a transporter or transporter upregulated together with PT sodium 
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transport might to be invented. Alternatively, urate may non-specifically permeate along with 
water through disrupted water barrier in the TALH. Another possibility is a defect in urate 
secretion or enhanced postsecretory reabsorption of urate linked to the absence of uromodulin in 
distal tubules or collecting duct. Effect of uromodulin on distal urate handling through direct 
binding of urate was nevertheless excluded by uromodulin-urate binding assays [189]. 
Regarding decreased urine concentration ability, we hypothesise that impaired water 
reabsorption may be due to enhanced urine flow consequently to the absence of uromodulin in 
urine and compromised cast formation in distal and collecting tubules. This notion is supported 
by abnormalities in urine flow and dysregulation of major distal tubule transporters observed in 
KO mice [172].          
Tubulointerstitial nephritis in UAKD is probably not due to a mere lack of uromodulin in 
the kidney. KO mice lacking uromodulin entirely did not show any kidney tissue abnormalities 
even after several years follow up [171, 172]. Most common opinion on development of 
histological findings in UAKD is that they are the result of events following abnormal 
processing and accumulation of uromodulin in the ER of respective cells. For example, massive 
cytoplasmic storage of uromodulin could ultimately lead to apoptosis that would lead to 
fibroblast infiltration and induction of interstitial inflammatory response by the cell debris. 
Moreover, inflammation caused by release of uromodulin aggregates to the interstitium could 
also play role. Several studies described abnormal interstitial deposits of uromodulin in various 
conditions where tubulointerstitial fibrosis occurs, including MCKD [124, 190, 191]. 
Uromodulin was shown to stimulate cytokine production in monocytes and granulocytes [192-
194]. Moreover, tubulointerstitial nephritis with presence of anti-uromodulin antibodies was 
experimentally induced in rabbits and rats administrated by uromodulin [195, 196]. 
Alternatively, abnormal processing of uromodulin in TALH cells could lead to loss of polarity 
and mistargeting of the protein to interstitium. However, available data on 
immunohistochemical staining of uromodulin in kidney sections from UAKD patients did not 
prove its interstitial localisation [81, 82, 133, 151, 159]. Yet another possibility is that 
inflammatory signals initiates in uromodulin storing cells. It was shown that one of the UPR 
pathways can lead to nuclear factor κB (NF-κB) activation, a well-known mediator of 
inflammatory and immune responses [197-199].  
Formation of cysts is only occasionally observed in UAKD patients [23, 59, 83]. They 
were observed in two variants, as glomerular cysts in GCKD patients and as medullary cysts in 
MCKD2 patients with UMOD mutations. Different cystic presentation of UMOD mutations 
suggests involvement of modifier genes or two-hit mechanism. Essentially, there is currently 
impossible to find the link between uromodulin dysfunction and cysts formation. Medullary 
 29 
cysts originate from tubules enlargements and remain connected to the original nephron. It was 
speculated that tubule swelling might occur because of water income due to impaired 
uromodulin water barrier in the TALH [83]. On the other hand, formation of glomerular cysts 
found invariably in GCKD patients with UMOD mutations most probably follows different 
mechanism [47, 135]. It could be the result of tubular obstruction, urine reflux and increased 
pressure in Bowman’s space [83, 133]. In favour of this hypothesis could speak abnormal 
presence of uromodulin in glomerular cysts of patients with GCKD of unknown molecular basis 
[124]. However, this has not been observed in GCKD due to UMOD mutations so far [83].  
 In conclusion, pathogenesis of UAKD is mostly unclear and it will require further formal 
studies of urate tubular handling as well as specific studies addressing cellular effects of UMOD 
mutations. 
 
3.3 UMOD in other diseases with renal involvement - Journal of Inherited Metabolic 
Disorders, 31(4): p. 508-517, 2008 
 
3.3.1 Introduction 
 
 In previous chapters, I described current knowledge of UMOD processing in UAKD. We 
were further interested if changes in UMOD expression, cellular localisation and urinary 
excretion are specific to FJHN/MCKD/UAKD and what is the range of these changes in various 
genetic diseases with severe renal involvement. Examination of these issues was enabled by our 
affiliation to Institute of Inherited Metabolic Disorders, where are several such diseases under 
investigation. In the first round, we focused on Fabry disease (OMIM 301500), caused by α-
galactosidase A (GLA) (EC 3.2.1.22) deficiency, in which renal involvement is very well 
documented and which has a long investigation history at our institute. 
 
3.3.2 Specific methods 
 
Total urine deglycosylation  
 For analysis of uromodulin glycosylation patterns in urines, we used GlycoProTM 
Enzymatic Deglycosylation Kit (ProZyme) according to manufacturer’s instructions. Briefly, 
spot urine sample was thawed, thoroughly vortexed and 15 µL were mixed with 5X Reaction 
buffer (kit component) and Denaturation buffer (kit component) in 0.2 mL tubes (Eppendorf). 
Reaction mix was denatured at 100°C/5 minutes in the thermal cycler (PTC-225 DNA Engine 
Tetrad, MJ Research), let cool down to RT and Detergent solution (kit component) was added. 
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Glycosidase N-glycanase® PNGase F was added to reaction mix and incubated at 37°C/3 hours 
in biological thermostat (BT 120 M, Ekom). Reactions were then mixed with 6X SDS-PAGE 
sample buffer, denatured at 100°C/5 minutes in the thermal cycler and analysed by SDS-PAGE 
and WB. 
 
Urine concentration 
 If concentrated for SDS-PAGE analysis, 500 µL of total urine was loaded on Microcon 
YM-50 filter (Millipore) and 1.5 mL tube assembly and centrifuged at 10000g until volume on 
the filter reached about 20-30 µL. Ultrafiltrate was discarded, retentate was recovered to a new 
tube, mixed with SDS-PAGE sample buffer, denatured at 100°C/5 minutes (Dri-Block DB-3 
thermostat, Techne) and separated by SDS-PAGE followed by Coomassie blue R 250 staining, 
as described in chapter 5.2. 
 
Other methods applicable to this section are described in General methods, chapters 5.1 - 5.3. 
 
3.3.3 Results and discussion 
 
 For urinary UMOD excretion analysis, we selected 15 male patients to cover the age 
range, severity of symptoms and treatment regimens. We also randomly selected 9 female 
carriers for comparison and for completeness’ sake. 
First, we analysed pretreatment urine samples by WB and found significant quantitative 
and qualitative changes in urinary UMOD excretion in about half of the hemizygous male 
patients as well as in 7 out of 9 heterozygous carriers. These changes consisted in strongly 
decreased or reduced UMOD excretion and presence of abnormal anti-UMOD immunoreactive 
protein of lower molecular mass or combination of both. 
Deglycosylation of the urine from one patient with abnormal anti-UMOD 
immunoreactive protein suggested that it was not UMOD glycoform but rather different form of 
the protein.  
We recovered normal as well as abnormal UMOD proteins from the concentrated urine 
of the same patient by SDS-PAGE and subjected them to mass spectrometry analysis. Abnormal 
polypeptide was shown to be UMOD lacking its C-terminal part, with cleavage site located 
somewhere between AA residues K432 and R449 (see chapter 3.1.3) 
 Our male patients were enrolled in different types of clinical trials - one using substrate 
reduction therapy (SRT) with ceramide glucosyltransferase (EC 2.4.1.80) inhibitor and two 
using enzyme replacement therapy (ERT) by different recombinant GLA preparations. To assess 
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the impact of different treatment regimens on UMOD excretion and processing, we analysed 
urine samples collected during individual courses along with pretreatment samples by WB. 
Abnormal processing clearly normalised in all patients on both ERTs, while the effect of SRT 
was not as striking. 
 To shed light on observed abnormalities in UMOD excretion and processing, we 
examined UMOD immunohistochemical and Gb3 storage patterns in different parts of the 
nephron in kidney sections from three untreated patients (different from those 15 male and 9 
female patients mentioned above). We observed abnormal UMOD localisation in TALH and 
collecting duct, with UMOD expression in TALH epithelial cells to be inversely proportional to 
the degree of storage. 
  Based on our results, we were not able to define the site and mechanisms leading to 
observed abnormalities in urinary UMOD processing. Basically, it may occur either 
intracellularly (for example due to storage-related proteasome and/or specific protease 
activation) or extracellularly, on the cell membrane as a result of abnormal ectodomain 
shedding. This process could be activated by glomerulopathy-related changes in tubular fluid 
composition altering the tertiary structure of UMOD and making it susceptible to aberrant 
cleavage. Another possibility might be that alternative processing takes place in desquamated 
storing epithelial cells.  
Reduced urinary UMOD excretion observed in some patients may be considered as a 
consequence of inverse proportion of the storage and UMOD expression, while normal, fully 
processed UMOD is most probably produced by cells not affected by the storage. 
In this work, we showed for the first time a biochemically defined alteration of tubular 
cell biology reflecting the process of storage in defined parts of the nephron. Our results warrant 
evaluation of tubular functions in Fabry disease patients and suggest UMOD as a potential 
biochemical marker of the therapy response.   
 
3.4 Identification of a new UAKD locus - Kidney International 68(4): p. 1472-1482, 2005 
 
3.4.1 Introduction  
 
Beside our work on UMOD-related issues (search for and collection of new families, 
mutation analysis, characterisation of mutations, the role of UMOD in other kidney-involved 
diseases), we attempted to identify new FJHN/MCKD loci in those families not linked to any of 
previously known loci on chromosomes 16p12 and 1q21. For this study, we selected large and 
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promising Belgian family (BE1) from our previous study [78], in which we tested only the 
linkage to locus 16p12, to perform genome-wide linkage analysis.  [81] 
 
3.4.2 Specific methods 
 
 Specific methods applicable to this section are described in chapter 3.2.2.1. Other used 
methods are described in General methods section, chapter 5.  
 
3.4.3 Results and discussion 
 
First, we focused on detailed clinical and biochemical characterisation of family 
members to minimise the risk of the disease status misclassification and consequent failure of 
the linkage analysis. The clinical phenotype was found to be atypical. In addition to usual signs 
of the disease like small kidney size, anaemia, hyperuricaemia, elevated plasma creatinine and 
hypouricuria appearing in early age [174], precocious anaemia, absence of gout and relatively 
late onset of renal insufficiency were also observed.  
First, we analysed qualitatively and quantitatively available spot urine samples from 
family members to obtain their up-to-date biochemical status.   
Qualitative SDS-PAGE and Western blot analyses showed reduction or absence of 
UMOD in urines as well as urinary sediments from affected members. 
Quantitatively, we determined several biochemical parameters including UMOD 
concentration to assess kidney functions. When comparing healthy family members and 
controls, no statistically significant changes in any parameter were found. On the other hand, we 
found significantly changed almost all biochemical parameters in affected individuals when 
compared to controls. We employed all of these significantly changed parameters as disease 
status characteristics in discriminant analysis to calculate posterior probabilities that individuals 
belonged to either affected or unaffected group. This kind of analysis provided a high degree of 
certainty in classification and confirmation of affection status.  
Comparison of biochemical parameters between affected and unaffected family member 
groups showed significantly reduced excretion of urate, calcium and UMOD in the former. No 
obvious explanation of decreased calcium excretion could be provided. One hypothesis might be 
that UMOD contributes to the regulation of calcium metabolism through its calcium binding 
domains. Unlike decreased urate excretion, which is one of the hallmarks of FJHN/MCKD2, 
reduced UMOD excretion in these patients with no UMOD mutation was surprising. Similar 
UMOD excretion pattern was so far observed only in patients with UMOD mutations [165].  
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Hence we further performed immunohistochemical analysis of kidney section from one 
affected family member to elucidate the cause of decreased urinary excretion in this family. It 
showed significantly and uniformly reduced UMOD staining in TALH epithelial cells and 
minimal tubulointerstitial involvement. In control kidney tissue, we observed cytoplasmic 
distribution of UMOD with maximal staining on the apical membranes of TALH epithelial cells. 
In contrast to both of these observations, kidney tissue from FJHN patient with UMOD mutation 
showed strong cytoplasmic (ER) accumulation of UMOD. Yet another staining pattern, 
characterised by irregular UMOD staining accompanied by interstitial fibrosis and tubular 
atrophy was detected in kidney section from FJHN patient coming from a family without proven 
linkage to any locus. These results suggested three different mechanisms of UMOD depletion 
and pathogenesis in FJHN/MCKD2 but featuring UMOD as a common denominator.  
Genome-wide linkage analysis in studied family employing 93 microsatellite markers 
revealed only one candidate region on chromosome 1 with relatively low LOD score (1.69). 
Fine mapping using 38 additional markers in this region provided LOD score of 3.27 and 
haplotype analysis identified a single haplotype segregating with the disease. Recombination 
events detected in affected individuals delimited critical region of 37.2 Mbp on chromosome 
1q41 containing about 300 genes. Consequently, we examined the linkage to this locus in eight 
FJHN families from our previous study [78] and in one additional MCKD family described 
earlier [17] and showing no linkage to already established FJHN/MCKD loci on chromosomes 
16p12 and 1q21. However, we were unable to confirm linkage to this newly identified locus in 
any of those families. On the other hand, atypical clinical presentation of FJHN in this Belgian 
family together with our immunohistochemical analysis is suggestive of different genetic origin 
and gives support to the validity of our linkage analysis. 
 Due to relatively high gene content in newly identified critical region, we applied several 
bioinformatic tools to effectively select for candidate genes. We focused first on genes 
specifically expressed in kidney and second on genes of which defect could be responsible for 
decreased UMOD expression observed in kidney tissue. As none kidney specific genes could be 
found in the critical region, we tried to identify genes possibly related to UMOD expression - 
transcription factors, hormones or proteins involved in posttranslational modification or cellular 
trafficking.  
Eventually, we selected nine candidate genes for sequence analysis. In none of these 
genes, however, classical deleterious mutation was found within the promoter regions, 
exon/intron junctions or coding sequences. That time, we proposed that further progress in 
finding and cloning of responsible disease gene was unfortunately hampered by the size of the 
critical region and number of genes to be considered and that the identification of other families 
 34 
linked to this region would be needed to further confirm and hopefully narrow the critical 
region. 
 
3.5 Evaluating REN as a candidate gene in 1q41 region - manuscript in preparation, 2008 
 
3.5.1 Introduction 
 
In previous chapter, I described results of our attempt to identify new UAKD loci. In 
single Belgian family (BE1), we were able to perform advanced clinical characterisation and 
classification and to identify significant locus segregating with the disease on chromosome 1q41 
by medium-density genome-wide scan. In this region, we analysed sequences of 9 candidate 
genes and found no deleterious mutation.  
Besides those genes, we also analysed the sequence of renin precursor (preprorenin) 
encoding gene (REN). In affected member of BE1 family, we found heterozygous mutation in 
exon 1 of REN gene, which was not present in healthy family member as well as in 200 healthy 
controls. However, we postponed the publication of this finding to further characterise and to 
functionally study wildtype and mutant preprorenin and the impact of the mutation on cell 
biology and its potential role in the disease pathogenesis.  
 
Renin 
Renin and prorenin are secretory proteins active in the renin-angiotensin system (RAS) 
[200] and the (pro)renin receptor signal transduction pathway which is distinct from RAS 
receptor signalling [201]. Both pathways play an important role in kidney physiology and 
pathology. 
Renin precursor or preprorenin is composed of 406 AA. It harbours several motifs - two 
potential N-glycosylation sites, signal peptide (residues 1-23), A1 propeptide (residues 31-59) 
and aspartyl protease domain (residues 85-405) 
(http://smart.embl.de/smart/show_motifs.pl?ID=P00797). 
REN gene is located in cytogenetic band q32 on chromosome 1 according to Entrez gene 
(http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=
5972&ordinalpos=1&itool=EntrezSystem2.PEntrez.Gene.Gene_ResultsPanel.Gene_RVDocSu
m) as well as Ensembl, UCSC, HGNC and Geneatlas databases. It spans 11.5 kbp of the 
genomic sequence on minus strand 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NC_000001.9&from=202390571&to=20
2402088&strand=2&dopt=gb).  
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Figure 3.3 REN gene organisation. On top, there is the accession number of REN genomic sequence. Numbered 
arrows indicate the position of the gene on the sequence of chromosome 1 and its orientation. On the left side, 
GenBank accession number of mRNA is given. On the right side, accession numbers of corresponding protein 
sequence and consensus coding sequence are given. Acquired from Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=5972&ordinalpos=1
&itool=EntrezSystem2.PEntrez.Gene.Gene_ResultsPanel.Gene_RVDocSum) 
  
REN is expressed most profoundly in the ovary, the uterus and the kidney 
(http://symatlas.gnf.org/SymAtlas). In the kidney, the expression is restricted to juxtaglomerular 
(granular) cells of the JGA. The hydrophobic core structure of the signal peptide binds to signal 
recognition particle (SRP), which ensures insertion of the signal peptide into translation-
translocation channel in the membrane of the ER [202]. Following proteosynthesis, 
glycosylation, signal sequence removal and proteolytic processing, both the prorenin and renin 
are sorted to secretory granules from which they are released in highly regulated manner into the 
circulation [203]. 
 
3.5.2 Specific methods 
 
Recombinant renin analysis 
Cultured cells lysis 
 Cells were harvested to PBS into 1.5 mL tubes, pelleted by centrifugation at 800g/5 
minutes and washed twice in PBS. The pellet was then resuspended in PBS with 1% (v/v) PIC 
(Sigma) and sonicated 5x10 seconds at output of 50% in the cuphorn filled with mixture of ice 
and water and connected to Ultrasonic Homogeniser (4710 series, Cole-Parmer Instrument Co). 
The suspension was then centrifuged at 14000g/5 minutes at 4°C to remove cell debris. The 
supernatant was collected to a new tube and analysed, or stored at -20°C. 
 
Preparation of cell culture medium for secreted renin analysis 
For secreted renin analysis, the foetal calf serum free medium was collected and 
centrifuged first at 800g/5 min at 4°C and then at 15000g/5 min at 4°C to remove residual cells 
and cellular debris, respectively. To the resulting supernatant, PIC (Sigma) was added to 1% 
(v/v). 500µl of the medium was then concentrated to a small volume and brought to PBS by two 
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successive rounds of concentration-refill on Microcon YM-10 filter and 1.5 mL tube assembly 
(Millipore) at 10000g. Retentate was then recovered to a new tube at 10000g and analysed by 
SDS-PAGE and WB as is or after the deglycosylation. 
 
Renin deglycosylation  
 For analysis of glycosylation patterns of wildtype and mutant renins expressed in cell 
cultures, we used GlycoProTM Enzymatic Deglycosylation Kit (ProZyme) according to 
manufacturer’s instructions. Briefly, cell lysate or concentrated cell culture medium (previous 
paragraph) was mixed with 5X Reaction buffer (kit component) and Denaturation buffer (kit 
component) in 0.2 mL tubes (Eppendorf). Reaction mix was denatured at 100°C/5 minutes in 
the thermal cycler (PTC-225 DNA Engine Tetrad, MJ Research), let cool down to RT and 
Detergent solution (kit component) was added. Glycosidase N-glycanase® PNGase F was then 
added to reaction mix and incubated at 37°C/3 hours in biological thermostat (BT 120 M, 
Ekom). Reactions were then mixed with 6X SDS-PAGE sample buffer, denatured at 100°C/5 
minutes in the thermal cycler and analysed by SDS-PAGE and WB. 
 
Antibodies fluorescein labelling  
 For FACS analysis, polyclonal Anti Preprorenin (21-64)(Human) Serum and Anti 
Preprorenin (288-317)(Human) Serum antibodies (Yanaihara Institute) were conjugated to 
fluorescein by Fluorescein Protein Labelling Kit (Roche) according to manufacturer’s 
instructions. Briefly, 20 mg/mL FLUOS reagent [5(6)-carboxyfluorescein-N-
hydroxysuccinimide ester] solution was prepared by dissolution of lyophilised reagent in 
DMSO. 1 mg of each polyclonal antibody was dissolved in 1 mL of PBS (kit component) and 
7.9 µL of FLUOS solution were added. Reaction mix was incubated at RT protected from light 
during gentle stirring in the rotamixer (Multi RS-60, Biosan). Meanwhile, Sephadex G-25 
column (kit component) was blocked by Blocking reagent (kit component) and rinsed by PBS 
several times. Reaction mix was then applied onto the column to remove non-reacted FLUOS. 
Labelled antibody was eluted from the column by PBS and fractions of about 0.5 mL were 
collected. The amount of antibody in individual fractions and labelling yield were calculated 
based on extinctions at 280 nm (protein) and 495 nm (fluorescein) measured by means of 
photometer (UV/VIS Spectrometer UV4-100, Unicam Ltd.) and applying the equation provided 
by the manufacturer. 
 
Other used methods are described in General methods section, chapters 5.2 - 5.3. 
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3.5.3 Results and discussion 
 
 To confirm and to define chromosome 1 candidate region more precisely, we performed 
again linkage analysis in BE1 family, that time using Affymetrix 10K SNP microarrays. It 
provided LOD score of 3.24 on chromosome 1. Haplotype analysis delimited candidate region 
of 24.7 Mbp containing that time 224 genes. 
 This region overlapped partially with the candidate region of Gordon hyperkalemia-
hypertension syndrome (OMIM 145260), presenting some clinical features found also in BE1 
family.  
The mutation in exon 1, mentioned in the chapter 3.5.1, causes the deletion of one 
leucine from pentaleucine hydrophobic core of renin precursor (preprorenin) signal peptide. In 
this work, we provided several lines of evidence indicating that this deletion leads to aberrant 
renin biosynthesis, secretion and localisation in the kidney, which may account for the 
phenotypic abnormalities observed in affected individuals. 
 Two independent in silico analyses showed that the deletion leads to the decrease in 
hydrophobicity of signal peptide while preserving predicted cleavage site and binding to SRP. 
 In vitro translation (IVT) analysis followed by SDS-PAGE suggested that the leucine 
deletion in signal peptide reduces the translocation efficiency into the rough ER (microsomes). 
Assay in similar system focused only on signal peptide revealed altered processing of deletion 
harbouring signal peptide compared to the wildtype. 
 We constructed transient cell culture models to establish effects of the deletion on 
(pro)renin translocation efficiency, post-translational processing and secretion rate and renin 
enzymatic activity in vivo. Compared to the wildtype, we found no change in the enzymatic 
activity either in cell lysates or in cell culture media but we found significant decrease of total 
prorenin and renin amount in both cell lysates and cell culture media. We further observed 
decreased rate and time delay in biosynthesis of deletion harbouring protein compared to the 
wildtype. However, we have never observed any qualitative differences in post-translational 
processing between both recombinant proteins as assessed by WB. 
 To broaden the range of available assays, we constructed also stable wildtype and 
deletion cell lines. Similarly to transient cultures, we found even more pronounced decrease in 
total amount of renin and prorenin in cell lysates as well as culture media in case of deletion. 
However, qualitative WB analysis with the potential, contrary to quantitative assay, to detect all 
protein forms showed marked accumulation of renin and prorenin in deletion harbouring clones. 
Again, no qualitative differences in post-translational processing between wildtype and deletion 
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proteins, as assessed by WB, were observed. Continuous monitoring of renin activity secretion 
by live cells, employing modified commercial fluorescent assay, showed its significant decrease 
in case of deletion.  
The impact of deletion on cell viability was also assessed using stable cell lines. During 
the first three days of cultivation, cultures with deletion showed significant delay in reaching the 
lag phase accompanied by the doubling-time increase from 46 hours to 78 hours when compared 
to wildtype and reference, antibiotic-selected culture with no renin expression. Following this 
three-day period, all cell lines became similar in their growth curves and doubling-times. 
Moreover, RT-PCR analysis showed in deletion cells the presence of the spliced XBP1(S) 
mRNA variant, which is a key effector of the mammalian UPR [204]. Examination of levels of 
early and late apoptotic signals (Annexin V and propidium iodide) showed no significant 
differences among cultures. 
We further investigated subcellular localisation of renin and prorenin in stable cell lines 
by immunofluorescence and confocal microscopy. In wildtype cultures, we observed renin 
specific granular material in the cytoplasm. Neither significant changes in granules’ shape, size 
or localisation nor signs of prorenin nor renin retention in ER, Golgi apparatus, cytoskeleton or 
plasma membrane were observed in deletion cell lines.  
EM examination of fixed stable cell lines pellets revealed membrane delimited granules 
compatible with characteristics of renin secretory granules in cytoplasm of both wildtype and 
deletion cells, but not in non-transfected cells. In both types of cell lines there were also 
observed membraned bodies of probably macroautophagic origin and considerable distension of 
predominantly rough endoplasmic reticulum cisternae. Those features seemed to be more 
frequent and pronounced in deletion cell lines.  
 Finally, renin was examined also in patients from BE1 family to confront results of in 
vitro and in vivo analyses with the real situation. Plasma renin activity and aldosterone 
concentrations measured in three patients were in normal ranges. We further broadened 
immunohistochemical examinations of UMOD and MUC1 expression presented in the previous 
study [81]. Here we further examined the expression of other RAS components (renin receptor, 
angiotensinogen (AGT), angiotensin II), KCNK2 (TREK-1) (as another candidate protein, of 
which gene is located within the chromosome 1 region and as the marker of proximal tubule 
brush border) and WNK4 kinase (as a protein involved in the pathogenesis of the Gordon 
hyperkalemia-hypertension syndrome [205]) in kidney sections from three patients. Compared 
to control tissues, we found considerably reduced expression of both, renin and prorenin. The 
observed pattern was disease-stage dependent. On the other hand, we observed abnormal 
localization/induction of both renin and prorenin inside the vessel wall of several arterioles and 
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small arteries in all three patients. Expression of renin receptor, detected on the basolateral pole 
of DCT and TALH in a set of controls, was unchanged in patients. Reduced expression of renin 
and other local kidney RAS components in both JGA and tubular epithelium was accompanied 
by AGT and angiotensin II tubular staining either comparable to controls or decreased, 
reflecting the disease stage. TREK-1 (apical pole of PT) and WNK4 (apical pole of TALH and 
CD) showed tendency to weakened immunostaining similarly to UMOD and MUC-1 [81]. 
Generally, patients’ kidneys showed progressive destruction of both glomeruli and renal 
tubules with some differences in severity between individual nephrons. 
 
Manuscript in preparation is presented in the appendix chapter 9.2 
 
Renin in disease 
Mutations in the RAS system components cause autosomal recessive renal tubular 
dysgenesis (RTD) [206-208]. The (pro)renin receptor knockout in mouse was lethal [209] and 
human (pro)renin receptor transgenic rats developed gradual proteinuria and glomerulosclerosis 
[210]. Moreover, selective ablation of juxtaglomerular cells in mouse resulting into renin 
insufficiency led to severe reduction of the kidney size, glomeruli hyperplasia and atrophy, 
tubular dilatation and alteration of renal functions [211].  
Amino acids changes within the hydrophobic core of signal peptides have potential to 
affect co-translational translocation and post-translational processing of corresponding proteins 
[212] and there were described several autosomal dominant phenotypes associated with such 
changes [213-215] and altogether about 30 human genetic diseases [216-219]. Functional 
characterisation of signal sequence mutations showed that their pathogenic potential depends on 
the site and the type of the mutation.  
We found that our mutation decreases signal sequence hydrophobicity required for 
efficient ER translocation, changes property of the off-cleaved signal sequence and limits 
biosynthesis of secretory competent and catalytically active prorenin and renin proteins. The 
mutation further causes intracellular retention of prorenin and renin, and cells expressing mutant 
protein have shown reduced growth rate, signs of activated ER stress, unfolded protein response 
(UPR) and pronounced autophagy, a features having potentially serious consequences especially 
for tissues dedicated to extracellular protein synthesis [220]. Constant ER stress and activated 
UPR signalling have generally serious impact on ER function and structure, trigger apoptosis, 
inflammation and eventually lead to reduced viability or even cell death [221] and disease 
development [222]. This pathogenetic mechanism is well plausible for this mutation as is in ER-
stress and apoptosis inducing signal sequence mutations found in autosomal dominant 
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neurohypophyseal diabetes insipidus [223], carbonic anhydrase IV causing retinitis pigmentosa 
[224, 225] or parathyroid hormone in autosomal dominant form of hypoparathyroidism [218]. 
Based on our results of in silico, in vitro, quantitative and qualitative and 
immunohistochemical experiments and observations, it is conceivable to predict, that our 
mutation reduces ability of regulated renin secretion in vivo. This probably affects renal 
development [206], sensitivity of the tubuloglomerular feedback mechanism and autoregulation 
of renal blood flow [226], which through altered renal hemodynamics and resulting hypoxia 
may lead to loss of glomeruli, tubulointerstitial injury and end-stage renal disease [227]. 
Mechanism of RAS blockage corresponds to anaemia, hyperkalemia and reduced GFR 
presented in the patients [228] and renal ischaemia well explains reduced expression of UMOD 
[229] and other tubular proteins. 
These proposed mechanisms with their consequences are consistent with multiple 
changes in kidney morphology, altered tubular function and clinical and biochemical 
abnormalities observed in patients from BE1 family.  
In conclusion, we identified mutation in signal sequence of preprorenin that, based on 
several lines of evidence, causes aberrant ER translation/translocation and intracellular 
accumulation of prorenin and renin. We suggest that these events lead gradually to cytotoxic 
stress of juxtaglomerular cells and result in autosomal dominant kidney phenotype. Detailed 
clinical, biochemical and molecular investigations of the patients together with further 
characterization of the wildtype and mutant preprorenin expressing cell lines are therefore of 
great interest. 
 
3.6 UMOD protein-protein interaction studies 
   
 In early years of my Ph.D. studies, when the role of UMOD in FJHN/MCKD was not 
known but the genetic heterogeneity of the disease was evident, we hypothesised the existence 
of a protein complex, of which components’ defects would lead to similar clinical presentations. 
After establishment of UMOD as one of the major player in the pathogenesis of the disease, we 
considered it as the component of such hypothetical protein complex and, as an alternative to 
positional cloning approach, we have attempted to apply protein-protein interaction approaches 
to hopefully identify other causal proteins and consequently genes underlying the disease. 
 That time, we took into consideration first of all a yeast two-hybrid system, probably the 
most common and available approach to identify unknown interaction partners of the protein of 
interest. In parallel, we tried to utilize high glycan content of UMOD protein to prepare solid, 
UMOD-bound matrix for probing complex mixtures of proteins in pull-down assay.   
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3.6.1 Yeast two-hybrid system (YTHS) 
 
3.6.1.1 Introduction 
 
This approach relies on expression of the protein of interest or its part in fusion with 
DNA-binding domain (so called bait) of a transcription factor in a yeast cell. Potential 
interacting protein, on the other hand, is expressed in the same cell in fusion with transcription-
activating domain (so called prey) of the same transcription factor. If bait and prey physically 
interact in the yeast cell nucleus, both domains of transcription factor are brought to close 
proximity on promoters of certain genes and their transcription takes place. These so called 
reporter genes are usually biosynthetic genes engineered under the control of fusion 
transcription factor and can be easily scored biochemically by nutritionally selective cultivation. 
 
3.6.1.2 Specific methods 
 
Yeast media and solutions 
YPAD (Yeast extract-Peptone-Dextrose + Adenine): 1% (w/v) yeast extract, 2% (w/v) peptone, 
2% (w/v) D-glucose, 50 mg/L adenine sulphate. All components except glucose were dissolved 
in water and the resulting solution was autoclaved (MLS-2420 autoclave, Sanyo). Filter 
sterilised (0.22 µm filter Milex GP, Millipore) 20% (w/v) D-glucose stock solution was added 
after autoclaving. For plates, agar to 2% (w/v) was added before autoclaving.  
SD (Synthetic Dextrose): 0.17% (w/v) yeast nitrogen base without AA and ammonium sulphate, 
0.5% (w/v) ammonium sulphate, 2% (w/v) D-glucose. All components except glucose were 
dissolved in water, pH was adjusted to 6-7 with 1 M NaOH (OP-274 pH/Ion Analyser, 
Radelkis) and the resulting solution was autoclaved. Filter sterilised (0.22 µm filter Milex GP, 
Millipore) 20% (w/v) D-glucose stock solution was added after autoclaving. For plates, agar to 
1.5% (w/v) was added before autoclaving. 
100X tryptophan (trp) solution: 2 mg/mL tryptophan, dissolved in autoclave-sterilised water. 
100X histidine (his) solution: 2 mg/mL histidine, dissolved in autoclave-sterilised water. 
100X leucine (leu) solution: 10 mg/mL leucine, dissolved in autoclave-sterilised water. 
100X methionine (met) solution: 2 mg/mL methionine, dissolved in autoclave-sterilised water. 
100X adenine sulphate (ade) solution: 5 mg/mL adenine sulphate, dissolved in autoclave-
sterilised water. 
100X uracil (ura) solution: 2 mg/mL uracil, dissolved in autoclave-sterilised water. 
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These 100x nutrient solutions combined with minimal SD medium were used to prepare 
yeast dropout media and plates for nutritional selection of transformed yeasts. In the text, they 
are referred to as -“nutrient” dropout medium/plate. For example, -trp dropout medium/plate 
corresponds to SD + ade, his, met, ura, leu. 
 
Glycerol storage solution: 30% (v/v) glycerol, filter sterilised (0.22 µm filter Milex GP, 
Millipore). For long-term storage of S. cerevisiae clones, overnight liquid culture was mixed 1:1 
with the glycerol storage solution, frozen in the mixture of dry ice and denatured ethanol and 
stored at -70°C. 
 
Yeast vector and strain 
Plasmid pGBD-B for construction of bait fusion proteins was a generous gift from David 
Markie, Ph.D. from Department of Pathology at Dunedin School of Medicine, New Zealand. 
This plasmid was derived from plasmid pGBD-C1 [230] by the replacement of multiple cloning 
site with a single BamHI site flanked by the attB1 and attB2 sequences that direct homologous 
recombination with the tagged insert in yeasts. It is a multi-copy shuttle vector containing TRP1 
gene for selection in yeasts and ampicillin resistance gene (Ampr) for selection in E. coli (Figure 
3.3).  
 
 
Figure 3.3 Map of pGBD-B vector. PADH1 - ADH1 promoter, GAL4 BD - GAL4 binding domain, TADH1 - ADH1 
terminator, TRP1 - tryptophan biosynthesis gene, ColE1 ori - bacterial ColE1 replication origin, Ampr - ampicillin 
resistance gene (bla), 2µ ori - yeast 2-micron replication origin 
 
S. cerevisiae host strain PJ69-4A was used for expression of baits [230]. Its genotype is 
MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆ LYS2::GAL1-HIS3GAL2-ADE2 
met2::GAL7-lacZ meaning that this strain is deficient in TRP1, LEU2, URA3, HIS3, ADE2 and 
BamHI
T ADH1
TRP1
P ADH1
GAL4 BD
ColE1 ori
Ampr
2 µ ori
attB1
attB2
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MET genes and consequently is able to grow only in presence of adequate concentrations of 
tryptophan, leucine, uracil, histidine, adenine and methionine in the media. At the same time, 
HIS3, ADE2 and lacZ (β-D-galactosidase) genes are placed under the control of different GAL4-
responsive promoters and serve as reporter genes in GAL4-based YTHS. 
  
Primer design for bait construction 
 Oligonucleotides for PCR amplification of bait fragments were designed to contain two 
distinct parts. The 3’ regions were UMOD specific and were designed using Oligo 6.44 software 
(Molecular Biology Insights) as common PCR primers. The 5’ regions were tags including 
sequences identical to attB1 and attB2 regions flanking BamHI cloning site in pGBD-B vector 
and enabling homologous recombination cloning in yeasts. To ensure oriented cloning of the 
bait fragment in proper reading frame, A1 tag (including attB1 sequence) was added to upper 
(sense) primer while A2 tag (including attB2 sequence) was added to lower (antisense) primer. 
Oligonucleotides designed for UMOD bait construction are summarised in Table 3.2.  
 
Table 3.2 UMOD specific primers used to amplify bait fragment from cDNA.  
Bait fragment Upper primer* 
Lower primer** 
PCR length*** (bp) 
UMOD 
(UMOD25-640) 
A1-GACACCTCAGAAGCAAGATG 
A2-CCGCTGTCAGTCACTGAA 
 
1924 
EGF domains 
(UMOD25-151) 
A1-GACACCTCAGAAGCAAGATG 
A2-GGAGCACTCACAGTGC 
 
447 
ZP domain 
(UMOD331-585) 
A1-CACAGGCTGGAATGTGG 
A2-GGTCCCAGAGCAGGTAGG 
 
831 
*
    A1: 5’ GAA TTC ACA AGT TTG TAC AAA AAA GCA GGC TGG 3’ 
**   A2: 5’ GTC GAC CAC TTT GTA CAA GAA AGC TGG GTG (TTA) 3’ 
***
 Including tags 
In A2 tag sequence, the stop codon (in parentheses) was included except for the largest fragment (UMOD25-640), in 
which it was naturally included. Ranges of AAs included are in superscript. 
 
PCR for bait fragments 
Solutions: 
10 mM deoxynucleoside triphosphates (dNTPs) mix: 10 mM dATP, 10 mM dCTP, 10 mM 
dGTP, 10 mM dTTP. 100 mM stock solutions of all dNTPs (USB) were mixed together and 
with water to 1:9 dilutions. 
 
 Bait fragments were amplified by “touch-down” approach to increase the chance of the 
positive result at a first attempt. UMOD cDNA fragments were amplified by Taq DNA 
polymerase (Promega, #M1861-discontinued) together with Deep VentR™ DNA Polymerase 
(New England Biolabs) from pCR3.1-UMOD construct (kindly provided by my colleagues 
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Marie Kalbáčová, Ph.D. and Kateřina Hodaňová, Ph.D.). For one PCR reaction, following mix 
was set: 
  
Component Amount (µL) 
Thermophilic DNA Polymerase 10X Reaction Buffer, Magnesium Free * 5 
10 mM dNTPs mix 1 
10 µM upper primer  2.5 
10 µM lower primer 2.5 
25 mM MgCl2 solution* 4 
5U/µL Taq DNA polymerase  0.25 
Deep VentR™ DNA Polymerase (1:20)** 1 
50 ng/µL pCR3.1-UMOD plasmid DNA 1 
Water to 50 
*  #M1901 (discontinued) and #A3511, respectively, supplied together with Taq DNA polymerase 
** Diluted in Vent Diluent (New England Biolabs) 
 
Tubes were placed to thermal cycler and the following thermal program was executed: 
  
Segment Number of cycles Temperature (°C) Time (s) 
1 1 95 180 
2 5 95 
60-1 per cycle 
72 
10 
30 
90 
3 25 95 
55 
72 
10 
30 
90 
4 1 72 600 
5 1 15 for ever 
 
After program termination, 10 µL of PCR reaction were analysed by agarose gel electrophoresis. 
 
Linearisation of pGBD-B vector 
Vector pGBD-B was propagated in and isolated from an overnight culture of E. coli 
strain DH5α (chapter Isolation of plasmid DNA from E. coli). Isolated plasmid DNA was 
linearised by restriction endonuclease BamHI in the following reaction: 
 
Component Amount 
10X Buffer BamHI* 2 µL 
BamHI (10 U/ µL)* 0.5 µL 
pGBD-B plasmid DNA 1 µg 
Water to 20 µL 
* Purchased from Fermentas 
 
Reaction mix was incubated at 37°C/1 hour in the incubator (Biological Thermostat BT 120 M, 
Ekom). Linearised vector was resolved by preparative agarose gel electrophoresis and isolated 
from the gel as described above (chapters 5.4 and 5.5).  
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Lithium acetate yeast transformation and bait cloning 
Buffers and solutions: 
10X Lithium acetate (LiAc) solution: 1 M Lithium acetate, pH 7.5 was adjusted by dilute acetic 
acid (OP-274 pH/Ion Analyser, Radelkis). 
10X TE (Tris-EDTA) buffer: 0.1 M Tris base, 0.01 M EDTA, pH 7.5 was adjusted by 
concentrated HCl. Solution was filter sterilised (0.22 µm filter Milex GP, Millipore) and stored 
at RT. 
LiAc/PEG/TE transformation buffer: 0.1 M LiAc, 40% (w/v) polyethylene glycol 3,350 (PEG), 
0.01 M Tris-Cl, 0.001 M EDTA, pH 7.5. The buffer was prepared by mixing 10X LiAc solution 
and 10X TE buffer. After addition of PEG, solution was autoclaved and stored at RT. 
 
 For up to ten small-scale transformations, 0.7 mL of YPAD broth in 50 mL tube (TPP) 
was inoculated with fresh colony of PJ69-4A yeast strain and the culture was grown overnight 
with shaking at 30°C (Cellstar incubator, Queue Systems). In the morning, 10 mL of YPAD 
broth was added and the culture was grown for next 4-5 hours. Cells were then harvested at 
700g/5 minutes (centrifuge MR22i, Jouan or 4K15, SIGMA Laborzentrifugen), resuspended in 
1 mL of 1X LiAc solution and transferred to 1.5 mL tube. Cells were harvested again in 
centrifuge and washed twice in 1 mL of 1X LiAc solution. Pellet was resuspended in 360 µL of 
LiAc/PEG/TE transformation buffer and 10 µL of 10 mg/mL heat-denatured salmon sperm 
DNA (Sigma, #D-9156) and 1 µL of BamHI linearised pGBD-B vector solution (about 9 ng of 
DNA) were added. For each transformation, 32 µL of this suspension was placed into 0.2 mL 
PCR tube (Eppendorf) and mixed with 4 µL of the bait fragment PCR reaction or 4 µL of sterile 
water as a transformation negative control. Tubes were incubated in the thermal cycler (PTC-
225 DNA Engine Tetrad, MJ Research) at 30°C/30 minutes, 42°C/1 minute and 30°C/1 minute. 
After transformation, 100 µL of sterile water were added to each tube, mixed well, spread over a 
selective -trp dropout plate and let grow for three days at 30°C. 
 
Identification of yeast clones containing baits and a test for reporter genes autoactivation  
For identification of colonies containing inserts, we used the same PCR reactions as for 
amplification of bait fragments from UMOD cDNA (chapter PCR for bait fragments). As a 
template, we used yeast lysates prepared as follows. After three days of growth on -trp plates, 
eight colonies of each bait were picked by sterile toothpick and resuspended each in 50 µL of 
sterile water dispensed in 96-well plate. In another 96 well plate, 20 µL of freshly prepared 20 
mM NaOH solution were dispensed accordingly. 3 µL of each yeast suspension were transferred 
into corresponding wells of NaOH plate. After incubation at RT/5 minutes, 80 µL of sterile 
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water were added to each well of NaOH plate. For each PCR reaction, 10 µL of this lysate was 
used as a template. 10 µL of each PCR reaction were analysed by agarose electrophoresis 
(chapter 5.4).  
To test for reporter genes autoactivation in bait clones, 3 µL of each yeast suspension in 
water were arrayed in duplicate onto -trp-his and -trp dropout plates and let grow for two days at 
30°C.  
  
Isolation of DNA from yeasts 
Buffers and solutions: 
Prespheroplasting buffer: 0.05 M EDTA, 1% (v/v) BME, pH 8. Solution was prepared from 0.5 
M EDTA stock solution, pH 8 (chapter 5.4).   
Lyticase buffer: 0.8 M KCl, 0.01 M EDTA, 0.1% (v/v) BME.  
Lyticase solution: 5 mg/mL Lyticase (Sigma, # L4025). Lyophilised enzyme preparation was 
dissolved in water and stored at -20°C.  
Lysis solution: 10% (w/v) SDS. 
Proteinase K solution: 20 mg/mL Proteinase K (Sigma). Lyophilised enzyme preparation was 
dissolved in water and stored at -20°C. 
Phenol/chloroform: phenol equilibrated with TE buffer (Sigma, #P4557) and chloroform were 
mixed in 1:1 ratio and stored at -20°C.   
Sodium acetate (NaAc) solution: 3 M NaAc, pH 5.5 was adjusted by concentrated acetic acid 
(OP-274 pH/Ion Analyser, Radelkis).  
 
 For isolation of plasmid DNA from PJ69-4A yeast cells containing bait constructs, 10 
mL of -trp dropout medium in 50 mL tube were inoculated by a large fresh colony grown on -trp 
plates and incubated at 30°C overnight with shaking (Cellstar incubator, Queue Systems). The 
following day, cells were harvested in the centrifuge at 1900g/10 min (MR22i, Jouan or 4K15, 
SIGMA Laborzentrifugen) and the pellet was resuspended in 0.5 mL of Prespheroplasting 
buffer. Cell suspension was transferred to 1.5 mL tube (Deltalab) and incubated at RT/20 
minutes. Cells were then harvested at 1900g/3 minutes and resuspended in 400 µL of Lyticase 
buffer. 40 µL of Lyticase solution was added and suspension was incubated at 28°C/1 hour (Dri-
Block DB-3, Techne) with turning the tube upside down every fifteen minutes. After the 
incubation, 40 µL of Lysis solution and 1 µL of Proteinase K solution were added and mixed 
gently. Following the incubation at 56°C/30 minutes, equal volume (480 µL) of 
phenol/chloroform mixture was added and vortexed thoroughly (Vortex-Genie 2, Scientific 
Industries). Phases were separated at 14000g/5 minutes and maximum of the upper aqueous 
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phase was transferred to a new tube. Equal volume of chloroform was added, vortexed 
thoroughly and centrifuged at 14000g/5 minutes. Maximum of the upper aqueous phase was 
transferred to a new tube and 1/10 volume of NaAc solution and 1 mL of 96% ethanol were 
added. DNA was precipitated at -20°C/1 hour and collected at 14000g/5 minutes. The pellet was 
washed in 1 mL of 70% (v/v) ethanol solution with vortexing, collected again at 14000g/5 
minutes and dried at RT. Dry pellet was dissolved in 30 µL of water. 
 
Sequence analysis of bait constructs 
Inserts of bait constructs propagated in E. coli (chapters 5.8.1 and 5.8.2) were sequenced 
on slab gel platform as described in chapter 5.7.1. The following primers were used in cycle 
sequencing reactions with UMOD25-640 bait constructs:  
 
5’ Cy5-CGGAGCAGTTGTGAGCT 3’  
5’ Cy5-CGTCCGTCCAGGTGAAGG 3’  
5’ Cy5-GTCGACCACTTTGTACAAGAAAGCTGGGTG 3’ 
 
First two primers are UMOD cDNA specific primers with antisense orientation and are labelled 
by Cy5 fluorescent dye. Third primer sequence is identical to A2 tag (without the stop codon) of 
lower primers used to amplify bait fragments (chapter Primer design for bait construction), 
again labelled by Cy5. For sequencing of EGF (UMOD25-151) and ZP (UMOD331-585) bait inserts 
(chapter Primer design for bait construction), only the primer Cy5-A2 was used.     
 
Preparation of yeast protein extracts for WB 
Buffers and solutions: 
Tris-Cl stock solution: 1 M Tris-Cl, pH 6.8 was adjusted by 1 M NaOH (OP-274 pH/Ion 
Analyser, Radelkis). 
Cracking buffer: 8 M urea, 5% (w/v) SDS, 0.04 M Tris-Cl, 0.1 mM EDTA, 1% (v/v) BME, 
0.04% (w/v) BPB. 1 M Tris-Cl stock solution, pH 6.8 was used for the preparation of the buffer.   
 
For extraction of proteins from PJ69-4A yeast cells containing bait constructs, 5 mL of -
trp dropout medium in 50 mL tube (TPP) were inoculated by a large fresh colony grown on -trp 
dropout plates and 5 mL of YPAD medium inoculated by untransformed PJ69-4A strain as a 
negative control. Cultures were incubated at 30°C overnight with shaking (Cellstar incubator, 
Queue Systems). Overnight cultures were vortexed for 0.5 to 1 minute to disperse cell clumps 
(Vortex-Genie 2, Scientific Industries) and OD600 was determined (BioPhotometer, Eppendorf). 
Cultures were diluted to OD600 0.15 by fresh medium to 10 mL and incubated until the OD600 
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reached 0.6 (about 4 to 5 hours). After chilling cultures on ice, cells were harvested at 1000g/5 
minutes at 4°C in 15 mL centrifuge tubes (Gama Group). Supernatant was discarded, pellets 
were resuspended in 5 mL of ice cold water and centrifuged again at 1000g/5 minutes at 4°C. 
Pellets were then frozen to -70°C and after 10 minutes thawed in turn in Cracking buffer 
prewarmed to 60°C with PIC (Sigma) added to concentration of 1% (v/v) right before use. 100 
µL of Cracking buffer was used for every 7.5 total OD600 units (OD600 x culture volume). Cell 
suspensions were transferred to 1.5 mL tubes (Deltalab) containing 80 µL of glass beads (425-
600 µm, Sigma, #G-87723) for every 7.5 total OD600 units. Samples were incubated at 70°C/10 
minutes (Dri-Block DB-3, Techne) and then vortexed vigorously for one minute. Cell debris, 
unbroken cells and glass beads were pelleted at 14000g/5 minutes and supernatants were 
transferred to new 1.5 mL tubes. Tubes with pellets were further incubated at 100°C/3-5 minutes 
in thermal block and then vortexed vigorously for one minute. Debris, unbroken cells and beads 
were pelleted again at 14000g/5 minutes and resulting supernatants were combined with first 
supernatants. If no supernatants were obtained in this second round, 50 µL of Cracking buffer 
were added to pellets and previous four steps were repeated. Extracts were denatured at 100°C/5 
minutes and stored frozen at -70°C.  
  
WB analysis of bait expression  
 Yeast protein extracts were analysed by SDS-PAGE (chapter 5.2) followed by WB 
(chapter 5.3) as described. Frozen samples were thawed and directly loaded onto SDS-PAGE 
gel. WBs were probed by monoclonal anti-GAL4 DNA-BD antibody (BD Biosciences 
Clontech, #5399-1) diluted 1:10000 followed by HRP-conjugated goat anti-mouse secondary 
antibody (Pierce) diluted 1:10000. In a separate run, WBs were probed by polyclonal anti-THP 
antibody followed by HRP-conjugated goat anti-rabbit secondary antibody as described.   
 
Construction of UMOD bait by restriction/ligation 
  As an alternative approach to UMOD25-640 bait construction, we cut out the central part 
of a pGBD-B-UMOD construct prepared by homologous recombination cloning, but containing 
multiple point mutations, and replaced it with the same part from pCR3.1-UMOD25-640 construct 
(see chapter PCR for bait fragments). This approach was designed to avoid PCR in bait 
construction.  
 Both constructs were amplified in and isolated from E. coli liquid cultures. Ampicillin 
supplemented LB medium was inoculated by TOP10 glycerol stock culture of pCR3.1-UMOD 
construct and DH5α glycerol stock culture of pGBD-B-UMOD. Plasmid DNA was isolated as 
described (chapter 5.8.2). Following reaction was set to double digest each construct: 
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Component Amount 
Plasmid DNA 10 µg 
10X NEBuffer 4* 10 µL 
SacII* 3 U 
PpuMI* 3 U 
Water to 20 µL 
*Purchased from New England Biolabs; analysis of restriction sites was performed in Oligo software (Molecular 
Biology Insights); SacII and PpuMI cut at positions c.545 and c.1933, respectively (based on GenBank UMOD 
mRNA sequence NM_003361.2) 
 
Reactions were incubated at 37°C in the incubator (Biological Thermostat BT 120 M, Ekom) for 
3 hours. Then, UMOD cDNA part from pCR3.1-UMOD digest and vector part from pGBD-B-
UMOD digest were purified by preparative gel electrophoresis (chapters 5.4 and 5.5). Both 
fragments were ligated overnight at 16°C in the thermal cycler (PTC-225 DNA Engine Tetrad, 
MJ Research) by T4 DNA ligase. Reaction mix was set as follows: 
 
Component Amount 
10X Buffer for T4 DNA Ligase* 4 µL 
10 mM ATP solution* 4 µL 
T4 DNA Ligase (1 U/µL)* 1 µL 
UMOD fragment 120 ng 
pGBD-B fragment 20 ng 
Water to 40 µL 
*Purchased from Fermentas 
 
Molar ratio of insert DNA termini to vector DNA was 3:1. Reaction volume was made up to 100 
µL and DNA was extracted and precipitated by phenol/chloroform and ethanol as described 
(chapter Isolation of DNA from yeasts). Purified DNA was used to transform DH5α cells by 
electroporation (chapter 5.8.1) to propagate the construct. Several resulting colonies were used 
to inoculate LB-ampicillin medium (chapter 5.8.2). Overnight cultures were PCR screened for 
the presence of the construct (according to chapter PCR for bait fragments; 1 µL of each 
overnight culture was directly used as a template in PCR reactions). 10 µL of each PCR reaction 
were analysed by agarose electrophoresis (chapter 5.4). The same cultures were further used for 
the isolation of plasmid DNA (chapter 5.8.2) and UMOD insert was sequenced (chapter 
Sequence analysis of bait constructs). Isolated construct was then introduced to PJ69-4A yeast 
strain by LiAc/PEG transformation (chapter Lithium acetate transformation and bait cloning) 
and resulting yeast clones were tested for reporter genes autoactivation (chapter Identification of 
yeast clones containing baits and a test for reporter genes) and BD fusion expression (chapters 
Preparation of yeast lysates for WB and WB analysis of bait expression). 
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3.6.1.3 Results and discussion 
 
For our experiments, we chose original-like system based on GAL4 transcription factor 
domains [231] and enabling simple nutritional selection, homologous recombination cloning 
[232, 233] and mating-based prey library screening [234, 235].    
 After invention of uromodulin causative role in FJHN/MCKD2 we prepared several 
uromodulin-based bait clones, comprising the whole coding sequence (CDS) except for N-
terminal signal sequence, or particular domains, namely ZP domain and EGF domain cluster 
(Figure 3.4).  
 
A 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UMOD25-640 
UMOD25-151 
UMOD231-585 
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ATG GGG CAG CCA TCT CTG ACT TGG ATG CTG ATG GTG GTG GTG GCC TCT TGG TTC ATC ACA ACT GCA GCC ACT GAC ACC TCA GAA GCA AGA TGG 
Met Gly Gln Pro Ser Leu Thr Trp Met Leu Met Val Val Val Ala Ser Trp Phe Ile Thr Thr Ala Ala Thr Asp Thr Ser Glu Ala Arg Trp 
1                                   10                                      20                                      30          
 
TGC TCT GAA TGT CAC AGC AAT GCC ACC TGC ACG GAG GAT GAG GCC GTT ACG ACG TGC ACC TGT CAG GAG GGC TTC ACC GGC GAT GGC CTG ACC 
Cys Ser Glu Cys His Ser Asn Ala Thr Cys Thr Glu Asp Glu Ala Val Thr Thr Cys Thr Cys Gln Glu Gly Phe Thr Gly Asp Gly Leu Thr 
                                40                                      50                                      60 
 
TGC GTG GAC CTG GAT GAG TGC GCC ATT CCT GGA GCT CAC AAC TGC TCC GCC AAC AGC AGC TGC GTA AAC ACG CCA GGC TCC TTC TCC TGC GTC  
Cys Val Asp Leu Asp Glu Cys Ala Ile Pro Gly Ala His Asn Cys Ser Ala Asn Ser Ser Cys Val Asn Thr Pro Gly Ser Phe Ser Cys Val 
                            70                                      80                                      90 
 
TGC CCC GAA GGC TTC CGC CTG TCG CCC GGT CTC GGC TGC ACA GAC GTG GAT GAG TGC GCT GAG CCT GGG CTT AGC CAC TGC CAC GCC CTG GCC 
Cys Pro Glu Gly Phe Arg Leu Ser Pro Gly Leu Gly Cys Thr Asp Val Asp Glu Cys Ala Glu Pro Gly Leu Ser His Cys His Ala Leu Ala 
                        100                                     110                                     120 
 
ACA TGT GTC AAT GTG GTG GGC AGC TAC TTG TGC GTA TGC CCC GCG GGC TAC CGG GGG GAT GGA TGG CAC TGT GAG TGC TCC CCG GGC TCC TGC 
Thr Cys Val Asn Val Val Gly Ser Tyr Leu Cys Val Cys Pro Ala Gly Tyr Arg Gly Asp Gly Trp His Cys Glu Cys Ser Pro Gly Ser Cys 
                    130                                     140                                     150 
 
GGG CCG GGG TTG GAC TGC GTG CCC GAG GGC GAC GCG CTC GTG TGC GCG GAT CCG TGC CAG GCG CAC CGC ACC CTG GAC GAG TAC TGG CGC AGC 
Gly Pro Gly Leu Asp Cys Val Pro Glu Gly Asp Ala Leu Val Cys Ala Asp Pro Cys Gln Ala His Arg Thr Leu Asp Glu Tyr Trp Arg Ser 
                160                                     170                                     180 
 
ACC GAG TAC GGG GAG GGC TAC GCC TGC GAC ACG GAC CTG CGC GGC TGG TAC CGC TTC GTG GGC CAG GGC GGT GCG CGC ATG GCC GAG ACC TGC 
Thr Glu Tyr Gly Glu Gly Tyr Ala Cys Asp Thr Asp Leu Arg Gly Trp Tyr Arg Phe Val Gly Gln Gly Gly Ala Arg Met Ala Glu Thr Cys 
            190                                     200                                     210            
 
GTG CCA GTC CTG CGC TGC AAC ACG GCC GCC CCC ATG TGG CTC AAT GGC ACG CAT CCG TCC AGC GAC GAG GGC ATC GTG AGC CGC AAG GCC TGC 
Val Pro Val Leu Arg Cys Asn Thr Ala Ala Pro Met Trp Leu Asn Gly Thr His Pro Ser Ser Asp Glu Gly Ile Val Ser Arg Lys Ala Cys 
        220                                     230                                     240 
 
GCG CAC TGG AGC GGC CAC TGC TGC CTG TGG GAT GCG TCC GTC CAG GTG AAG GCC TGT GCC GGC GGC TAC TAC GTC TAC AAC CTG ACA GCG CCC 
Ala His Trp Ser Gly His Cys Cys Leu Trp Asp Ala Ser Val Gln Val Lys Ala Cys Ala Gly Gly Tyr Tyr Val Tyr Asn Leu Thr Ala Pro 
    250                                     260                                     270 
 
CCC GAG TGT CAC CTG GCG TAC TGC ACA GAC CCC AGC TCC GTG GAG GGG ACG TGT GAG GAG TGC AGT ATA GAC GAG GAC TGC AAA TCG AAT AAT 
Pro Glu Cys His Leu Ala Tyr Cys Thr Asp Pro Ser Ser Val Glu Gly Thr Cys Glu Glu Cys Ser Ile Asp Glu Asp Cys Lys Ser Asn Asn 
280                                     290                                     300                                     310 
 
GGC AGA TGG CAC TGC CAG TGC AAA CAG GAC TTC AAC ATC ACT GAT ATC TCC CTC CTG GAG CAC AGG CTG GAA TGT GGG GCC AAT GAC ATG AAG 
Gly Arg Trp His Cys Gln Cys Lys Gln Asp Phe Asn Ile Thr Asp Ile Ser Leu Leu Glu His Arg Leu Glu Cys Gly Ala Asn Asp Met Lys 
                                    320                                     330                                     340 
 
GTG TCG CTG GGC AAG TGC CAG CTG AAG AGT CTG GGC TTC GAC AAG GTC TTC ATG TAC CTG AGT GAC AGC CGG TGC TCG GGC TTC AAT GAC AGA 
Val Ser Leu Gly Lys Cys Gln Leu Lys Ser Leu Gly Phe Asp Lys Val Phe Met Tyr Leu Ser Asp Ser Arg Cys Ser Gly Phe Asn Asp Arg 
                                350                                     360                                     370 
 
GAC AAC CGG GAC TGG GTG TCT GTA GTG ACC CCA GCC CGG GAT GGC CCC TGT GGG ACA GTG TTG ACG AGG AAT GAA ACC CAT GCC ACT TAC AGC 
Asp Asn Arg Asp Trp Val Ser Val Val Thr Pro Ala Arg Asp Gly Pro Cys Gly Thr Val Leu Thr Arg Asn Glu Thr His Ala Thr Tyr Ser 
                            380                                     390                                     400 
 
AAC ACC CTC TAC CTG GCA GAT GAG ATC ATC ATC CGT GAC CTC AAC ATC AAA ATC AAC TTT GCA TGC TCC TAC CCC CTG GAC ATG AAA GTC AGC 
Asn Thr Leu Tyr Leu Ala Asp Glu Ile Ile Ile Arg Asp Leu Asn Ile Lys Ile Asn Phe Ala Cys Ser Tyr Pro Leu Asp Met Lys Val Ser 
                        410                                     420                                     430 
 
CTG AAG ACC GCC CTA CAG CCA ATG GTC AGT GCT CTA AAC ATC AGA GTG GGC GGG ACC GGC ATG TTC ACC GTG CGG ATG GCG CTC TTC CAG ACC 
Leu Lys Thr Ala Leu Gln Pro Met Val Ser Ala Leu Asn Ile Arg Val Gly Gly Thr Gly Met Phe Thr Val Arg Met Ala Leu Phe Gln Thr 
                    440                                     450                                     460 
 
CCT TCC TAC ACG CAG CCC TAC CAA GGC TCC TCC GTG ACA CTG TCC ACT GAG GCT TTT CTC TAC GTG GGC ACC ATG TTG GAT GGG GGC GAC CTG 
Pro Ser Tyr Thr Gln Pro Tyr Gln Gly Ser Ser Val Thr Leu Ser Thr Glu Ala Phe Leu Tyr Val Gly Thr Met Leu Asp Gly Gly Asp Leu 
                470                                     480                                     490 
 
TCC CGA TTT GCA CTG CTC ATG ACC AAC TGC TAT GCC ACA CCC AGT AGC AAT GCC ACG GAC CCC CTG AAG TAC TTC ATC ATC CAG GAC AGA TGC 
Ser Arg Phe Ala Leu Leu Met Thr Asn Cys Tyr Ala Thr Pro Ser Ser Asn Ala Thr Asp Pro Leu Lys Tyr Phe Ile Ile Gln Asp Arg Cys 
            500                                     510                                     520 
 
CCA CAC ACT AGA GAC TCA ACT ATC CAA GTG GTG GAG AAT GGG GAG TCC TCC CAG GGC CGA TTT TCC GTC CAG ATG TTC CGG TTT GCT GGA AAC 
Pro His Thr Arg Asp Ser Thr Ile Gln Val Val Glu Asn Gly Glu Ser Ser Gln Gly Arg Phe Ser Val Gln Met Phe Arg Phe Ala Gly Asn 
        530                                     540                                     550 
 
TAT GAC CTA GTC TAC CTG CAC TGT GAA GTC TAT CTC TGT GAC ACC ATG AAT GAA AAG TGC AAG CCT ACC TGC TCT GGG ACC AGA TTC CGA AGT 
Tyr Asp Leu Val Tyr Leu His Cys Glu Val Tyr Leu Cys Asp Thr Met Asn Glu Lys Cys Lys Pro Thr Cys Ser Gly Thr Arg Phe Arg Ser 
    560                                     570                                     580 
 
GGG AGT GTC ATA GAT CAA TCC CGT GTC CTG AAC TTG GGT CCC ATC ACA CGG AAA GGT GTC CAG GCC ACA GTC TCA AGG GCT TTT AGC AGC TTG 
Gly Ser Val Ile Asp Gln Ser Arg Val Leu Asn Leu Gly Pro Ile Thr Arg Lys Gly Val Gln Ala Thr Val Ser Arg Ala Phe Ser Ser Leu 
590                                     600                                     610                                     620 
 
GGG CTC CTG AAA GTC TGG CTG CCT CTG CTT CTC TCG GCC ACC TTG ACC CTG ACT TTT CAG TGA CTGACAGCGGAAAGCCCT... 
Gly Leu Leu Lys Val Trp Leu Pro Leu Leu Leu Ser Ala Thr Leu Thr Leu Thr Phe Gln *** 
                                    630                                     640 
B 
 
Figure 3.4 Schematic representation of uromodulin bait fragments used in YTHS. A) Double arrows delimit 
bait fragments on domain structure representation of uromodulin protein. Bait fragment labelling on the right 
conforms to chapter Primer design for bait construction. B) Uromodulin CDS (upper line, based on GenBank 
sequence NM_003361.2) with numbered three-letter code translation (middle and lower line). Grey-highlighted 
AAs indicate N-terminal signal sequence and GPI attachment site 614Ser, respectively. Arrows denote position and 
orientation of PCR amplification primers (according to chapter Primer design for bait construction) 
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N-terminal signal peptide was omitted from UMOD25-640 and UMOD25-151 bait fragments, 
as YTHS requires fusion proteins to be transferred to the yeast nucleus. Bait fragments were 
PCR amplified from UMOD cDNA cloned to pCR3.1 eukaryotic expression vector (Figure 3.5) 
and transformed together with BamHI linearised vector pGBD-B to yeast strain PJ69-4A. Bait 
construct formation takes place in the yeast cell by homologous recombination between A1 and 
A2 tags included in bait PCR primers and identical sequences flanking the BamHI site in 
pGBD-B vector. Resulting clones were tested by PCR for the presence of the construct (Figure 
3.6). For this purpose, the same PCR primers as for bait fragment amplification were used as we 
were unable to perform these screening PCRs with primers based on A1 and A2 sequences.  
 
A      B      C   
 
Figure 3.5 Bait fragments PCR products. A) UMOD25-640, B) UMOD25-151, C) UMOD331-585. The order of 
samples on agarose gels was as follows (from left to right): GeneRuler™ 100bp DNA Ladder Plus marker 
(Fermentas), bait PCR aliquot, blank (no template) PCR aliquot.     
 
A    B    C   
Figure 3.6 PCR screening of yeast bait clones. A) UMOD25-640; order of samples on agarose gel (from left to 
right): GeneRuler™ 100bp DNA Ladder Plus marker (Fermentas), PCR aliquots of six individual clones, positive 
control (pCR3.1-UMOD) PCR aliquot, blank (no template) PCR aliquot. B) UMOD25-151; order of samples on 
agarose gel (from left to right): GeneRuler™ 100bp DNA Ladder Plus marker, PCR aliquots of eight individual 
clones, positive control (pCR3.1-UMOD) PCR aliquot, blank (no template) PCR aliquot. C) UMOD331-585; order of 
samples on agarose gel (from left to right): GeneRuler™ 100bp DNA Ladder Plus marker, PCR aliquots of eight 
individual clones, blank (no template) PCR aliquot. 
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Positive clones were further tested for activation of reporter genes transcription in the 
absence of the interactor (autoactivation) by nutritionally selective cultivation on -trp-his 
dropout plates. Significant autoactivation was observed only in case of some UMOD25-640 bait 
clones. Only clones showing no autoactivation were selected for further analyses. 
Several clones of each bait were tested for expression of bait fusion protein by WB with 
both anti-GAL4 BD monoclonal antibody and anti-THP polyclonal antibody (Figure 3.7). Two 
clones with ZP domain bait showed specific signal on WB of correct MW (45 kDa) with anti-
GAL4 BD monoclonal antibody. However, this bait fusion protein was not detected by WB with 
anti-THP polyclonal antibody. One clone with EGF bait showed specific signal on WB with 
anti-GAL4 BD monoclonal antibody, of which MW (about 19 kDa), however, corresponded to 
GAL4 BD only (theoretical MW of bait fusion protein was about 30 kDa). In bait clones with 
the whole UMOD CDS, no specific signal could be detected on WB with either antibody. 
 
A                    B                 
Figure 3.7 GAL4 BD WBs of yeast bait clones lysates. A) UMOD331-585 (ZP) bait; order of samples (from left to 
right): SeeBlue® Pre-Stained Marker (Invitrogen), lysates of two bait clones, negative control (lysate of 
nontransformed strain PJ69-4A), B) UMOD25-151 (EGF) bait; order of samples (from left to right): SeeBlue® Pre-
Stained Marker, lysates of four bait clones, negative control (lysate of nontransformed strain PJ69-4A). 
 
Selected constructs of each bait were also analysed by sequencing on slab gel platform to verify 
the correctness of insert sequences. It required DNA isolation from yeasts, its transformation to 
E. coli by electroporation for amplification, isolation from E. coli cultures and finally 
sequencing. We found that all analysed constructs repeatedly showed multiple single nucleotide 
changes. 
To exclude the possibility that these errors arose during PCR amplification of bait 
fragments, we prepared another UMOD25-640 construct by classical restriction/ligation approach. 
As a template, we used one of UMOD25-640 bait constructs from which most of the UMOD CDS 
was cut out by two different restriction endonucleases. The removed part was then replaced by 
16  
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30  
36  
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64  
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the same fragment from pCR3.1-UMOD construct. Resulting construct was then transformed to 
E. coli (Figure 3.8) to be amplified and sequenced before the transformation to yeasts. Sequence 
of the insert was correct. Construct was then transformed to PJ69-4A yeast strain as usually and 
selected clones were PCR screened (Figure 3.9) and tested as described above. No apparent 
autoactivation was observed. The sequence of the construct isolated from single yeast clone was 
proved to be correct. However, expression of bait fusion protein could not be detected by WB 
with either antibody mentioned above.  
 
 
Figure 3.8 PCR screening of E. coli bait construct clones. Order of samples on agarose gel (from left to right): 
GeneRuler™ 100bp DNA Ladder Plus marker (Fermentas), four individual E. coli clones PCR aliquots and positive 
control (pCR3.1-UMOD) PCR aliquot.  
 
 
Figure 3.9 PCR screening of yeast bait clones. Order of samples on agarose gel (from left to right): GeneRuler™ 
100bp DNA Ladder Plus marker (Fermentas), PCR aliquots of eight individual yeast clones and positive control 
(pCR3.1-UMOD) PCR aliquot. 
 
In conclusion, we failed to proceed to further steps of two-hybrid screening due to 
inability to avoid obstacles described above. We also got insecure that YTHS was appropriate 
tool for studying uromodulin interactions. One of the main drawbacks of classical YTHS is 
unavailability of proper posttranslational modifications and folding of baits due to the omission 
of the original signal sequence and due to the fusion to BD directing the resulting fusion protein 
to the nucleus [236, 237]. In case of uromodulin, which is heavily glycosylated and extensively 
stabilised by disulfide bridges, this could be critical.  
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Sequence errors found in constructs prepared by gap repair cloning in yeasts were 
suggestive of bad tolerance of UMOD cDNA by yeast cells, resulting in higher mutation rate 
and absence of bait fusion expression. However, correct sequence of the UMOD25-640 construct 
prepared by restriction/ligation spoke against this possibility. In these clones, absence of bait 
fusion expression could be rather caused by preserving the UMOD C-terminal segment 
(containing GPI attachment site) in bait constructs that could interfere with proper protein 
processing. This segment should have been probably omitted in bait design. Finally, PCR 
amplified bait fragments should had been sequenced in advance of gap repair cloning, which 
could probably a priori identify potential sequence errors introduced by PCR and suggest the 
employment of different amplification system. 
 
3.6.2 Concanavalin A (ConA) pull-down assay 
 
3.6.2.1 Introduction 
In this assay, we utilised the high oligosaccharide content of uromodulin protein for its 
immobilisation on sepharose beads with covalently bound lectin (glycan binding protein) ConA 
[238]. Under certain conditions, lectins are able to bind complex as well as simple saccharides 
in solution. The majority of known lectins come from plants. In general concept, ConA pull-
down assay is similar to immunoprecipitation but instead of capturing antibody immobilised on 
beads through antibody binding molecule (for example bacterial Protein A or Protein G), protein 
of which interactors we are intended in (bait) is employed. 
 
3.6.2.2 Specific methods 
Buffers and solutions: 
Tris-buffered saline (TBS): 0.01 M Tris-Cl, 0.15 M NaCl, pH 7.5 adjusted by 1M NaOH (OP-
274 pH/Ion Analyser, Radelkis). 
 
Precondensation of Triton X-114 detergent [239] 
As Triton X-114 often contains hydrophilic contaminants, it is reasonable to precondense 
it by several rounds of phase separation. 
1.5 g of detergent was dissolved in 50 mL of TBS in 50 mL tube (TPP) and placed on 
ice. Solution was then brought to 37°C in a water bath (B.Braun), which made it turbid. Phases 
were separated by centrifugation at 1000g/10 minutes at RT. Upper phase (detergent-depleted) 
was removed and discarded. Lower phase (detergent-enriched) was redissolved in an equal 
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volume of ice-cold TBS and that partitioning was repeated three times. The final detergent-
enriched phase contains about 12% of detergent.   
 
Extraction of total proteins from cells by Triton X-114   
Buffers and solutions: 
Precondensed Triton X-114 (chapter Precondensation of Triton X-114 detergent) 
 
2.4-3x107 cells of human embryonic kidney cell line 293 (HEK293) (60 mg wet pellet) 
was resuspended in 5 mL of ice-cold TBS and 1 mL (1/5 volume) of precondensed Triton X-114 
(Sigma) and 60 µL (1/100 volume) of PIC (Sigma) were added. Extraction of cells was carried 
out for 15 minutes on ice with occasional mixing. Lysate was then centrifuged at 10000g/10 
minutes at 4°C (centrifuge MR22i, Jouan or 4K15, SIGMA Laborzentrifugen) and supernatant 
was transferred to a new tube. Pellet was resuspended in 1 mL of ice-cold TBS and 
homogenised by sonication in cuphorn connected to Ultrasonic Homogenizer 4710 series for 
3x15 seconds at 50% output (Cole-Parmer Instrument Co.). Supernatant was warmed to 37°C 
until it became cloudy. This emulsion was then centrifuged at 1000g/10 minutes and resulting 
upper and lower phases were collected in separate tubes.  
Similarly, 1mL of Tris-Cl homogenate of random kidney tissue (about 75 mg/mL, kindly 
provided by my colleague Blanka Stibůrková, Ph.D.) was mixed with 4 mL of ice-cold TBS on 
ice and 1 mL of precondensed Triton X-114 and 60 µL of PIC (Sigma) were added. The mixture 
was further processed in the same way as described for HEK293 cells. Triton X-114 fractions of 
the kidney tissue were then tested for uromodulin by SDS-PAGE and WB. 
 
Immobilisation of urinary uromodulin on Concanavalin A-sepharose 4B 
Buffers and solutions: 
Immobilisation buffer (TBS/Mn/Ca): 0.01 M Tris-Cl, 0.15 M NaCl, 0.001 M MnCl2, 0.001 M 
CaCl2, pH 7.5 adjusted by 1M NaOH. 
 
For each assay, 50 µL of ConA-sepharose (Sigma #C-9017) suspension was placed to 
1.5 mL tube (TPP) and centrifuged at 10000g/1 minute to remove storage buffer (centrifuge 
MR22i, Jouan or 4K15, SIGMA Laborzentrifugen). Beads were then washed three times with 
immobilisation buffer and finally resuspended in 50 µL of the same buffer with the addition of 
33 µg or 50 µg of uromodulin for HEK293 or kidney tissue assay, respectively. Mixture was 
incubated at 37°C/1 hour (Biological Thermostat BT 120 M, Ekom) with gentle mixing (Multi 
RS-60 rotamixer, Biosan), beads were collected by centrifugation and washed three times with 
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immobilisation buffer and finally resuspended in TBS to the original volume. For blank assay, 
ConA beads were processed in the same way except that incubation at 37°C was carried out 
only with immobilisation buffer, without the addition of uromodulin. 
 
ConA pull-down assay 
To 50 µL of uromodulin coated beads suspension or blank beads suspension, 100 µL of 
each HEK293 or kidney tissue fraction were added. The mixture was incubated for 90 minutes 
on ice with occasional gentle mixing. Beads were then collected in the centrifuge at 10000g/1 
minute and washed tree times by ice-cold TBS. After the last wash, supernatant was aspirated 
and beads were resuspended in 100 µL of 1X SDS-PAGE sample buffer and denatured at 
95°C/10 minutes (Dri-Block DB-3, Techne). Beads were then separated in the centrifuge 
10000g/5 minutes and 20-µl aliquot of the supernatant was analysed by SDS-PAGE followed by 
Sypro Ruby (Molecular Probes) staining. 
 
3.6.2.3 Results and discussion          
 
 As the bait, we used uromodulin isolated from healthy male urine. Initially, we have 
determined uromodulin by WB in bead supernatant after immobilisation as well as in 
subsequent washes to find uromodulin saturation threshold for sepharose beads. Coated beads 
were incubated with two different cell lysates prepared by means of non-ionic detergent Triton 
X-114.  
Triton X-114 forms two-phase micellar system in aqueous solutions at temperatures 
above 20°C, while at low temperatures forms a homogenous solution. It is therefore possible to 
use this detergent for separation of membrane and soluble cell fractions during lysis. Cold lysis 
buffer first lyses cells and any insoluble material is separated by centrifugation. Resulting pellet 
contains some of the GPI-anchored species and cellular components insoluble in non-ionic 
detergents. If the supernatant is warmed, amphiphilic proteins (including GPI-modified) 
partition to detergent-rich phase while hydrophilic (soluble) proteins partition to detergent-
depleted phase. Both phases can be subsequently separated by centrifugation at room 
temperature with detergent rich phase sedimenting on the bottom of the test tube [239].    
Partitioned lysates were prepared from HEK293 cells and from kidney tissue 
homogenate. HEK293 cell line does not express uromodulin and it was chosen to probe for 
general interactors. Kidney homogenate, on the other hand was chosen to probe for kidney 
specific interactors.  
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WB of the three fractions of kidney homogenate showed uromodulin to be most 
abundant in the pellet (non-ionic detergent insoluble material) (Figure 3.10). Detergent 
insolubility of some GPI proteins develops shortly after synthesis [142], and is thought to be due 
to aggregation of GPI modified proteins with glycosphingolipids during secretion.  
 
 
 
Figure 3.10 Uromodulin WB of Triton X-114 fractions of kidney homogenate. Samples: 1) uromodulin 
standard (isolated from healthy male urine), 2) detergent depleted (upper) fraction, 3) detergent enriched (lower) 
fraction, 4) detergent insoluble fraction (pellet). 
 
Uromodulin coated beads were incubated with all three phases (pellet, detergent-rich and 
detergent depleted phase) recovered by Triton X-114 partitioning of both cell sources. As 
blanks, we used ConA beads with no uromodulin in ConA binding reaction and otherwise 
treated in the same way as coated beads. Material bound on beads during incubation with 
fractions of lysates was released under denaturing condition and analysed by SDS-PAGE 
(Figure 3.11 and 3.12).  
 
 
Figure 3.11 ConA pull-down assay of kidney homogenate fractions (SDS-PAGE). Samples: 1) SeeBlue® Pre-
Stained Marker (Invitrogen), not stained, 2) detergent insoluble fraction (pellet), 3) detergent depleted (upper) 
fraction, 4) detergent enriched (lower) fraction, 5) the pellet fraction-blank, 6) upper fraction-blank, 7) lower 
fraction-blank; U - uromodulin. 
 
   1     2      3      4 
    1      2     3     4      5     6      7 
U 
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A                 B     C   
Figure 3.12 ConA pull-down assay of HEK293 fractions (SDS-PAGE). Order of samples (from left to right): A) 
detergent insoluble fraction (pellet), the pellet fraction-blank B) detergent depleted (upper) fraction, upper fraction-
blank, C) uromodulin standard (isolated from healthy male urine), detergent enriched (lower) fraction, lower 
fraction-blank; U - uromodulin. 
 
By this approach, however, we have never observed a protein(s) specifically present in 
uromodulin-containing incubations, i.e. not present also in blank reactions. However, 
uromodulin isolated from urine might not be suitable for this assay. It is known that peptide as 
well as glycosyl structure of kidney-synthesised uromodulin and its counterpart found in urine 
differ (chapter 3.1.3). Moreover, binding of uromodulin to solid phase through its glycosyl 
chains might block its potential binding sites. Low amounts of potential interactors in examined 
samples or transient character of interaction could also explain our results. Another possibility is 
that uromodulin has no interacting proteins in situ.  
 
In the meantime, there were described interactions between uromodulin and 
immunoglobulin G (IgG) [240], complement components 1q and 1 [241, 242], recombinant 
interleukin-1 (rIL-1) [105] and recombinant tumour necrosis factor (rTNF) [243] in vitro. 
Uromodulin was also co-immunoprecipitated with Na+-K+-ATPase (NKA) from rat kidney 
protein extract and cultured TALH cells, which probably reflects their common localization in 
lipid rafts [244]. 
 
 
 
 
 
U 
 60 
4 CONCLUSIONS 
 
1) We were able to gather one of the largest sets of families with UAKD in the world. Through 
international collaboration and urinary uromodulin screening, we were able to gain biological 
materials from members of altogether 31 families (including unpublished results).  
 
2) Using genotyping, linkage analysis and UMOD sequencing we proved genetic heterogeneity 
of the disease. We identified UMOD mutation in 8 families (including unpublished results) and 
characterised molecular properties and aberrant cellular trafficking of 6 mutant recombinant 
UMOD proteins. 
 
3) By genome wide linkage analysis we identified new UAKD locus on chromosome 1q41. In 
large Belgian family (BE1) with atypical FJHN, we identified single locus and single haplotype 
segregating with the disease, performed sequence analysis of 9 candidate genes in which we 
found no classical deleterious mutation. Finally, we found heterozygous deletion mutation in 
REN gene and characterised molecular properties and numerous cellular effects of mutant 
recombinant renin and suggested probable pathogenetic mechanisms. 
 
4) We provided evidences that alteration of uromodulin biology is common to genetically 
heterogenous UAKD. We showed decreased UMOD urinary excretion in almost all investigated 
families. Accordingly, immunohistochemical analyses of kidney sections revealed abnormal 
uromodulin expression in FJHN/MCKD patients with different genetic backgrounds. 
 
5) We were not able to identify any uromodulin interacting proteins by means of yeast two-
hybrid system and concanavalin A pull-down assays. 
 
Practical outputs 
1) We introduced numerous molecular genetic, molecular biological and biochemical methods 
for the analysis of recombinant as well as native UMOD and renin proteins. 
 
2) Western blot of urinary uromodulin is used routinely in our Institute for selective screening of 
hyperuricaemic conditions. By this approach, we identified 5 Czech UAKD families and 
subsequently UMOD mutation in 3 of them (including unpublished results). 
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Through international collaboration, we similarly identified 1 Danish family with UMOD 
mutation and 5 families from the United Kingdom, 3 of them with UMOD mutation 
(unpublished results). 
 
3) We provide unique, complex diagnostic service for this group of disorders. 
 
Special notes 
1) Oral presentation of our results, subsequently published in our article titled “Alterations of 
uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD 
syndrome” (chapter 9.2.2), was awarded the best presentation on the 31st congress of Czech 
Society for Nephrology held 24. 6. 2006 in Hradec Králové. 
 
2) Figure 5 in our article “Alterations of uromodulin biology: a common denominator of the 
genetically heterogeneous FJHN/MCKD syndrome” (chapter 9.2.2) titled “Cellular localization 
of wildtype UMOD and individual UMOD mutants in permeabilised AtT-20 cells studied 18 h 
after transfection” was selected by the editors of Kidney International journal for cover page of 
the second September issue (6th issue of 70th volume) in 2006.   
 
5 GENERAL METHODS 
Unless otherwise stated, water used in experiments was ultrapure water prepared from 
common distilled water in Milli-Q® RG Ultrapure Water Purification System (Millipore). 
 
5.1 Isolation of uromodulin from urine 
Urinary uromodulin was isolated from one litre of healthy male urine collected between 
7 am and 17 pm by the salt out method similar to original procedure reported by Tamm and 
Horsfall [91]. NaCl was added to urine to 0.58 M and the solution was stirred overnight at 4°C. 
Precipitate was collected in high-speed benchtop centrifuge (MR22i, Jouan or 4K15, SIGMA 
Laborzentrifugen) at 5000g/20 minutes into 50 mL tubes (TPP), washed once with 0.58 M NaCl 
solution and then collected again at 5000g/10 minutes. After aspiration of supernatant, 
precipitate was dissolved in distilled water, transferred to 1.5 mL test tubes (Deltalab) and 
centrifuged 5000g/10 minutes to remove insoluble material. Supernatant from all tubes was 
collected to presoaked 25 mm dialysis tube (Sigma), dialysed against four litres of distilled 
water at 4°C for 3 days and then lyophilised (Christ Alpha 1-4, B.Braun Biotech International). 
Lyophilisate was weighted and dissolved in water with 0.02% (w/v) NaN3. The evaluation of 
purified uromodulin was done by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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as well as by Western blot with mouse monoclonal (Cedarlane) or rabbit polyclonal 
(Biogenesis) anti-THP antibody as described in chapters 5.2 and 5.3. 
 
5.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Buffers and solutions: 
Acrylamide/bisacrylamide stock solution: 29% (w/v) acrylamide (AA), 1% (w/v) 
methylenebisacrylamide (bisAA). 
4X SDS-PAGE separating gel buffer: 1.5 M Tris base, 0.0139 M SDS, pH 8.8 was adjusted by 1 
M HCl (OP-274 pH/Ion Analyser, Radelkis). 
4X SDS-PAGE stacking gel buffer: 0.5 M Tris base, 0.0139 M SDS, pH 6.8 was adjusted by 1 
M HCl. 
10X SDS-PAGE running buffer: 1.918 M glycine, 0.248 M Tris base, 0.0347 M SDS, pH 8.3 
(not adjusted) 
6X SDS-PAGE sample buffer: 0.012% (w/v) bromphenol blue, 30% (v/v) glycerol, 0.347 M 
SDS, 6% (v/v) β-mercaptoethanol (BME). 
10% ammonium persulphate (APS): 1 g of APS was dissolved in 10 mL of water, aliquoted and 
stored at -20°C.  
Coomassie blue staining solution: 0.1% (w/v) coomassie blue R250, 50% methanol (v/v), 10% 
(v/v) acetic acid. Coomassie blue was dissolved in methanol before addition of other 
components. 
Coomassie blue destain solution: 10% (v/v) methanol, 10% (v/v) acetic acid. 
Sypro Ruby fix solution: 50% (v/v) methanol, 7% (v/v) acetic acid, prepared freshly. 
Sypro Ruby wash solution: 10% (v/v) methanol, 7% (v/v) acetic acid, prepared freshly. 
 
Separating gels were prepared by mixing AA/bisAA stock solution, 4X SDS-PAGE 
separating gel buffer and water. Polymerisation was initiated by addition of tetramethyl-
ethylenediamine (TEMED) and APS solution to concentration 0.06% (v/v and w/v, 
respectively). This mixture was poured between assembled glasses and overlaid by water. After 
minimum 45 minutes, water was poured off and stacking gel prepared by mixing AA/bisAA 
stock solution, 4X SDS-PAGE stacking gel buffer, water and TEMED and APS solutions to 
concentrations 0.152% (v/v) and 0.14% (w/v), respectively, was poured. Comb was set 
immediately and after minimum 15 minutes, assembly was fixed in vertical electrophoresis 
apparatus (MightySmall II SE250 or SE260, Hoefer). Samples were prepared by mixing with 
6X SDS-PAGE sample buffer in 1.5 mL or 0.2 mL (Eppendorf) tubes and denaturation at 100°C 
for five minutes in dry block thermostat (Dri-Block DB-3, Techne) or PCR thermal cycler 
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(PTC-225 DNA Engine Tetrad, MJ Research). After pouring 1X SDS-PAGE running buffer, 
samples were loaded and electrophoresed at 100V in stacking gel and at up to 160V in 
separating gel.  
 
Gels after electrophoresis were stained in Coomassie blue staining solution for at least 30 
minutes and destained by at least two successive washes in Coomassie blue destain solution. 
Alternatively, gels were stained by SYPRO® Ruby protein gel stain (Molecular Probes) solution 
according to manufacturer’s instructions for Rapid Protocol. Images were acquired by digital 
camera (Camedia C2000Z, Olympus) on UV transilluminator (Macrovue 2011, LKB).          
 
5.3 Western blotting (WB) 
Buffers and solutions: 
Blotting buffer: 0.048 M Tris Base, 0.039 M glycine, 0.037% (w/v) SDS, 20% (v/v) methanol, 
pH 9.2 (not adjusted) 
10X Phosphate-buffered saline (10X PBS): 1.37 M NaCl, 0.27 M KCl, 0.78 M Na2HPO4, 0.15 
M KH2PO4, pH 7.3 was adjusted by 1M NaOH (OP-274 pH/Ion Analyser, Radelkis).  
1X Phosphate-buffered saline (PBS): prepared by ten-fold dilution of 10X PBS with water. 
Blocking buffer (PBS-T/5%BSA): 0.137 M NaCl, 0.027 M KCl, 0.078 M Na2HPO4, 0.015 M 
KH2PO4, pH 7.3, 0.05% (v/v) Tween 20, 5% (w/v) bovine serum albumin (BSA). 
Washing buffer (PBS-T): 0.137 M NaCl, 0.027 M KCl, 0.078 M Na2HPO4, 0.015 M KH2PO4, 
pH 7.3, 0.05% (v/v) Tween 20. 
Antibody buffer (PBS-T/0.1%BSA): 0.137 M NaCl, 0.027 M KCl, 0.078 M Na2HPO4, 0.015 M 
KH2PO4, pH 7.3, 0.05% (v/v) Tween 20, 0.1% (w/v) BSA. 
 
Proteins separated by SDS-PAGE were transferred onto PVDF membranes (Immobilon-
P, Millipore) in semidry blotting apparatus (PHERO-multiblot, Biotec-Ficher). Blotting buffer 
was prepared and stored without methanol, which was added right before use. Gels were soaked 
in blotting buffer for at least twenty minutes. In parallel, PVDF membranes were activated in 
methanol for 20 seconds and then soaked in blotting buffer. Before blotting, six blotting papers 
were soaked in blotting buffer. Blotting sandwich was assembled onto carbon anode as follows: 
three blotting papers-PVDF membrane-gel-three blotting papers. Sandwich was then covered by 
carbon cathode wetted by blotting buffer. Transfer was carried out at 1.6 mA/cm2 of blotting 
sandwich for one hour. 
 Membranes were blocked in blocking buffer for one hour, washed three times for seven 
minutes in washing buffer and incubated for one hour with primary monoclonal (Cedarlane) or 
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polyclonal (Biogenesis) anti-THP antibody diluted 1:2000 or 1:10000, respectively, in antibody 
buffer. Following washing in washing buffer three times for 7 minutes, membranes were 
incubated for 45 minutes with secondary goat anti-mouse IgG or goat anti-rabbit IgG antibody 
conjugated to horseradish peroxidase (HRP) (Pierce) diluted 1:5000 or 1:10000, respectively, in 
antibody buffer. Following washing in washing buffer once for 15 minutes, twice for 7 minutes 
and finally once for 7 minutes in PBS, membranes were developed by SuperSignal West Pico 
Chemiluminescent Substrate Kit (Pierce) according to manufacturer’s instructions. 
Chemiluminescent signal was detected manually by exposition to Medical X-ray Blue Films 
(Agfa). Films were developed for 2 minutes and fixed for 2 minutes in Fomadent set solutions 
(Foma Bohemia). After extensive washing in tap water, films were let dry. 
All antibody incubations and washes were performed during horizontal shaking on KM-
2 Miniature Shaker (Edmund-Bühler Gmbh) or Orbital Shaker OS-20 (Biosan) at 60 revolutions 
per minute (rpm). 
 
5.4 DNA electrophoresis in agarose gel 
Buffers and solution: 
0.5 M disodium ethylenediamine tetraacetate (EDTA): 18.6 g of Na2EDTA.2H2O was mixed 
with 70 ml of water and 1M NaOH was added during mixing until dissolution of solid, then pH 
was checked (OP-274 pH/Ion Analyser, Radelkis) and volume was made up to 100 mL.  
10X TBE (Tris-Borate-EDTA): 0.89 M Tris Base, 0.89 M Boric acid, 0.02 M EDTA. 
50X TAE (Tris-Acetate-EDTA): 2 M Tris Base, 5.7 % (v/v) acetic acid, 0.1 M EDTA. 
10X loading buffer: 20% (w/v) Ficoll 400, 0.1 M EDTA, 1% (w/v) SDS, 0.25% (w/v) BPB, 
0.25% (w/v) xylene cyanol (optional). 0.5 M EDTA stock solution, pH 8 was used for the 
preparation of the buffer. 
1000X Ethidium bromide solution (EtBr): 0.5 mg/mL EtBr. 
 
 Agarose (Serva, #11404) was mixed with 1X TBE buffer to desired concentration and 
the suspension was boiled in microwave oven (MW 736, Clatronic) until clearing. Hot liquid gel 
was then cooled to about 40°C, poured to electrophoretic chamber and let solidify. Gel was then 
covered by 1X TBE buffer, samples were mixed with 10X loading buffer in 1:9 ratio and loaded 
on the gel together with appropriate DNA molecular weight marker. Electrophoresis was 
performed at the intensity of 10 V/cm (PS143 electrophoresis power supply, EMBL). For DNA 
visualisation, the gel was submerged into 1X EtBr solution. Images were acquired by digital 
camera (Camedia C2000Z, Olympus) on UV transilluminator (Macrovue 2011, LKB). If DNA 
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fragments were to be isolated from the gel, the same procedure was followed but 1X TAE buffer 
was used for gel preparation and electrophoresis. 
 
5.5 Isolation of DNA fragments from the agarose gel 
 After separation of DNA fragments by 1% (w/v) agarose gel electrophoresis (chapter 
5.4), gel was briefly submerged to 1X EtBr solution, fragments of interest were excised from the 
gel by clean scalpel on UV transilluminator (Macrovue 2011, LKB) and slices were placed to 
1.5 ml tubes (Deltalab). DNA was then extracted from slices by the Wizard® SV Gel and PCR 
Clean-Up System (Promega) according to manufacturer’s instructions. Briefly, gel slice was 
differentially weighed and 10 µL of Membrane Binding Solution (kit component) per 10 mg of 
gel slice was added. Mixture was then vortexed (Vortex-Genie 2, Scientific Industries) and 
incubated at 65°C (Dri-Block DB-2A thermostat, Techne) with occasional mixing until 
complete dissolution of the slice. SV Minicolumn and Collection Tube (kit components) were 
then assembled, gel solution was transferred to the assembly and let stand at RT/1 minute. 
Assembly was centrifuged at 16000g/1 minute (5415 D centrifuge, Eppendorf), flow-through 
was discarded and column was washed twice with 700 and 500 µL of Membrane Wash Solution 
(kit component) with added ethanol at 16000g/1 and 5 minutes, respectively. Empty assembly 
was then centrifuged at 16000g/1 minute with the centrifuge lid off. Minicolumn was transferred 
to a clean 1.5 ml tube, 50 µL of Nuclease Free-Water (kit component) was added and after 
incubation at RT/1 minute, DNA was eluted at 16000g/1 minute. 
 
5.6 Determination of DNA concentration 
 Concentration and quality of DNA isolated from agarose gels or from bacterial cultures 
were determined by either BioPhotometer (Eppendorf) or Nanodrop® ND-1000 
Spectrophotometer (Nanodrop Technologies). For BioPhotometer (one point measurement at 
280 nm), 100 µL of diluted sample (1:99) were used. For Nanodrop ND-1000 (spectral 
measurement from 220 nm to 350 nm) operated by Nanodrop software v3.1.0, 1.5 µL of neat 
sample was used. In both cases, appropriate blanking was used. 
 
5.7 DNA sequencing 
 
5.7.1 Cycle sequencing on slab gel platform  
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Buffers and solutions: 
10X TBE for sequencing: 1 M Tris Base, 0.91 M Boric acid, 0.01 M EDTA. The solution 
components were dissolved in water and solution was filtered through VacuCap® 60 Filter Unit 
with 0.2 µm membrane (Pall, #4632). 
Sequencing polymer: 5.5% Long Ranger Gel Solution (Cambrex), 6 M urea in 1.5X TBE for 
sequencing. Urea was dissolved in water and then 10X TBE for sequencing stock solution and 
50% Long Ranger Gel Solution stock (Cambrex) were added. Solution was then gently stirred at 
RT/30 minutes (MR 3001K magnetic stirrer, Heidolph) with PlusOne™ Amberlite IRN-150L 
resin (Amersham Biosciences) added to 10% (w/v) and then filtered through Stericup™ Filter 
Unit with 0.22 µm Millipore Express PLUS membrane (Millipore, #SCGP U05 RE). 
Stop sequencing mix: 0.6% (w/v) dextran blue, 0.02 M EDTA in formamide. Formamide was 
stirred at RT for 30 minutes (MR 3001K magnetic stirrer, Heidolph) with AG® 501-X8 resin 
(Bio-Rad, #142-6424) added to 10% (w/v). Mixture was then filtered through Whatmann 1 filter 
paper and dextran blue and EDTA were added to the filtrate. 
Dideoxyadenosine triphosphate (ddATP) termination mix: 1 mM each deoxyadenosine 
triphosphate (dATP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate 
(dTTP), 0.67 mM deoxyguanosine triphosphate (dGTP), 0.33 mM 7-deaza-dGTP, 0.00833 mM 
ddATP. 
Dideoxycytidine triphosphate (ddCTP) termination mix: 1 mM each deoxyadenosine 
triphosphate (dATP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate 
(dTTP), 0.67 mM deoxyguanosine triphosphate (dGTP), 0.33 mM 7-deaza-dGTP, 0.00833 mM 
ddCTP. 
Dideoxyguanosine triphosphate (ddGTP) termination mix: 1 mM each deoxyadenosine 
triphosphate (dATP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate 
(dTTP), 0.67 mM deoxyguanosine triphosphate (dGTP), 0.33 mM 7-deaza-dGTP, 0.00833 mM 
ddGTP. 
Dideoxythymidine triphosphate (ddTTP) termination mix: 1 mM each deoxyadenosine 
triphosphate (dATP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate 
(dTTP), 0.67 mM deoxyguanosine triphosphate (dGTP), 0.33 mM 7-deaza-dGTP, 0.00833 mM 
ddTTP. 
10% APS: 1 g of ammonium persulphate was dissolved in 10 mL of water, aliquoted and stored 
at -20°C. 
 
 For cycle sequencing of polymerase chain reaction (PCR) products or plasmids on slab 
gel platform we used dideoxynucleotide termination approach utilising universal primers 
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labelled by carbocyanine 5 (Cy5) fluorescent dye on their 5’ends and termostable DNA 
polymerase (AmpliTaq® FS DNA Polymerase, Applied Biosystems). Accordingly, PCR 
oligonucleotides were designed to be composed of two distinct parts: target specific part on 3’ 
end and sequence resembling labelled universal primer on 5’ end. Target specific parts were 
designed mainly using Oligo 6.44 software (Molecular Biology Insights). We used following 
labelled primers for cycle sequencing (Genset Oligos): 
 
T7:  5´ Cy5-AATACGACTCACTATAG 3´  
RP: 5´ Cy5-GAAACAGCTATGACCATG 3´  
 
They conform to T7 priming site and M13 Reverse priming site present in the vicinity of 
multiple cloning site of many cloning vectors. We usually added the T7 sequence to a PCR 
upper primer and RP sequence to a lower primer.  
 For single sequence analysis, following reaction mix was set to 1.5 ml tube (Deltalab): 
 
Component Amount 
Template DNA 100-200 fmol* 
10X PC2 buffer** 2.8 µL 
2 µM Cy-5 labelled sequencing primer 1.5 µL 
AmpliTaq® FS DNA Polymerase 0.7 µL 
25 mM MgCl2 solution** 3.4 µL 
Water to 21 µL 
*Amount of substance of DNA fragments were calculated with the assumption that one base pair corresponds to 
660 g/mol. 
**Purchased from Ab Peptides, Inc. 
 
5 µL of this mix was dispensed to each of four 0.2 mL tubes (Eppendorf) each containing 2 µL 
of corresponding dideoxynucleoside triphosphate (ddNTP) termination mix. Tubes were then 
placed to the thermal cycler (PTC-225 DNA Engine Tetrad, MJ Research) and went through the 
following thermal program: 
 
Segment Number of cycles Temperature (°C) Time (s) 
1 1 95 180 
2 35 95 
50 
68 
15 
25 
40 
3 1 68 300 
4 1 15 for ever 
 
After the program termination, 5 µL of Stop sequencing mix were added to each tube. Reaction 
tubes were then placed to thermal cycler again, denatured at 95°C/3 minutes and at 85°C/10 
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minutes and then placed immediately on ice. Usually 9 µL from each tube were loaded on 
sequencing gel.  
The gel was prepared by mixing Sequencing polymer with APS and TEMED to 
concentrations of 0.054% (w/v and v/v, respectively). As an anodic and cathodic buffer, 0.5X 
TBE for sequencing was used. Electrophoresis was run in ALFexpress™ or ALFexpress™ II 
DNA Automated Sequencer under following conditions: 
 
Parameter Value 
Runtime 700 minutes 
Voltage 1500 V 
Current 60 mA 
Power 25 W 
Temperature 55°C 
 
ALFexpress™ operation, data collection and their analysis were assisted by Alfwin™ 
Sequence Analyser 2.0 software (Pharmacia Biotech). 
 
5.7.2 Cycle sequencing on capillary platform 
On this platform, we used complete instrumentation and chemistry from Applied 
Biosystems. BigDye Terminator v3.1 Cycle Sequencing Kit was used for cycle sequencing 
reactions. This kit contains ddNTPs each labelled by a different fluorescent dye, enabling the 
use of unlabelled primers for sequencing, including those used for PCR amplification of 
sequenced DNA fragments. Template DNA was purified by ethanol precipitation according to 
manufacturer’s instructions. Following thermal program was acquired for cycle sequencing: 
 
Segment Number of cycles Temperature (°C) Time (s) 
1 1 96 60 
2 25 96 
50 
60 
10 
5 
240 
3 1 15 for ever 
 
 After program termination, Hi-Di™ Formamide was added to each reaction and after 
denaturation at 95°C/3 minutes and cooling down on ice, samples were run on ABI Prism 3100-
Avant™ Genetic Analyzer equipped with 50 cm four-capillary array filled with POP-6™ 
Polymer for 3100/3100-Avant™ Genetic Analyzers. Electrode buffer was prepared from 10X 
Running Buffer. Data were collected by 3100-Avant Data Collection Software v2.0 and 
analysed by Sequencing Analysis Software v5.1.  
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All the work along the analytical pipeline except for template preparation and the analysis of 
resulting sequences were performed by my colleague Helena Myšková, B.Sc. at the Institute of 
Inherited Metabolic Disorders of First Faculty of Medicine of Charles University in Prague. 
 
5.8 Bacteriology 
Bacterial media and solutions: 
SOC medium: 2% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose. Tryptone, Yeast extract and NaCl were 
completely dissolved in water first followed by KCl. pH was adjusted to 7 - 7.2 by 1 M NaOH 
(about 1 mL) and the resulting solution was autoclave sterilised. Filter sterilised (0.22 µm filter 
Milex GP, Millipore) 1 M stock solutions of MgCl2, MgSO4 and D-glucose were added 
eventually. Medium was aliquoted and stored at -20°C. 
LB (Luria-Bertani) medium: 0.5% (w/v) Yeast extract, 1% (w/v) Tryptone, 1% (w/v) NaCl. All 
components were dissolved in water and pH was adjusted to 7.0 - 7.2 by 1 M NaOH (about 1 
mL) and the resulting solution was autoclave sterilised. 
Ampicillin stock solution: 50 mg/mL ampicillin. The antibiotic was dissolved in water, 
aliquoted and stored at -20°C. 
LB (Luria-Bertani) ampicillin plates:  0.5% (w/v) Yeast extract, 1% (w/v) Tryptone, 1% (w/v) 
NaCl. All components were dissolved in water, pH was adjusted to 7.0 - 7.2 by 1 M NaOH 
(about 1 mL), agar was added to 1.5% (w/v) and the resulting solution was autoclave sterilised. 
Medium was let cool down to about 50°C, ampicillin was added to 50 µg/mL, plates were 
poured and after the solidification stored at 4°C. 
Glycerol storage solution: 65% (v/v) glycerol, 0.1 M MgSO4, 0.025 M Tris-Cl pH 8. The 
solution was prepared from 1 M Tris-Cl stock solution, pH 8 (adjusted by 1M NaOH using OP-
274 pH/Ion Analyser, Radelkis) and filter sterilised. For long-term storage of E. coli clones, 
overnight cultures were mixed 1:1 with the glycerol storage solution, frozen in mixture of dry 
ice and denatured ethanol and stored at -70°C.  
 
Bacterial strains: 
XL1-Blue strain has genotype recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr)]. Electrocompetent XL1-Blue cells were kindly provided by Martin 
Pospíšek, Ph.D. from Laboratory of RNA Biochemistry at Department of Genetics and 
Microbiology, Faculty of Science of Charles University, Czech Republic. 
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DH5α strain has genotype F-, φ80dlacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1. Electrocompetent DH5α cells were 
kindly provided by my former colleague Miroslav Janošík, Ph.D. 
OneShot® TOP10 strain (Invitrogen) has genotype F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(araleu) 7697 galU galK rpsL (StrR) endA1 nupG. 
 
5.8.1 Transformation of E. coli with plasmid DNA 
For propagation of pGBD-B bait constructs isolated from yeasts by Lyticase-
phenol/chloroform method (previous chapter), electrocompetent E. coli strains XL1-Blue or 
DH5α were transformed by electroporation in E. coli Pulser (Bio-Rad) according to 
manufacturer’s instructions. Transformed cells were then spread over and selected on LB-
ampicillin plates.  
Briefly, for one transformation, 40 µL of cold competent cells and 1 µL of DNA 
preparation were mixed and transferred to cold 0.2 cm cuvettes. Cuvettes were then placed to 
cold cuvette slide and quickly pulsed at 2.5 kV. Immediately after pulse, 1 mL of RT SOC 
medium was added to the cuvette. Cell suspension was transferred to 15 mL polystyrene tube 
(Gama Group) and incubated at 37°C/1 hour with shaking (Cellstar incubator, Queue Systems). 
After the incubation, 200 µL of suspension were spread over LB-ampicillin plates followed by 
overnight incubation at 37°C (Biological Thermostat BT 120 M, Ekom). 
 
5.8.2 Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated from E. coli liquid cultures by QIAprep Spin Miniprep Kit 
(Qiagen, #27106). Briefly, 5 mL of LB medium supplemented with ampicillin to the 
concentration of 50 µg/mL were inoculated by bacterial clone transformed with plasmid of 
interest and incubated at 37°C overnight with shaking (Cellstar incubator, Queue Systems). The 
following day, cells were harvested from 4 mL of overnight culture by two successive 
centrifugations in 2 mL tubes (Deltalab) at 4500g/5 minutes (5415 D centrifuge, Eppendorf). 
Pellets were resuspended in 250 µL of Buffer P1 (kit component) and 250 µL of Buffer P2 (kit 
component) were added. Tubes were inverted four to six times and 350 µL of Buffer N3 were 
added. Tubes were inverted four to six times immediately and centrifuged at 16100g/10 
minutes. Supernatants were directly applied to the QIAprep spin columns (kit component). 
Columns were centrifuged at 16100g/30 seconds and the flow-throughs were discarded. 
Columns were then washed by 0.75 mL of Buffer PE (kit component) at 16100g/30 seconds, 
flow-throughs were discarded and columns were centrifuged for one additional minute to 
remove residual wash buffer. Finally, QIAprep columns were placed in a clean 1.5 ml tubes 
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(Deltalab) and DNA was eluted by 40 µL of water at 16100g/1 minute after one-minute standing 
at RT. 
 
6 LIST OF SUPPLIERS 
 
6.1 Chemicals 
Ab Peptides, Inc.  St. Louis, MO, USA; www.abpeps.com  
Amersham Biosciences Corp. Piscataway, NJ, USA; www.amersham.com or 
www.gelifesciences.com 
Applied Biosystems Foster City, CA, USA; www.appliedbiosystems.com 
BD Biosciences Clontech Palo Alto, CA; www.bdbiosciences.com 
Biogenesis Ltd Poole, UK; www.biogenesis.co.uk 
Bio-Rad, s.r.o. Prague, Czech Republic; www.bio-rad.com 
Cambrex Corporation East Rutherford, NJ, USA; www.cambrex.com 
Cedarlane Hornby, Ontario, Canada; www.cedarlanelabs.com 
CONLAC, s.r.o. Prague, Czech Republic; www.conlac.cz 
Fermentas International, Inc. Burlington, Ontario, Canada; www.fermentas.com 
Foma Bohemia, s.r.o. Hradec Králové, Czech Republic, www.foma.cz 
Generi Biotech, s.r.o. Hradec Králové, Czech Republic; www.generi-
biotech.com 
Genset Oligos La Jolla, CA, USA; www.proligo.com or 
www.sigmaaldrich.com 
Lach-Ner, s.r.o. Neratovice, Czech Republic; www.lach-ner.com 
Molecular Probes Eugene, OR, USA; http//probes.invitrogen.com 
New England Biolabs Ipswich, MA, USA; www.neb.com 
Penta Prague, Czech Republic; www.penta-chem.cz 
Pharmacia Biotech AB Uppsala, Sweden; www.gelifesciences.com 
Pierce Rockford, IL, USA; www.pircenet.com or 
www.thermo.com 
Promega Madison, WI, USA; www.promega.com 
ProZyme, Inc.  San Leandro, CA, USA; www.prozyme.com 
RNDr. Jan Kulich, s.r.o. Hradec Králové, Czech Republic; www.kulich.cz 
Roche, s.r.o. Prague, Czech Republic; www.roche-applied-
science.com 
Serva Electrophoresis GmbH Heidelberg, Germany; www.serva.de 
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Sigma-Aldrich, s.r.o. Prague, Czech Republic; www.sigmaaldrich.com 
USB Europe GmbH Staufen, Germany; www.usbweb.com 
 
6.2 Consumables 
Agfa-Gevaert N.V. Mortsel, Belgium; www.agfa.com 
Deltalab, S.L. Rubí (Barcelona), Spain; www.deltalab.es 
Eppendorf AG Hamburg, Germany; www.eppendorf.com 
Gama Group, a.s. Trhové Sviny, Czech Republic; www.gama.cz 
Millipore Billerica, MA, USA; www.millipore.com 
Pall Life Sciences Ann Arbor, MI, USA; www.pall.com 
Sigma-Aldrich s.r.o. Prague, Czech Republic; www.sigma-aldrich.com 
TPP Trasadingen, Switzerland; www.tpp.ch 
 
6.3 Instruments 
A&D Engineering, Inc. San Jose, CA, USA; www.andweighing.com 
Amersham Biosciences Corp. Piscataway, NJ, USA; www.amersham.com or 
www.gelifesciences.com 
Applied Biosystems Foster City, CA, USA; 
www.appliedbiosystems.com 
B.Braun Biotech International GmbH Melsungen, Germany; www.sartorius.de 
Biosan Riga, Latvia; www.biosan.lv 
Biotec-Fischer GmbH Reiskirchen, Germany; www.biotec-fischer.de 
BioTek Instruments, Inc. Winooski, VT, USA; www.biotek.com 
Clatronic International GmbH Kempen, Germany; www.clatronic.de 
Cole-Parmer Instrument Co. Chicago, IL, USA; www.coleparmer.com 
Consort nv Turnhout, Belgium; www.consort.be 
Edmund Bühler GmbH  Hechingen, Germany; www.edmund-buehler.de 
Ekom, s.r.o. Polná, Czech Republic 
EMBL Heidelberg, Germany 
Eppendorf AG Hamburg, Germany; www.eppendorf.com 
Gibco-BRL Geithersburg, MD, USA; www.gibcobrl.com or 
www.invitrogen.com 
Heidolph Instruments GmbH & Co. KG Schwabach, Germany; www.heidolph-
instruments.de 
Hoefer Scientific Instruments San Francisco, CA, USA; www.hoeferinc.com or 
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www.gelifesciences.com 
IKA Werke GmbH Staufen, Germany; www.ika.net 
Jouan S.A. St. Herblain, France; www.thermo.com 
LKB-Produkter AB Bromma, Sweden; www.amersham.com or 
www.gelifesciences.com 
Millipore Billerica, MA, USA; www.millipore.com 
MJ Research, Inc. Watertown, MA, USA; www.bio-rad.com 
NanoDrop Technologies, Inc. Wilmington, DE, USA; www.nanodrop.com 
Ohaus Pine Brook, NJ, USA; www.ohaus.com 
Olympus  Prague, Czech Republic; www.olympus.cz 
Pharmacia Biotech AB Uppsala, Sweden; www.gelifesciences.com 
Queue Systems, Inc. Asheville, NC, USA 
Radelkis Kft. Budapest, Hungary; www.radelkis.hu 
SANYO E&E Europe BV Loughborough, UK; www.sanyo-
biomedical.co.uk 
Scientific Industries, Inc. Bohemia, NY, USA; 
www.scientificindustries.com 
SIGMA Laborzentrifugen GmbH Osterode am Harz, Germany; www.sigma-
zentrifugen.de 
SLT Laboratory Instruments  Salzburg, Austria; www.tecan.com 
Unicam Ltd Cambridge, UK; www.thermo.com 
 
6.4 Software 
Applied Biosystems Foster City, CA, USA; www.appliedbiosystems.com 
Microsoft, s.r.o. Prague, Czech Republic; www.microsoft.com/cze 
Molecular Biology Insights, Inc. Cascade, CO, USA; www.oligo.net 
Pharmacia Biotech AB Uppsala, Sweden; www.gelifesciences.com 
Schoeller Pharma Praha, s.r.o. Prague, Czech Republic; www.schoeller.cz 
 
7 LIST OF ABBREVIATIONS 
 
AA acrylamide, amino acid(s) 
AD activation domain, autosomal dominant 
AGT angiotensinogen 
APS ammonium persulphate 
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BD binding domain 
bisAA methylenebisacrylamide 
BME β-mercaptoethanol 
bp base pair 
BPB bromphenol blue 
BSA bovine serum albumin 
cDNA complementary  or coding DNA 
CDS coding sequence 
cM centimorgan 
ConA Concanavalin A 
Cy5 carbocyanine 5 
Da Dalton 
DCT distal convoluted tubule(s)  
ddNTP dideoxynucleoside triphosphate 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
EDTA ethylenediamine tetraacetate 
EGF epidermal growth factor 
ELISA enzyme-linked immunosorbent assay 
EM electron microscopy 
ER endoplasmic reticulum 
ERAD ER associated protein degradation 
ESRD end-stage renal disease 
EtBr ethidium bromide 
FACS fluorescent automated cell sorting 
FEur urate fractional excretion 
FJHN familiar juvenile hyperuricaemic nephropathy 
GFR glomerular filtration rate 
GPI glycosyl phosphatidylinositol 
HEK human embryonic kidney 
HGPRT hypoxanthine-guanine phosphoribosyl transferase 
HRP horseradish peroxidase  
IVT in vitro translation 
JGA juxtaglomerular apparatus 
LiAc lithium acetate 
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LOD logarithm of odds 
MCKD medullary cystic kidney disease 
MS mass spectrometry 
MW molecular weight 
NaAc sodium acetate 
NPH, NPHP nephronophthisis 
NTP nucleoside triphosphate 
PAGE polyacrylamide gel electrophoresis 
PIC protease inhibitor cocktail 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PRPS phosphoribosyl pyrophosphate synthetase 
PT proximal tubule(s) 
RAS renin-angiotensin system 
RNA ribonucleic acid 
rpm revolutions per minute 
RT room temperature 
SDS sodium dodecylsulphate 
SNP single nucleotide polymorphism 
SRP signal recognition particle 
TALH thick ascending loop of Henle 
TBS tris-buffered saline 
TEMED tetramethyl ethylenediamine 
THP Tamm-Horsfall protein 
UAKD uromodulin associated kidney disease 
UPR unfolded protein response 
UTR untranslated region 
UV ultraviolet 
WB Western blot(ting) 
YTHS yeast two-hybrid system 
ZP zona pellucida 
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Abstract 
We analysed family with autosomal-dominant tubulointerstitial nephropathy characterized by 
combination of hyperuricemia, decreased urinary uromodulin (UMOD) excretion and abnormal 
UMOD expression in the kidney. Using positional cloning we identified in affected individuals 
deletion of one of the leucine residues forming hydrophobic pentaleucine motif of the 
preprorenin signal sequence. We found that the mutation decreases signal peptide 
hydrophobicity required for efficient ER translocation, changes property of the out cleaved 
signal peptide and limits biosynthesis of secretory competent and catalytically active prorenin 
and renin proteins. Cells stably expressing mutant protein retained prorenin and renin 
intracellularly and showed reduced growth rate and signs of activated ER stress, unfolded 
protein response and pronounced autophagy. The immunohistochemical analysis of kidney 
tissues showed in patients reduced expression of prorenin and renin in site of juxtaglomerular 
apparatus, absence of renin expressing cells along the tubules and enhanced ectopic expression 
of prorenin and renin in arterioles and arteries. Our results indicates that the identified mutation 
leads to aberrant prorenin and renin biosynthesis, ER-stress mediated cytotoxicity and slowly 
progressing damage of renin expressing cells which probably affects structure and function of 
juxtaglomerular apparatus, changes sensitivity of the tubuloglomerular feedback mechanism and 
alters renal blood flow autoregulation, which lead to ischemia, loss of glomeruli, 
tubulointerstitial injury and end-stage renal disease. We believe that the presented genetic defect 
and phenotype define and document the range and functional importance of juxtaglomerular 
cells and the intra-renal RAS system, which is still not well understood in humans.  
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Introduction 
The term of the uromodulin-associated kidney diseases (UAKD) emerged recently for a group 
of autosomal-dominant tubulointerstitial nephropathies characterized by combination of 
hyperuricemia, gouty arthritis, decreased urinary uromodulin (UMOD) excretion and abnormal 
UMOD expression in the kidney [1]. UAKD comprises phenotypes known as a familial juvenile 
hyperuricemic nephropathy (FJHN) (OMIM 162000) [2, 3], medullary cystic kidney diseases 
type 1 (MCKD1) (OMIM 174000) [4], and type 2 (MCKD2) (OMIM 603860) [5]. The 
association of these phenotypes with disturbances of the UMOD biology was established 
following the identification of UMOD mutations in some of the families [6]. Although present 
in majority of the cases [7-12], UMOD mutations are clearly not the only cause of the UAKD 
phenotype [1, 13-18]. The other disease causing gene(s) still remain(s) to be identified.  
In this work we advanced our analysis in a single UAKD family showing linkage to 
chromosome 1q41 [19], and identified in affected individuals a deletion of one of the leucine 
residues forming hydrophobic pentaleucine motif of the preprorenin signal sequence. 
Preprorenin is expressed by juxtaglomerular (JG) cells in the kidney. It is a biosynthetic 
precursor of prorenin and renin which are produced by glycosylation and proteolytic processing 
of the nascent preproprotein [20]. Both, prorenin and renin are secretory proteins active in the 
renin-angiotensin system (RAS) [21], and the (pro)renin receptor signal transduction pathway 
which is distinct from RAS receptor signalling [22]. Both pathways play an important role in 
kidney physiology and pathology. Mutations in the RAS system components cause autosomal 
recessive renal tubular dysgenesis [23-25]. The (pro)renin receptor knockout in mouse was 
lethal [26], and human (pro)renin receptor transgenic rats developed gradual proteinuria and 
glomerulosclerosis [27]. Moreover renin-1 in mice is essential for normal JG cell granulation, 
macula densa morphology and tubuloglomerular feedback signalling [28] and selective ablation 
of JG cells resulted into renin insufficiency and led to alteration of renal functions and 
morphology [29]. 
Signal peptides are typically N-terminus located 15-25 amino acid residues creating 
characteristic hydrophilic-hydrophobic structures fundamental for proper ER co-translational 
translocation and modulation of secretory proteins biogenesis [30]. In addition to that some of 
the signal peptides removed from the nascent preproprotein by signal peptidase (SPase), and 
their fragments produced by signal peptide peptidase (SPPase) have other post-targeting 
function [31-34]. Considering their biological importance, it is therefore not surprising, that 
about 30 human genetic disorders, both dominant and recessive, have been described as to be 
associated with mutations in signal sequences [35-38]. 
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Inspired by these facts, we therefore further studied biosynthesis, catalytic properties and 
cellular localization of the prorenin and renin expressed from the wild-type and mutant 
preprorenin cDNA constructs, assessed effect of the expressed proteins on cell viability and 
correlated the results with expression of prorenin, renin, other phenotype related proteins and 
selected tubular markers in available kidney biopsies. Our results provided several lines of 
evidence indicating that the identified mutation leads to aberrant prorenin and renin 
biosynthesis, cytotoxic stress and slowly progressing damage of renin expressing cells which 
affects local intra-renal RAS system, alters structure and function of JG apparatus, and similarly 
to renal tubular dysgenesis [23] and animal model with ablated JG cells [29], end up in 
deterioration of kidney functions and observed clinical abnormalities. 
 
Results 
Genotyping and linkage analysis identified single genomic region on chromosome 1. 
To corroborate the results of the medium-dense scan [19], we performed genome-wide linkage 
analysis and identified single genomic region with statistically significant LOD score of 3.24 on 
chromosome 1 (Fig. 1A). Using haplotype analysis we delimited the candidate region between 
the SNP_A_1517951 and SNP_A_1509750 markers (Fig. 1B). The identified 24.7 Mb region, 
(position chr1:186,798,293-211,538,405) have contained 242 genes (NCBI Build 36.2). It has 
overlapped partially with recently defined candidate region for the Gordon syndrome (OMIM 
145260), which is characterized by hyperkalemia, mild hyperchloremia, suppressed plasma 
renin activity and hypertension [39]. 
Sequencing of candidate genes revealed mutation in the signal sequence of renin. 
Sequencing candidate genes we revealed in the proband heterozygous deletion c.[44_46delTGC] 
in exon 1 of the renin gene (REN) (Fig. 2A). The mutation causes a deletion of one of the 
leucine residues forming hydrophobic pentaleucine motif of the preprorenin signal sequence 
(∆L16REN). Subsequent genotyping showed that the identified deletion is present in all affected 
individuals, while healthy individuals from the family as well as 200 unrelated Caucasian 
controls have normal genotype (Fig. 2B). 
∆L16REN mutation may affect various steps of prorenin and renin biosynthesis. 
Human prorenin and renin are synthesized in JG cells from 406 amino acid preproprotein 
composed of a 23 amino acid N-terminal signal sequence, 43 amino acid “pro“ domain, and 340 
amino acid mature renin [20]. Deleted leucine residue is located in the conserved hydrophobic 
core of the preprorenin signal sequence (Fig.3 A and B), which ensures insertion of the signal 
sequence into translation-translocation channel in the endoplasmic reticulum (ER) membrane 
[40]. Following proteosynthesis, glycosylation and signal sequence removal, both the prorenin 
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and renin are sorted to secretory granules from where they are released in highly regulated 
manner into the circulation [41]. Based on its position, the pathogenic effect(s) of the ∆L16REN 
mutation may be associated either with aberrant prorenin and renin biosynthesis, intracellular 
trafficking and secretion or with the loss or gain of function effect of the mutated signal peptide. 
In silico analysis suggests decreased hydrophobicity of the ∆L16REN signal sequence. 
The hydrophobic region of the human preprorenin signal sequence is not perfectly conserved 
among the mammals (Fig. 3B). Using SignalP 3.0 server [42], we noticed that ∆L16REN 
mutation decreases the signal sequence prediction probability, (D score value) [35] by 4%, and 
has no effect on predicted signal peptide cleavage site (data not shown). Other calculation [43] 
showed decrease in the hydrophobicity of the ∆L16REN signal sequence compare to that of the 
WTREN (1,689 vs. 2,156, respectively) (Fig. 3C). 
∆L16REN mutation reduces the translocation efficiency and mutant signal peptide behaves 
differently under in vitro conditions. 
To study the effect of the identified mutation on biosynthesis of prorenin and renin in vitro, we 
cloned the WTREN, ∆L16REN and an artificial, effect enhancing mutant ∆L14-16REN cDNAs into 
pCR3.1 expression vector and transcribed and translated encoding transcripts in rabbit 
reticulocyte lysate in the absence/presence of rough microsomes (RMs) and tripeptide 
glycosylation acceptor (AP) (Fig. 4A). In vitro translation performed in the absence of RMs 
produced from all three transcripts a single protein of 42 kDa that correlates with the theoretical 
molecular weight of preprorenin precursor (Fig. 4A; lanes 1, 6, 11). In the presence of RMs, the 
in vitro translation reactions were separated into membranes and cytosol fractions. WTREN 
transcript produced an additional protein of 47 kDa, which appeared predominately in the 
membrane fraction, while the 42 kDa protein was mainly detected in the supernatant (Fig. 4A; 
lanes 2 and 3). In the presence of AP, the 42 kDa protein was found again in the supernatant 
(Fig. 4A; lane 4), while the 47 kDa protein amount was reduced and a 41 kDa protein appeared 
in the pellet fraction (Fig. 4A; lane 5). Considering the signal sequence cleavage and two N-
glycosylation sites in preprorenin sequence (N71 and N141), which alter the molecular weight 
by 2-3 kDa each, the 47 kDa represents probably the signal sequence cleaved, ER-translocated 
and fully glycosylated prorenin, while the 41 kDa protein represent the signal sequence cleaved, 
unglycosylated prorenin. The other minor protein bands represent probably bi- and mono-
glycosylated forms which were produced due to incomplete inhibitory effect of AP. Mutant 
∆L16REN transcript produced protein that was also translocated (Fig. 4A; lanes 7-10) but less 
efficiently than WTREN (compare Fig. 4A; lanes 3 and 8). Furthermore, a higher amount of 
precursor molecules was detected in the pellet fraction (Fig. 4A; lane 8), which suggests that 
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these molecules are attached but not inserted into RMs. The artificial mutant ∆L14-16REN 
transcript was also translated, but not translocated (Fig. 4A; lanes 12-15). 
To further investigate the WTREN and ∆L16REN signal sequence properties, the in vitro 
translation/translocation assay was performed in the presence/absence of signal peptide 
peptidase inhibitor (ZZ-L)2 – ketone and the resulting products were analysed using high 
resolution SDS-PAGE for small peptides (Fig. 4B). The analysis revealed in case of WTREN 
presence of a 3 kDa peptide in the pellet fraction (Fig. 4B; lane 4). In the absence of RMs, this 
peptide was not identified (data not shown), which suggests that this molecule is the renin 
precursor-derived signal peptide, SPWT-REN. When SPPase inhibitor was added to the in vitro 
translation/translocation reaction, the amount of SPWT-REN increased accordingly (Fig. 4B; lane 
6). In case of ∆L16REN, only small amounts of a 3 kDa SP∆L16-REN peptide was observed and the 
addition of the SPPase inhibitor had no effect on its presence (Fig. 4B; lanes 8 and 9). The 
translation and translocation of mature WTREN or ∆L16REN proteins was not affected by the 
SPPase inhibitor or its organic solvent (data not shown). 
Normal renin activity but decreased prorenin and renin secretion in AtT-20 cells 
transiently expressing ∆L16REN. 
To investigate co-translational translocation efficiency, post-translational processing and 
secretion rate of prorenin and renin and renin activity in vivo, we used WTREN, ∆L16REN and 
∆L14-16REN cDNA expression vectors and transiently expressed corresponding recombinant 
proteins in AtT-20 cells. We measured and found numerical, but not significant decrease in 
renin enzymatic activity between WTREN and ∆L16REN proteins in cell lysates and medium (Fig. 
5A). Measuring active renin amount, we found significant decrease in total prorenin and renin 
amount in cell lysates as well as significant decrease of prorenin and renin secreted into medium 
from ∆L16REN cDNA construct. Prorenin and renin synthesis from ∆L14-16REN cDNA construct 
and the renin activity were negligible (Fig. 5B). Reduced rate and time delay in ∆L16REN protein 
synthesis compared to WTREN were apparent also from Western blot analysis, which further 
showed no differences in post-translational processing between WTREN and ∆L16REN protein 
products (Fig. 5C-F). We obtained similar results from transiently transfected HEK 293 cells 
(data not shown). 
Prorenin and renin secretion is impaired in ∆L16REN stable cell lines. 
To overcome limitations of transient expression for quantitative renin analysis and intracellular 
localization studies, we transfected HEK 293 cell lines with WTREN and ∆L16REN cDNA 
constructs and selected stable prorenin and renin producing clones. Using IRMA assay detecting 
selectively active renin we found significant decrease in prorenin and renin amounts in lysates 
and medium of ∆L16REN cells (Fig. 6A). Contrary to this result, Western blot analysis, detecting 
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whole protein mass, showed significant intracellular accumulation of prorenin and renin in 
∆L16REN cells (Fig. 6B). Prorenin and renin amounts in medium of ∆L16REN cells were reduced 
on Western blot in accordance with IRMA assay (Fig. 6C). As in transient expression 
experiments, we found no differences in post-translational processing of prorenin and renin 
between WTREN and ∆L16REN stable cell lines (Fig. 6 B and C). 
To investigate differences in a mode (semi-quantum vs. continuous) and dynamics of the renin 
secretion between WTREN and ∆L16REN stable cell lines, we modified commercially available 
fluorescence resonance energy transfer (FRET) method based on renin mediated cleavage of 5-
FAM and QXL520 containing renin substrate. We continuously monitored the activity of the 
renin secreted by live cells by means of 5-FAM fluorescent signal release from the cleaved 
substrate. We found no difference in the mode of renin secretion, however the rate of renin 
synthesis was considerably decreased in ∆L16REN cell lines (Fig. 6D). 
∆L16REN stable cells show reduced growth rate and a signs of unfolded protein response. 
To asses the effect of the signal sequence mutation on cell viability, we determined and 
compared cell growth characteristics of HEK 293 and MDCK cell lines stably expressing 
WTREN and ∆L16REN. As a control we also determined growth rate curves in antibiotics selected 
cell lines, which showed no renin expression by, RT-PCR and Western blot analysis (0REN cell 
lines). The WTREN and 0REN cells showed very similar exponential growth rates with population-
doubling times of 46 hours during seven days of the cultivation. Compared to the WTREN and 
0REN, the ∆L16REN cells showed significant lag phase delay with population-doubling time of 78 
hours during first three days of the cultivation. Following this period the cell growth curve and 
population-doubling time of ∆L16REN cells became similar to that of the WTREN and 0REN cells 
(Fig. 7A and B). RT-PCR analysis further showed in ∆L16REN cells presence of the spliced 
XBP1(S) mRNA variant, which is a key effector of the mammalian unfolded protein response 
(UPR) [44] (Fig. 7C). 
∆L16REN mutation has no effect on prorenin and renin localization in stable cell lines. 
To see whether signal sequence mutation affects cellular distribution of prorenin and renin, we 
studied their localization in WTREN and ∆L16REN stable cell lines by immunofluorescence and 
confocal microscopy. The analysis showed expected localization of prorenin and renin 
containing granules in cytosol of the investigated cells. We did not find any visible differences 
in granule size, shape and localization and found no signs of prorenin and renin retention in ER, 
Golgi apparatus, cytoskeleton or plasma membrane neither in WTREN nor ∆L16REN expressing 
cell lines (Fig. 8). 
Macroautophagy and distension of rough endoplasmic reticulum cisternae seems to be 
more pronounced in ∆L16REN cells.  
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To reveal eventual impacts of reduced translocation efficiency of ∆L16REN on cellular 
ultrastructure we analysed WTREN and ∆L16REN stable cell lines and non-transfected HEK 293 
cells (NT) by electron microscopy (EM). The images (Fig. 9) showed in the cytosol of both 
WTREN and ∆L16REN cells numerous, variously sized, round, electron dense and membrane 
delimited granules, which characteristic is compatible with those of secretory renin granules 
(Fig. 9A-C) and [45]. These structures were not present in NT cells (data not shown). Despite 
extensive evaluation, no direct sites of active exocytosis were observed; nevertheless, a number 
of granules were localized in close vicinity to plasma membrane. In addition to renin granules, 
cells of both lines contained numerous, often double membrane bound bodies with pleomorphic 
content which was suggestive of degraded cytoplasmic contents including remnants of 
organelles (Fig. 9D and E). These ultrastructural features are characteristic [46] and therefore 
highly suggestive of autophagic origin of this compartment. Furthermore we observed 
considerably distended rough endoplasmic reticulum cisternae (compare Fig. 9F to Fig. 9A). 
Even though focused quantification of these changes (macroautophagy and ER distension) was 
not performed, both changes seemed to be more frequent and pronounced in ∆L16REN cells. 
Plasma renin activity is normal in affected individuals. 
To correlate the results from in vitro and in vivo studies with the situation in the patients, we 
measured plasma renin activity (PRA) and aldosterone (Ald) concentration in patients DIII.6 
(PRA 0,7 and 1,00 µg/L/h; Ald 158 and 390 ng/L, respectively), DIV4 (PRA 3,10 µg/L/h; Ald 
134 ng/L) and DIV.7 (PRA 0,50 µg/L/h, Ald 255 ng/L). Measured values were within control 
ranges (PRA 0,40-2,78 µg/L/h; Ald 20-330 ng/L). This may be well explained by activated extra 
renal prorenin and renin production - see bellow and [47], and correspond with normal blood 
pressure of the investigated individuals. 
Reduced expression and abnormal localization of prorenin and renin and altered 
expression of RAS components in patients´ kidney. 
To asses prorenin and renin expression in patients´ kidney samples, we performed in three 
patients immunohistochemical staining with antibody specifically detecting prorenin, prorenin + 
renin, and active renin. In addition to that and to previous immunohistochemical study of 
UMOD and MUC1 [1], we further investigated expression of other RAS components (renin 
receptor, angiotensinogen, angiotensin II), KNK2 (TREK-1) as another candidate gene located 
within the identified genomic region and WNK4 kinase as a marker of proximal tubule brush 
border and protein involved in the pathogenesis of Gordon syndrome [48].  
Compared to control tissues (Fig.10A-C), we found in patients considerably reduced expression 
of both, renin and prorenin. In early disease stage, the signal was strongly decreased in JG 
granular cells and undetectable in tubular cells (Fig.10D-F). In advanced destructive stage of the 
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disease, the signal was absent in both JGA and tubular epithelium (Fig.10G-I). However, we 
observed abnormal localization/induction of both, renin and prorenin inside the vessel wall of 
several arterioles and small arteries in all three patients (Fig.10J-L). Staining intensities of other 
analyzed renal RAS components, angiotensinogen, angiotensin II and pro/renin receptor, were 
decreased compared to controls. The decrease was proportional to the stage of the disease 
(Figure 11). TREK-1 (apical pole of PT) and WNK4 (apical pole of TALH and CD) showed 
tendency to weakened immunostaining similarly to UMOD and MUC-1 [1] (not shown). 
From a morphological point of view, patients´ kidney showed progressive destruction of both 
glomeruli and renal tubules with some differences in severity between individual nephrons 
(details are given in legend to Figure 10).  
 
Discussion 
We identified ∆L16REN mutation in the signal sequence of preprorenin segregating with a 
phenotype of autosomal dominant tubulointerstitial nephropathy fulfilling the clinical and 
biochemical criteria of UAKD [1]. We found, that the mutation decreases sequence 
hydrophobicity required for efficient ER translocation, changes property of the out cleaved 
signal sequence and limits biosynthesis of secretory competent and catalytically active prorenin 
and renin proteins. The mutation further causes intracellular retention of prorenin and renin, and 
cells expressing mutant protein have shown reduced growth rate, signs of activated ER stress, 
unfolded protein response (UPR) and pronounced autophagy, a features having potentially 
serious consequences especially for tissues dedicated to extracellular protein synthesis [49]. 
Constant ER stress and activated UPR signalling have generally serious impact on ER function 
and structure, trigger apoptosis, inflammation and eventually lead to reduced viability or even 
cell death [50] and disease development [51]. This pathogenetic mechanism is well plausible for 
the ∆L16REN mutation as is in ER-stress and apoptosis inducing signal sequence mutations 
found in autosomal dominant neurohypophyseal diabetes insipidus [52], carbonic anhydrase IV 
causing retinitis pigmentosa [53, 54] or parathyroid hormone in autosomal dominant form of 
hypoparathyroidism [37]. 
The major site of prorenin and renin synthesis are JG cells [55]. JG cells execute tight control on 
renin synthetic capacity and secretion rate in order to regulate precisely blood pressure, renal 
hemodynamics and electrolyte balance [56]. The patients with ∆L16REN mutation presented with 
small kidney, progressive hyalinosis of glomeruli, tubular atrophy or cystic dilatation, interstitial 
renal fibrosis, reduced glomerular filtration rate (GFR), urinary concentration defect with mild 
hyperkalemia and hyperchloremia [19], which phenotype is remarkably similar to mice with 
ablated JG cells [29]. The immunohistochemical analysis of kidney tissue showed reduced 
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expression of prorenin and renin in site of JG apparatus and absence of renin expressing cells 
along the tubules with enhanced ectopic expression or uptake of prorenin and renin in arterioles 
and arteries. These observations provide evidence for malfunction of the autocrine and paracrine 
effects of renin in the intra-renal RAS [57], and explains (enhanced ectopic expression) 
normotension, near normal plasma renin activity as well as normal endocrine function of RAS 
system in affected individuals.  
Based on our experiments and observations, it is conceivable to predict, that the ∆L16REN 
mutation reduces ability of regulated renin secretion in vivo. This probably affects renal 
development [23], sensitivity of the tubuloglomerular feedback mechanism and autoregulation 
of renal blood flow [56], which through altered renal hemodynamics and resulting hypoxia may 
lead to loss of glomeruli, tubulointerstitial injury and end-stage renal disease [58]. Mechanism 
of RAS blockage corresponds to anemia, hyperkalemia and reduced GFR presented in the 
patients [59] and renal ischemia well explains reduced expression of UMOD [60] and other 
tubular proteins. 
We believe that the genetic defect and phenotype presented by affected individuals directly 
defines and documents functional importance of JG cells and the local intra-renal RAS system 
which is not well understood in humans. Detailed clinical, biochemical and molecular 
investigations of the patients together with further characterization of the wild-type and mutant 
preprorenin expressing cell lines are therefore of great interest. 
 
Methods 
Patients 
The investigated family was described in detail in our previous studies [1, 19]. 
Genotyping and linkage analysis 
Genomic DNA was isolated by standard methods. Samples were genotyped using Affymetrix 
GeneChip Mapping 10K 2.0 Xba Arrays according to the manufacturer’s protocol. Raw feature 
intensities were extracted from the Affymetrix GeneChip Scanner 3000 7G images using the 
GeneChip Operating Software. Individual SNP calls were generated using GeneChip 
Genotyping Analysis Software (GTYPE) 4.0. Resulting genotypes were exported and analysed 
in the Merlin software v1.1.2 [61] . Multipoint parametric linkage analysis along with 
determination of the most likely haplotypes were carried out under the assumption of a 
dominant mode of inheritance with a 0.99 constant, age independent penetrance, 0.01 
phenocopy rate and 0.001 frequency of disease allele. The results were visualized in the 
HaploPainter software v29.5 [62] and in the R-project v2.1. 
REN gene analysis 
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Genomic fragments covering promoter region and all of the exons with their corresponding 
exon-intron boundaries of the REN were PCR amplified from genomic DNA and sequenced as 
previously described [63]. Segregation of the c.[88_90delTGC] mutation in the family was 
assessed by PCR-RFLP analysis of the mutation that created MwoI restriction site. Presence of 
the mutation in a control population was assessed by sizing and determination of the 
trinucleotide repeat number on Li-CoR IR2 system [19].  
REN cDNA expression constructs 
WTREN cDNA was reverse transcribed and PCR amplified from the human total kidney RNA 
and cloned into pCR4- TOPO vector (Invitrogen, Paisley, UK).  ∆L16REN cDNA was prepared 
by subcloning of the corresponding DNA fragment obtained by PCR amplification of the patient 
DNA. Both constructs were introduced into the Escherichia coli TOP 10´F strain (Invitrogen, 
Paisley, UK) and individual clones were sequence verified. ∆L14-16REN cDNA was identified 
among the clones during the sequencing process. Mammalian expression constructs 
WTREN/pCR3.1, ∆L16REN/pCR3.1 and ∆L14-16REN/pCR3.1 were prepared by subcloning of 
corresponding inserts into pCR3.1 vector (Invitrogen, Paisley, UK) using PmeI and NotI 
restriction sites.  
In silico analysis 
Signal peptide sequences were obtained from the UniProtKB/Swiss-Prot database. Multiple 
alignment and evaluation of the amino acids conservation were performed by ClustalW2 
software (EMBL-EBI database). 
In vitro translation and translocation 
WTREN, ∆L16REN and ∆L14-16REN encoding plasmid DNA were linearised, purified and used for 
in vitro transcription with T7 polymerase as described previously [64]. Transcripts were treated 
with RQ1 DNase (Promega, Mannheim, Germany) and purified with G-25 columns (GE 
Healthcare, Freiburg, Germany). In vitro translation was performed in 10 µl reactions with 70% 
rabbit reticulocyte lysate (Promega, Mannheim, Germany) and 150 ng of each transcript in the 
presence of 35S EasyTag EXPRESS35S Protein Labeling Mix (Perkin Elmer, Rodgau 
Jügesheim, Germany). Reactions were incubated at 30°C for 30 min in the absence or presence 
of 1 eq of Micrococcus nuclease-treated rough microsomes (RMs) produced according to the 
protocol of Walter and Blobel [65]. Acceptor tripeptide (AP, N-benzoyl-Asn-Gly-Thr-
methylamide, Bachem, Weil am Rhein, Germany) was dissolved in MetOH. 7.5 µl of 0.5 M 
solution were lyophilised in an Eppendorf tube prior to the addition of the in vitro translation 
reaction components to a final concentration of 375 µM. The signal peptide peptidase inhibitor 
(Z-LL)2-ketone (Calbiochem, Darmstadt, Germany) was dissolved in DMSO and added to a 
final concentration of 10 µM. In vitro reactions were either directly precipitated or membranes 
 111 
were separated by centrifugation through a sucrose cushion as described elsewhere [34], except 
that the sucrose cushion contained 250 mM KAc. The pellet was resuspended either in SDS 
sample buffer or Wiltfang gel sample buffer, and the supernatant was precipitated as described 
above. 
For a time course experiment, in vitro translation was stopped after 30 min by the addition of 
1.25 mM cycloheximide (Sigma, Taufkirchen, Germany), and the reaction was incubated at 
30°C for different periods of time prior to the separation of membranes.  
Translation products were separated in 10% SDS gels (T: 10%, C: 0.8% according to Lämmli) 
or in Wiltfang gels [66] with the following modifications: gels were sized up to 200 x 200 mm, 
the AA-bisAA concentration of the separating gel was 15% and the gels were run at constant 
voltage of 180V with cooling. 
Transient expression of REN 
AtT-20, HEK 293, and MDCK cells were maintained in DMEM High Glucose medium 
supplemented with 10% (v/v) fetal calf serum (PAA), 100 U/ml penicillin G (Sigma, Prague, 
Czech Republic) and 100 µg/ml streptomycin sulphate (PAA Laboratories GmbH, Pashing, 
Austria). Transfections were carried out using Lipofectamine 2000TM (Invitrogen, Paisley, UK) 
and either 1,5 µg or 4µg of DNA for 1,5x105 or 8x105 cells, respectively. 
REN expressing stable cell lines  
HEK 293 and MDCK cells were maintained as described above and transfected at 85% 
confluence using cell specific kits and Amaxa Nucleofector System (Amaxa, Koln, Germany). 
Three days post nucleofection, cells were trypsinised and diluted in selective medium containing 
0,8 mg/ml G418 (Invitrogen-Gibco, Paisley, UK). 1, 10 or 100 cells per well were seeded into 
96-well plates. Selected cells were transferred into 12-well plates and later into 25 cm2 flasks. 
Integration of REN construct and REN expression were confirmed using PCR, sequencing and 
Western blot analyses. All the selected, sequence verified and REN positive clones were 
maintained for further analyses in the selective medium supplemented with 0,5 mg/ml of G418 
or cryopreserved with 10% DMSO in FCS. 
REN analysis 
Western blot analysis and deglycosylation studies 
Cells were seeded into 6-well plate (8x105 cells/well) and grown in standard, serum-
supplemented medium. 24 hours before the analyses the supplemented medium was replaced by 
serum free medium. For secreted renin analysis, the medium was collected and centrifuged at 
800g/5 min and then at 15000g/5 min for residual cells and cellular debris removal, respectively. 
Resulting supernatant was mixed with Protease inhibitor cocktail (Sigma, Prague, Czech 
Republic) in 100:1 (v/v) ratio. 500µl of this medium was then concentrated on Microcon YM-10 
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filters (Millipore, Billerica, MA) and total protein was recovered and mixed with SDS sample 
buffer.  
Harvested cells were resuspended in PBS containing Protease inhibitor cocktail, sonicated twice 
for 30 sec on ice and centrifuged at 15000 g/5 min. Supernatant was mixed with SDS sample 
buffer.  
Denatured protein samples were separated on 13% SDS-PAGE, blotted onto PVDF membrane, 
probed either with Rabbit Anti-Preprorenin (288-317) (detection of renin and prorenin) or 
Rabbit Anti-Preprorenin 21-64 (detection of prorenin) antibody (Yanaihara, Shizuoka, Japan) 
and detected with Anti-Rabbit IgG antibody conjugated to horseradish peroxidase (Pierce, 
Rockford, IL).  
Deglycosylation experiments were performed on medium extracts or cell lysates using the 
GlycoPro™ enzymatic deglycosylation kit (ProZyme Inc., San Leandro, CA). Deglycosylated 
products were analysed by SDS-PAGE and Western blot as described above. 
Renin activity measurement 
Renin activity was measured using Angiotensin I RIA kit (Immunotech, Prague, Czech 
Republic) following manufacturer’s instructions. Briefly, cells were seeded into 6-well plates 
and transfected. 24 hours after the transfection, the medium was collected and the cell lysate was 
prepared as described above. For renin activity, 50 µl of medium and 5 µl of lysate were diluted 
to final volume of 200 µl with PBS. For trypsine activated renin activity 5 µl of medium and 2,5 
µl of lysate were incubated at 37°C for 30 minutes in 50 µl PBS reactions containing 20 µg and 
5 µg of trypsine, respectively. The reaction was stopped by 1 µl of 10mg/mL trypsine inhibitor 
(PMSF, Roche, Prague, Czech Republic) and diluted to a final volume of 200 µl with PBS. 20 
µl of the trypsinised mixtures were mixed with 80 µl of a solution containing 25 µl PBS, 5 µl of 
0,5 µg/µl human angiotensinogen (Sigma, Prague, Czech Republic) and 50 µl of the ACE 
inhibitor (part of the RIA kit). This mixture was incubated at 37°C for 1 hour. 
Active renin IRMA measurement 
Renin amount was measured by Active Renin IRMA kit (DSL, Webster, TX) following 
manufacturer’s instructions. Cell culturing, media collection, lysate preparation and sample 
trypsinisation was essentially the same as described above. 10 µl of the trypsinised mixtures 
were mixed with 190 µl of PBS and 100 µl of the anti-hRenin (I-125) reagent (kit component).  
Renin secretion, FRET measurement 
Stably transfected HEK 293 cells were seeded at 1,5 x 105 cells per well and cultured in 96-well 
plate in standard, serum-supplemented medium without phenol red. After 20 hours, the medium 
was replaced with medium containing renin substrate conjugated with 5-FAM and QXL520 
(component of SensoLyte 520 Renin Assay Kit, AnaSpec, San Jose, CA). Fluorescent signal 
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was monitored at 520 nm every 5 minute for 8 hours at 37°C or 42°C on Synergy 2 Microplate 
Reader (BioTek, Winooski, VT). 
Immunofluorescence analysis 
Stably transfected HEK 293 cells were grown on glass chamber slides (BD Falcon - 4Chamber 
Polystyrene Vessel Tissue Culture Treated Glass Slide). After 48 hours the cells were washed 
with PBS, fixed with 100% ice-cold methanol, blocked with 5% FCS and incubated with rabbit 
Anti-Preprorenin (288-317) and rabbit Anti-Preprorenin (21-64) polyclonal antibodies for renin 
detection. Organelle specific primary antibodies and fluorescent-labelled secondary antibodies 
were described previously [1]. Nucleus was stained by 4´, 6-diamidino-2-phenylindole (DAPI). 
Slides were mounted in fluorescence mounting medium Immu-Mount (Shandon Lipshaw, 
Pittsburgh, PA) and analysed by confocal microscopy [1].  
Growth rate analysis 
Stably transfected HEK 293 cells were seeded in a 6-well plate at 4x105 cells per well and 
cultured in the selective, G418 containing medium. Cells were counted every 24 hours for 7 
days using standard Bürger’s cell. The medium was changed at 3rd, 5th and 6th day. 
XBP1 analysis 
Total RNA was isolated from cells using TRIZOL (Invitrogen, Carlsbad, Ca) and reverse-
transcribed with oligo-dT primer and SuperScript II (Invitrogen, Carlsbad, Ca). XBP1 was PCR 
amplified from the corresponding cDNA with gene specific primers.  
Electron microscopy 
Pellets of stably transfected HEK 293 cells were fixed with 3% glutaraldehyde (GA) in 0.1 M 
phosphate buffer for 30 min and by buffered 1% OsO4 for 2 h, then dehydrated and embedded 
into Epon. Thin sections were double-contrasted with uranylacetate and lead nitrate. Grids were 
observed and photographs were obtained on JEOL 1200 electron microscope. 
Plasma renin activity measurement 
Plasma renin activity was measured by Angiotensin I RIA kit (Immunotech, Prague, Czech 
Republic) according to manufacturer’s instructions.  
Immunohistochemistry studies 
Formaldehyde or ethanol-fixed kidney samples from 5 controls and patients DII.1, DIV.3 and 
DIV.7 were analysed essentially as previously described [1]. Selected antigens were investigated 
using the following primary antibodies: prorenin - Rabbit Anti-Preprorenin (21-64); prorenin + 
renin - Rabbit Anti-Preprorenin (288-317); active renin - Mouse Anti-Renin R3-36-16 (a gift 
from Novartis AG, Basel Switzerland); Pro/renin receptor - Rabbit Anti-P/RR, (a gift from 
Genevieve Nguyen, Paris); angiotensinogen - Mouse Anti-Angiotensinogen (US Biological, 
Swampscott, MA); angiotensin II - Mouse Anti-Angiotensin II (Acris, Herford, Germany); 
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TREK-1 - Rabbit Anti- TREK-1 (H-75); WNK4 – Goat Anti-WNK4 (N-12), both from Santa 
Cruz Biotechnology, Heidelberg, Germany. 
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Figure legends 
Figure 1 Linkage analysis in the UAKD family. (A) A whole genome parametric linkage 
analysis showing single statistically significant region on chromosome 1q41. (B) Haplotype 
analysis delimiting the candidate region between the markers SNP_A_1517951 and 
SNP_A_1509750. Black symbols denote affected individuals, open symbols denote unaffected 
individuals. 
Figure 2 Mutation ∆L16REN in the preprorenin gene. (A) Chromatogram of preprorenin 
genomic DNA sequence showing deletion of a trinucleotide repeat in the proband. (B) PCR 
RFLP analysis showing segregation of the mutation in affected individuals. 
Figure 3 Bioinformatic analysis of the preprorenin. (A) Diagram of the preprorenin sequence 
showing the locations of the identified ∆L16REN mutation and epitopes recognized by prorenin 
(21-64) and preprorenin (288-317) specific antibodies. (B) Homology of the mutant and wild-
type human preprorenin signal peptide sequences with those of higher mammals. (C) 
Hydrophobicity plot of the WTREN, ∆L16REN, ∆L14-16REN signal sequences calculated using the 
Kyte and Doolittle method and scale.  
Figure 4 In vitro transcription, translation and translocation. (A) Corresponding transcripts 
transcribed and translated in nuclease-treated rabbit reticulocyte lysate in the absence (-), or 
presence (+), of rough microsomes (RM) and tripeptide glycosylation acceptor (AP). (B) 
Translation/translocation assay performed in the presence (+), and absence (-) of signal peptide 
peptidase inhibitor (ZZ-L)2. The s and p denote supernatant and pellet fractions. 
Figure 5 Transient expression of preprorenin in AtT-20 cells. (A) Renin (REN) and trypsine 
activated total renin + prorenin (ProREN+REN) activities, and (B) active renin (REN) and 
trypsine activated total renin + prorenin (ProREN+REN) amounts measured in cell lysates and 
medium 24 hours after the transfection with WTREN, ∆L16REN, ∆L14-16REN constructs and 
an empty Vector. The values represent means ± s.d. from three transfection experiments carried 
out in triplicates. The statistical significance of the differences between WTREN and ∆L16REN 
protein activities and amounts was tested by t-test (Microsoft Office Excel 2003). *P<0,05; ** 
P<0,01; NS - not significant. (C-D) Western blot analysis of prorenin and renin in cell lysates 
collected at indicated time point after the transfection. (C) (21-64) antibody detection of 
prorenin in untreated lysates; (D) (21-64) antibody detection of prorenin in N-deglycosylated 
lysates; (E) (288-311) antibody detection of prorenin and renin in untreated lysates; (F) (288-
317) antibody detection of prorenin and renin in N-deglycosylated lysates; - denotes WTREN 
protein product before deglycosylation. 
Figure 6 Stable expression of prorenin and renin in HEK 293 cell lines. (A) Active renin (REN) 
and trypsine activated total renin + prorenin (ProREN+REN) amounts measured in cell lysates 
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and medium. The values represent means ± s.d. of the measurements performed in two 
independent clones for each of the constructs. The individual measurements were carried out in 
triplicates. The statistical significance of the differences between WTREN and ∆L16REN protein 
amounts was tested by t-test. *P<0,05; ** P<0,01; *** P<0,001. 0REN is antibiotics selected cell 
line, which showed no renin expression by RT-PCR and Western blot analysis. (B) Western blot 
analysis of prorenin and renin in cell lysates before (-) and after (+) N-deglycosylation. (C) 
Western blot analysis of prorenin and renin in medium before (-) and after (+) N-
deglycosylation. (D) Renin secretion from living HEK 293 cell lines. The fluorescent signal is 
released from 5-FAM and QXL520 conjugated renin substrate and corresponds to the activity of 
the renin secreted in medium. 
Figure 7 Growth curves and XBP1 expression in stably transfected WTREN and ∆L16REN cell 
lines. (A) HEK 293 cells. (B) MDCK cells. (C) RT-PCR detection of XBP1 splicing variants in 
WTREN, ∆L16REN and 0REN cells. XBP1(U) is constitutively expressed form. XBP1(S) is formed 
by alternative splicing upon ER stress and encoded protein is a key effector of the mammalian 
unfolded protein response (UPR). 
Figure 8 Cellular localisation of the prorenin and renin in stably transfected WTREN and 
∆L16REN HEK 293 cells. (A, B) Prorenin and renin detected using renin 288-317 antibodies 
(green signal) and its colocalisation with (C, D) endoplasmic reticulum detected using PDI 
antibody; (E, F) Golgi apparatus detected using GS28 antibody; (G, H) cytoskeleton detected 
using Acetylated alpha-Tubulin antibody and (I, J) plasma membrane detected using Pan-
Cadherin antibody (red signals). 
Figure 9 Electron microscopy of stably transfected WTREN and ∆L16REN HEK 293 cells. 
(A) Overview of the WTREN cell with numerous electron dense granules marked by the arrows. 
(B) Detail of the electron dense granules in WTREN cell. (C) Granules in ∆L16REN cell. Compare 
the morphology of these granules to additional numerous membrane bound bodies containing 
pleomorphic and partly degraded cytosolic components (compatible with autophagic 
compartment) both in (D) WTREN and (E) ∆L16REN cells. (F) Considerable distension of ER 
cisternae (asterisk) observed more frequently in ∆L16REN cells. Actual magnification in 
thousands is provided for each of the images. 
Figure 10 Immunohistochemistry and nephropathology. (A, B, C) Renin expression in control 
kidney. (A) Renin expression in JG cells and individual cells of collecting ducts; a 7 years aged 
control. (B, C) Renin staining in an adult control (B) in JG apparatus and (C) in renal cortical 
tubules where the signal is restricted to individual cells of the collecting ducts. 
(D, E, F) Kidney biopsies in an early disease stage. The common denominator is a strong 
reduction of renin signal in the JG apparatus and its absence in the surrounding tubules. (D) 
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Structural abnormalities in patient DIV.3 at 8 years of age are minimal with enlarged glomeruli 
and borderline tubulointerstitial changes. In patient DIV.7 at 4 years of age, there were (E) some 
glomeruli in various stages of hyalinization and (F) occasionally foci of tubular atrophy with 
mild interstitial fibrosis. 
(G, H, I) Patient DII.1 at 60 years of age in advanced stage of kidney disease. (G, H) 
Pronounced tubular atrophy and loss of tubules is accompanied with prominent interstitial 
fibrosis. Some of the atrophic tubules are surrounded by thickened basement membranes. Many 
of the remaining tubules reveal cystic dilatation (see G). Glomeruli exhibit various degrees of 
sclerosis. Some glomeruli are collapsed in the enlarged Bowman spaces suggesting block in 
tubular fluid passage (see H). Periglomerular fibrosis is frequently present, (see H). Note 
regional heterogeneity in the severity of structural alteration. H&E staining. (I) Renin staining is 
absent in both JG apparatus and tubular epithelium even in relatively well preserved regions. 
(J, K, L) Renin expression inside the wall of small size vessels, probably in a sub/endothelial 
localization, more prominent in patient DII.1 (the main pictures) than in patients in early stage 
of the disease (inserts). (J) Prorenin and renin detected by preprorenin antibody, (K) mouse 
monoclonal antibody, and (L) prorenin antibody. Insert (J) demonstrates situation in patient 1, 
inserts (K) and (L) in patient 2. 
Figure 11 Detection of renal RAS components. (A-E) Immunodetection of pro/renin receptor. 
(A,B) Strong signal at the basolateral pole of distal convoluted tubules and thick ascending loop 
of Henle in (A) 7 years aged control, and (B) adult control. Expression pro/renin receptor is in 
patients reduced proportionally to the disease stage (C) patient DIV.7, (D) patient DIV.3, (E) 
patient DII1.  
(F-J) Immunodetection of angiotensinogen (AGT). (F) Mild and heterogenous intracellular 
granular positivity in proximal tubules in 7 years aged control and (H, I) comparable or slightly 
weakened signal in patients in early stage of the disease (H) patient DIV.7, (I) patient DIV.3. 
(G) Pronounced AGT expression in proximal tubules in adult control and (J) significantly 
decreased intensity in the kidney of patient DII1. 
(K-O)  Immunodetection of angiotensin II. (K)  Presence of angiotensin II at the apical pole of 
proximal tubules, in the tubular fluid and in distal nephron epithelium in 7 years aged control 
and reduced signal in both (M) patient DIV.7, and (N) patient DIV.3. (L) Positivity in adult 
control kidney is seen in the same locations as in the infantile control but with an increased 
intensity. This contrasts with (O) markedly decreased signal in adult patient DII.1. In the 
advanced stage of the disease (patient DII.1) immunostaining signals of all the followed RAS 
components were always restricted to the foci of relatively preserved renal parenchyma. 
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